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ABSTRACT 
 
 DNA is the central molecule in cells. The correct function of cells depends on the 
structure of DNA. DNA damaging natural products often show cytotoxic or mutagenic 
properties, which many times land them medicinal value as antibacterial or anticancer 
therapeutics. Efficient DNA modifications by these agents usually endow them with 
outstanding biological efficiency. In the present dissertation, we investigated novel DNA 
damaging natural products with novel DNA modification strategies.  
We showed that weak noncovalent binding of the natural product leinamycin to 
DNA accelerates its DNA-alkylation reaction (Chapter 1). We demonstrated that 
leinamycin intercalates DNA with an unprecedented DNA-intercalating functional group. 
Likewise, we uncovered novel molecular recognition features of the natural product 
azinomycin using similar tools (Chapter 4). We characterized novel, reversible chemical 
reactions of leinamycin (Chapter 3). Amongst these were reversible DNA-alkylation and 
reversible adduct formation with biologically relevant nucleophiles. We showed that 
thiols and chloride ion can add to the leinamycin episulfonium ion reveribly to protect it 
from unproductive hydrolysis and to help its transport to DNA. We synthesized 
precursors for the biosynthesis of leinamycin (Chapter 5) to prove the principle that 
synthetic molecules can be incorporated into the biosynthetic machinery of natural 
products. 
 We worked with the labile and mutagenic fatty acid metabolite: fecapentaene-12, 
and clarified its mechanism of oxidative DNA damage. We also showed that this poly-
unsaturated hydrocarbon compound binds the DNA duplex noncovalently (Chapter 6)
  iii 
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Chapter 1. DNA Alkylation by Leinamycin: Measurement of the Rate 
Acceleration Provided By Noncovalent Binding In The Major Groove of 
the Double Helix 
 
1.1. Discovery and Biological Activity of Leinamycin 
 Leinamycin (1), initially named DC107, was found in Japanese soils, during 
screening for antibiotics. It was isolated in 1985 from a species of Streptomyces 1,2 by the 
Kyowa Hakko Kogyo (KHK) Pharmaceutical Company. Soon, 1 showed antibacterial 
activity against Bacillus subtilis (IC50 = 80 ng/mL; 160 nM) and mouse sarcoma (1 
mg/kg). Additionally, 1 displays antitumor activity (IC50 of 11 nM against HeLa S3 
tumor cells). Leinamycin increases the life span of mice with murine leukemia P388 by 
~60% at a dosage of 0.38 mg/kg.3 Leinamycin and its derivatives continue to be 
investigated as potential anticancer agents. 4-7  
 The structure of 1 was elucidated by spectroscopic means.2,3,8 Leinamycin 
possesses an unusual 1,2-dithiolan-3-one 1-oxide moiety that is connected by a spiro-
linkage to an 18-membered macrocycle that contains a novel Z,E-5-(thiazol-4-yl)-penta-
2,4-dienone assembly. The 1,2-dithiolan-3-one 1-oxide moiety (Figure 1) is crucial for 
the antitumor activity of the drug, shown by the fact that the S-deoxy analog 2 (Figure 1) 
showed much less efficient antitumor properties.2 
 DNA is an important biological target of the natural product. 2,9 The natural 
product activates Ckh2 kinase enzymes in human pancreatic carcinoma cells, indicating 
that the apoptotic cell death is the result of extensive fragmentation of genomic DNA by 
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the drug. This further suggests that leinamycin mostly expresses its biological activity via 
oxidative DNA damage.9 
 
 
   
  
 
Figure 1. The chemical structure of leinamycin (1) and its S-deoxy analog (2). 
 
 
 
1.2. DNA Binding and the Mechanism of DNA Damage by 1 
 Because DNA is an important target for antitumor agents,10 detailed studies of the 
DNA damaging properties of 1 were undertaken in 1990. 2 In this study, leinamycin was 
seen to cleave pBR322 DNA at micromolar concentrations. Only nicked (form II) DNA 
was found to be the product, meaning that 1 does not cause double-strand breaks. DNA 
cleavage by 1 is thiol dependent, but the identity of the thiol does not affect the efficiency 
of DNA-damage.  
1.2.1. Thiol-Triggered Oxidative DNA Damage by Leinamycin11 
 Leinamycin is a thiol-triggered DNA damaging agent (Scheme 2). The DNA-
cleaving properties of small synthetic analogs of the leinamycin (Scheme 1, 3-5) were 
studied in our laboratory. 12 The strand cleavage caused by these molecules exclusively 
involves the conversion of molecular oxygen to DNA damaging hydroxyl radical (OH•) 
as shown at the bottom of Scheme 2. Mechanistic studies in our laboratory earlier showed 
the production of reactive oxygen species and thiol-mediated DNA-cleavage by 
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S
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leinamycin.13 In this process initial attack of the thiol at the S2-sulfur of the dithiolanone-
1-oxide ring results in the formation of a sulfenic acid (6) intermediate. The oxygen of 
this sulfenic acid will form the 5-membered 1,2-oxathiolan-5-one ring (9) and yields the 
labile hydrodisulfide (7). The unstable hydrodisulfide intermediate (RSSH, 7) will reduce 
molecular oxygen to superoxide-radical species and the DNA-damaging hydroxyl radical 
via Fenton chemistry. This, in turn, initiates oxidative DNA damage. The details of this 
chemistry are shown in Scheme 3. 
 
 
 
 
Scheme 1.  Small synthetic analogs of leinamycin (1) 
 
 
1.2.2. Thiol-Triggered DNA Alkylation by Leinamycin11 
 In addition to the oxidative DNA damage described above, leinamycin damages 
DNA by another mechanism, which involves the alkylation of duplex DNA. 8 After thiol-
triggered formation of the 1,2-oxathiolan-5-one (9) ring, this species undergoes 
intramolecular reaction with the C6-C7 alkene of the natural product and forms an 
episulfonium-ion alkylating agent (10). The episulfonium-ion efficiently alkylates 
double-stranded DNA with a covalent attachment at the N7 atom of deoxyguanosine 
residues (Scheme 2). DNA alkylation competes with hydrolysis of the episulfonium ion,8 
however, DNA alkylation takes place efficiently (75%) in the presence of 400 µM 
S
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S
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O
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leinamycin and 600 µM thiol at physiological DNA concentrations (7.6 mM)14,15.  
Interestingly, 10 does not alkylate single stranded DNA or 2’-deoxyguanosine, 8,16 which 
suggests a role for noncovalent binding of 10 to duplex DNA in the efficient N7G-
alkylation. 
  The leinamycin derived episulfonium-ion (10) exists in equilibrium with its 
constitutional isomer, the leinamyin-epoxide (11). The episulfonium ring of 10 is opened 
by the nucleophilic attack of the C8-OH group to form the epoxide 11 in an equilibrium 
reaction. 17 One might ask if this epoxide can be a DNA-alkylating species. There are 
known epoxide DNA alkylating agents, 18 however, in case of leinamycin, DNA 
alkylation clearly occurs via the episulfonium intermediate 10, as was proved by NMR 
studies.8 The leinamycin-DNA adduct is an unusually labile lesion, prone to rapid 
depurination (t1/2 ~ 3 h at 37 °C). The typical half-life of this reaction is 100 h amongst all 
known N7G adducts.19 
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Scheme 2. Thiol triggered DNA damage by the natural product leinamycin 
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Scheme 3. Fate of polysuflides in the presence of thiol 
 
 
 
1.2.3. DNA Alkylation May Be Driven by Noncovalent Association of the Natural 
Product With the Double Helix 
 Several lines of evidence indicate that leinamycin associates noncovalently with 
DNA. 8,16 For example, it was noticed that 1 did not react with the guanosine nucleotide 
monomer or single-stranded DNA in aqueous buffer under conditions where DNA 
alkylation is efficient.8,16 This suggests a role for the duplex DNA structure in the 
alkylation. Later, we discovered16 that 1 alkylates duplex DNA in a sequence specific 
manner with the following order of efficiency: 
5’-GG>GT>GC>GA 
This data implies that noncovalent interaction between the natural product and the DNA-
base on the 3’-side of the alkylation site is important. This interaction will be further 
investigated in Chapter 2. 
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 The facts that leinamycin alkylated only duplex DNA and in a sequence specific 
manner were intriguing, because leinamycin does not contain any classical DNA-binding 
functional groups,20 like a positively charged functional group as seen in spermine, a 
polyamide-type groove binder as seen in distamycin, or a polycyclic aromatic 
intercalators as seen in ethidium bromide (Figure 2).  
 
 
 
 
 
 
Figure 2. Typical DNA-binders that can associate DNA noncovalently. Spermine: electrostatic DNA 
binders; distamycin: minor-groove binding agent, ethidium-bromide: DNA-intercalator. 
 
 We suspected that the thiazole-dienone moiety of the leinamycin macrocycle 
might be the noncovalent DNA-binding domain of the natural product,21 as it represents a 
large hydrophobic surface in the molecule, which might drive noncovalent association of 
the molecule in the hydrophobic DNA grooves. This was confirmed by studying the 
binding constants of truncated leinamycin analogs (14-17, Figure 3) in our group. 22 
Additionally, an affinity cleaving approach 23-25 was used to compare the DNA alkylation 
ability of an epoxide analog (18) with the small epoxide molecule glycidol. The epoxide 
in the molecular framework of leinamycin (18) alkylates DNA more efficiently than the 
small epoxide glycidol. The noncovalent binding of 1 and its hydrolysis product (13) to 
DNA was also measured by dialysis methods, and a binding constant ~ 1000 M-1 was 
obtained (Figure 1).  
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Figure 3. Small synthetic analogs of leinamycin. 
 
 
1.3. Noncovalent Binding by Natural Products Can Enhance their DNA Alkylation 
There are known DNA damaging agents that bind DNA noncovalently, which 
enhances their DNA alkylation (Figure 4).26-32 
The idea that DNA binding can enhance the rate of DNA-damage has been 
demonstrated chemically by attaching small electrophilic organic molecules to 
noncovalent DNA binders. For example, the alkylation rate of the small N7G-DNA-
HO O
O
O
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O
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alkylator α-bromo-acetamide was studied and compared to that of α-bromo-acetamide 
attached to an oligonucleotide capable of triple-helix formation. Attachment of α-bromo-
acetamide to a triple helix forming oligonucleotide yields an effective molarity of 0.8 M 
α-bromo acetamide in the major groove of DNA.33 The attachment of an electrostatic 
DNA-binding polyamine to chlorambucil (20) increased its DNA-damaging potency. 34 
These and other examples showed that noncovalent DNA binding can enhance the 
efficiency of DNA-damaging agents compared to small molecules with a similar DNA-
alkylating electrophilic functional group. 24,32,35-38 
 
 
 
 
 
 
 
 
 
Figure 4. DNA damaging agents that bind DNA noncovalently. 
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1.4. The Goals of Our Work 
 Surprisingly, only a few studies have qualitatively examined how noncovalent 
association facilitates DNA modification by drugs, toxins and mutagens.27,28,33 With the 
evidence showing the noncovalent association of 1 to DNA, we hypothesized39 that 
noncovalent binding plays an important role in its efficiency of DNA alkylation.8 We set 
out to measure the rate acceleration/equivalent molarity that 1 achieves upon DNA 
binding in the major-groove of DNA in its N7G alkylation in comparison to 2’-dG. 
Additionally, we wanted to establish the binding constant of the active (episulfonium ion) 
form of leinamycin (10) using enzyme-kinetic analysis. 
  
1.5. DNA Alkylation by Activated Leinamycin (10) Under Physiological Conditions 
Follows Michaelis-Menten Kinetics 
1.5.1. Initial Rates of DNA Alkylation by 10 Followed by UV Absorbance 
Measurements 
 Initially, we measured the initial rates of DNA alkylation by 10 using a UV-
absorbance based kinetic assay. DNA alkylation by 10 is accompanied by an increase in 
UV-absorbance at 380 nm. At this wavelength, the contribution of the competitive 
hydrolysis reaction of 10 is negligible. Initial rates of DNA alkylation were derived from 
the first derivative of the A380nm vs. time curve, and plotted as a function of applied DNA 
concentration (Figure 5). This plot, along with the Eadie-Hoofstee, Hanes-Woolf, 
Lineweaver-Burk and Kitz-Wilson plots were analyzed in terms of Michaelis-Menten 
kinetics (Equation 1 and Equation 2, Section 1.5.2.) for the calculation of the maximum 
rate constant of DNA alkylation, k2 = 1.68 ± 0.05 x 10-3 s-1, (t1/2 = 7 min), the Michaelis-
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constant (KM = 4.2 ± 0.1 x 10-4 M) and the binding constant of 10 to the DNA duplex (KB 
= 2 065 ± 60 M-1). These values represent the average of those originated from each of 
these plots (Table 1).  
 
 
 
 
 
 
Figure 5. Initial rate constants of DNA alkylation by 10 using an UV based kinetic assay. 200 µM 1 was 
incubated with 1 mM β-mercaptoethanol in 50 mM MOPS buffer (pH 7.4) at 8 °C. UV-absorbance 
readings were taken every 5 s at 380 nm for 20 min. Errors were calculated using 67% confidence (n=2). 
 
 
 
 
 
 
 
 
 
 
Figure 6. of the Eadie-Hoofstee, Hanes-Woolf, Lineweaver-Burk and Kitz-Wilson plots of the initial rate 
constants of DNA alkylation by 10. 200 µM 1 was incubated with 1 mM β-mercaptoethanol in 50 mM 
MOPS buffer (pH 7.4) at 8 °C. UV-absorbance readings were taken every 5 s at 380 nm for 20 min. Errors 
were calculated using 67% confidence (n=2). 
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Table 1. Maximum rate of DNA alkylation, KM and KB calculated from different graphical representation 
of the initial rates. Errors were calculated using 67% confidence (n=2). 
 
 
 
1.5.2. Rates of DNA Alkylation by 10 Using Competition Kinetic Analysis 
Alternatively, we measured the partitioning of activated leinamycin (10) between 
formation of the guanine adduct (12) and the hydrolysis product (13) as a function of 
DNA concentration. The products were quantitatively measured using HPLC.  
 The thiol-activation of 1 to generate the DNA-alkylation episulfonium (10) is a 
fast process kact = 1.6 ± 0.3 x 10-3 s-1, (t1/2 = 7.5 ± 1.5 min, Section 1.9.6.), thereby it does 
not limit the rate of noncovalent complex and covalent adduct formation. The products of 
this reaction are solely the guanine adduct (12) and the hydrolysis product (13) (Figure 
13). The identity of the peaks in this HPLC were previously confirmed by LC-MS 
methods. 
 As expected, the yield of the guanine adduct increases with increasing DNA 
concentration (Figure 7). More interestingly, the alkylation rate reaches a plateau at high 
DNA concentrations when virtually all of the activated leinamycin in the reaction mixture 
becomes complexed with the duplex. This is consistent with a process involving a 
 
 
k2 (s-1) KM (M) KB (M-1) 
Eadie-Hofstee plot 1.73 ± 0.05 x 10-3 4.3 ± 0.1 x 10-4 2 327 ± 49 
Hanes-Woolf plot 1.76 ± 0.06 x 10-3 4.8 ± 0.1 x 10-4 2 100 ± 44 
Lineweaver-Burk plot 1.6 ± 0.03 x 10-3 3.6 ± 0.1 x 10-4 2 775 ± 58 
Kitz-Wilson plot 1.6 ± 0.03 x 10-3 3.7 ± 0.1 x 10-4 2 774 ± 58 
Pseudo-Michaelis-Menten plot 1.71 ± 0.06 x 10-3 4.5 ± 0.1 x 10-4 2 240 ± 50 
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reversible noncovalent binding step prior to DNA alkylation. This type of DNA-
alkylation reaction can be analyzed in terms of Michaelis-Menten-type kinetics (Equation 
1 and Equation 2), as has been recognized for other DNA-damaging agents.  27,40,41 
 
Equation 1 
 
Equation 2 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Yields of the DNA adduct (12, LM-G) and hydrolysis product (13, LM-OH) as a function of 
DNA concentration. Leinamycin (1, 400 µM) and β-mercaptoethanol (1.5 equiv, 600 µM) were incubated 
in the presence of varying concentrations of herring DNA in 50 mM MOPS buffer (pH 7.0) at 4 °C for 2 h. 
Products were analyzed by RP-HPLC and their amounts measured using the HPLC data. The applied DNA 
concentrations were as follows: 0 mM, 0.8 mM, 1.6 mM, 3.2 mM, 4.8 mM, 6.4 mM, 8 mM, 11.2 mM, 14.4 
mM, 17.6 mM. The maximum error in these data was 1.95 %, calculated by statistical analysis. 
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 Competition kinetic analysis employing the data in Figure 7 along with the rate 
constant measured independently for the hydrolysis of leinamycin (kH2O = 4.3 ± 0.1 x 10 -
5
 s -1, t1/2 = 5 ± 0.3 h, Section 1.9.6.) in the absence of DNA (Eqn 3-4) allows us to 
calculate the average velocity of the alkylation reaction at each DNA concentration 
examined. This is different from the initial rate measurements by UV (Section 1.5.1) in 
that there the fastest initial rate is calculated at each DNA concentration within the first 5 
s of DNA alkylation. Here, we obtain DNA alkylation rates that is the average DNA 
alkylation rate over the full course of the reaction (full consumption of 10 ~ 40 min). 
Equation 3 
 
 
 
Equation 4 
 
 
 
 
At saturating DNA concentrations the ratio of products 12 and 13 provide us with 
the maximum observed rate constant k2 = 9.0 ± 0.5 x 10 -4 s -1, (t ½ = 13 ± 0.6 min) of 
DNA alkylation according to Equation 4. The apparent rate of DNA alkylation can be 
determined using this equation, by measuring the ratio of [12]/[13] (Equation 9 in 
Experimental). The calculated apparent rates of DNA alkylation were plotted vs. [DNA] 
(Figure 8) and are shown in Table 2.  
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Figure 8. The apparent rates of DNA alkylation by 10 as a function of DNA concentration. Errors were calculated using 67% 
confidence (n=2). 
 
 
 
 
 
 
Table 2. The apparent rates of DNA-alkylation by leinamycin. Errors were calculated using 67% confidence (n=2). 
 
A Hanes-Woolf plot 42 of these apparent velocities (Figure 9) yields the KM (k-1/k1) = 
1.05 ± 0.01 x 10-3 M, and confirmation of our rate constant k2 = 9.0 ± 0.6 x 10-4 s-1. 
Alternatively (and perhaps more appropriately), a Kitz-Wilson plot (Figure 9), 42,43  
typically used for the analysis of covalent enzyme modification by mechanism-based 
inactivators and affinity-labeling agents, can be employed to obtain a KI of 1.13 ± 0.01 x 
10-3 M, kinact = 9.7 ± 0.6 x 10-4 s-1. These plots are all functionally equivalent in this 
context. The apparent association constants for activated leinamycin (10) obtained using 
this kinetic approach are comparable to those measured previously for the parent 
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compound (1) and its synthetic analogs under thermodynamic conditions described in 
Section 1.2.3. The calculated binding constant of 10 to duplex DNA, KB ~ 1/KM = 935 ± 
26 M-1 represents a weak noncovalent binding. 
 
 
Figure 9. Hanes-Woolf plot (A) of the apparent rates of DNA alkylation and the Kitz-Wilson replot (B) of 
t1/2 of DNA alkylation by leinamycin. Leinamycin (1, 400 µM) and β-mercaptoethanol (1.5 equiv, 600 µM) 
were incubated in the presence of varying concentrations of herring DNA in 50 mM MOPS buffer (pH 7.0) 
at 4 °C for 2 h. Products were analyzed by RP-HPLC and their amounts measured using the HPLC data. 
The applied DNA concentrations were as follows: 0 mM, 0.8 mM, 1.6 mM, 3.2 mM, 4.8 mM, 6.4 mM 8 
mM, 11.2 mM, 14.4 mM, 17.6 mM. Errors were calculated using 67% confidence (n=2). 
 
 
 
 
1.5.3. Comparison of the Kinetic and Thermodynamic Parameters Obtained by 
The Initial Rate (UV) and Competition Kinetic (HPLC) Methods. 
For a comparison, we tabulated the second order rate of DNA alkylation (k2/KM), 
KM and KB obtained by the two different methods: initial rates (UV), and competition 
kinetics in (Table 3). In addition the rate of activation of leinamycin and that of its 
hydrolysis is tabulated in the same table. 
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Table 3. Second order rate of DNA alkylation, Effective Molarity, Rate Acceleration and rate of activation 
and hydrolysis in the initial rate method (UV) and the competition kinetic method (HPLC). Reactions were 
carried out at the following temperatures: Initial rates method: 7 °C, Competition method: 4 °C. Errors 
were calculated using 67% confidence (n=2). 
 
 
1.6. Measuring the Rate of the “Uncatalyzed” Reaction: Alkylation of 2’-
Deoxyguanosine in TFE:Water Buffer 
1.6.1. Alkylation of 2’-Deoxyguaosine by 10 in TFE:MOPS Buffer 
 The apparent association constants measured here for the interaction of activated 
leinamycin with duplex DNA are rather modest, KB = 935 ± 26 M-1 (for comparison, the 
binding constant for ethidium bromide is 9.5 x 106 M-1 and that for distamycin A is 2.5 x 
107 M-1.) 38,44 It is interesting to consider the extent to which this level of noncovalent 
binding can accelerate reaction of the alkylating agent with guanine residues in the 
double helix. To address this issue it is necessary to measure the rate of the “background 
or uncatalyzed reaction” of activated leinamycin with a 2’-deoxyguanosine residue that 
does not reside within the context of double-helical DNA.  
 
Initial Rates method 
(UV) 
Competition Method 
(HPLC) 
Second order DNA alk. 
k2/KM (M-1s-1) 
4.32 ± 0.13 0.86 ± 0.03 
Effective Molarity 
k2/kdG (M) 
6.0 ± 0.4 3.4 ± 0.2 
Rate acceleration versus hydrolysis 
k2/KM / kH2O/[H2O] 
5.5 x 106 times 1.1 x 106 times 
Rate of activation 
kact 
1.6 ± 0.3 x 10-3 s-1 
t1/2=7.5 ± 1.5 min 
 
Rate of hydrolysis 
kOH of 10 
4.3 ± 0.5 x 10-5s-1 
t1/2=5.0±0.3 h 
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 Accordingly, we analyzed the reaction of activated leinamycin with the free 
nucleoside 2’-dG in a 1:1 (v/v) mixture of 2,2,2,-trifluoroethanol:MOPS buffer (50 mM, 
pH 7.0). This solvent system offers two distinct advantages for our studies: 
(1) it provides a dielectric constant of about ε ~ 55, 45 comparable to that of the major 
groove of DNA (Figure 12), 46 where alkylation by leinamycin takes place. 
(2) it suppresses the hydrolysis of activated leinamycin that would normally 
overwhelm an attempt to observe alkylation of the free 2’-deoxyguanosine 
nucleoside in aqueous solution. 8,47 
The 2’-deoxyguanosine adduct (21, Figure 10), its depurination product (12, Scheme 2)  
and hydrolyzed leinamycin (13, Scheme 2) are the only major products generated under 
these conditions (sample HPLCs in Figure 20). Competition kinetic analysis involving 
the independent measurement of the rate of hydrolysis under these conditions kH2O,ε=55 = 
6.6 x 10-6 s-1, (t1/2 = 29 ± 0.7 h) and measurement of the relative yields of LM-2’dG (21) 
and LM-OH (13) at several concentration yielded pseudo-first order rate constants at each 
applied 2’-dG concentrations (1 mM, 2 mM, 4 mM, 6 mM). These rate constants (Table 
4) were plotted versus the concentration of 2’-deoxyguanosine (Figure 11), and the slope 
of this curve provided us with the second-order rate constant: 2.7 ± 0.2 x 10 -4 M -1s -1 
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Figure 10. The 2’-deoxyguanosine adduct of leinamycin. 
 
 
 
 
 
 
 
 
 
 
Table 4. The pseudo-first-order rate constants of alkylation of 2’-dG by activated leinamycin 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The pseudo-first-order rates of 2’-dG alkylation by 10 plotted vs. [2’-dG]. Conditions are 
described above. Concentrations of 2’-deoxyguanosine: 1 mM, 2 mM, 4 mM, 6 mM. The slope gives the 
second-order rate of 2’-dG alkylation: kdG, 2nd = 2.7 ± 0.2 x 10 -4 M-1s-1. Errors were calculated using 67% 
confidence (n=2). 
 
 
[2’-dG] (M) Kψ x 107 (s-1) 
0.001 1.82 ± 0.05 
0.002 3.74 ± 0.18 
0.004 7.82 ± 0.12 
0.006 12.72 ± 0.63 
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Figure 12. The grooves of the DNA duplex, showing their effective dielectric constants. 
 
 
 
1.7. Rate Acceleration and Equivalent Molarity in the Major Groove of DNA for 
The N7-G Alkylation Reaction 
 There are only a few examples where rate acceleration by noncovalent binding of 
DNA-alkylating agent was measured. 28,33 Most of these examples involved agents with 
strong binding constants (CC-1065: KB ~ 106 M-1) 40, although an example involving a 
natural product with weaker binding (aflatoxin B1 epoxide: KB ~ 103 M-1) has been 
reported.27 It is interesting to calculate how much the modest noncovalent binding of 1 
can accelerate its DNA-damaging reaction. 
Our measurements reported in this chapter allow us to calculate the rate 
acceleration provided by noncovalent binding of leinamycin in the major groove of DNA. 
Comparison of the apparent second-order rate constant for the reaction of leinamycin 
with duplex DNA (k2/KM = 0.86 M-1s-1) with the second-order rate constant for the 
alkylation of 2’deoxyguanosine (2.7 ± 0.2 x 10 -4 M -1s -1) reveals a 3200 ± 100 fold rate 
enhancement. This represents a conservative estimate because the inherent reactivity of 
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guanine is decreased in the duplex as compared to monomeric nucleosides (measured in 
the yield of their reactions with simple alkylating agents like dimethylsulfate). 
Alternatively, we can think of rate acceleration in terms of effective molarity. 48,49 Our 
results indicate that the effective concentration (k2/kdG) of leinamycin in the major groove 
of DNA is 3.4 ± 0.1 M.  
Two previous studies have considered how noncovalent binding favors the 
reaction of alkylating agents with DNA over that with water. 27,28 Such measurements are 
of great value, because hydrolysis is likely to be the primary reaction that competes with 
DNA alkylation. The apparent second-order rate constant for the reaction of the CC 1065 
analogue (Figure 4) with duplex DNA is approximately 1010 times larger than the rate 
constant for the reaction of this compound with water. 28 The apparent second-order rate 
constant for the reaction of aflatoxin B1 epoxide (Figure 4)  with DNA is 2.3 x 106 times 
larger than the rate constant for hydrolysis. 27 Finally, the apparent second-order rate 
constant for the reaction of activated leinamycin with DNA is 1.1 x 106 times larger than 
the rate for its reaction with water. Large differences are seen in the magnitude of the 
kinetic advantage afforded by noncovalent DNA association for the various alkylating 
agents discussed here. This reflects an interplay of binding affinity, rigidity of the 
alkylating agent, and proper alignment of the reaction partners in the noncovalent 
complex. 
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1.8.Chapter Discussion and Conclusions 
 Noncovalent binding of natural products to DNA enhance their alkylation 
rate. 26,27 Noncovalent binding of 1 has been suggested and provided the foundation of 
our kinetic studies. We studied the alkylation of DNA by 1 using pseudo-Michaelis-
Menten kinetics, using two different methods: 
(1) Measurement of initial rates of DNA alkylation by 10 using a UV assay. 
(2) Competition kinetics between the hydrolysis and DNA alkylation by 10 using 
HPLC based assay. 
The active form of leinamycin (10) binds non-covalently to DNA prior to alkylation with 
a modest binding strength KB = 2 065 ± 60 M-1 (initial rate method), KB = 935 ±26 M-1 
(competition kinetics method). During these reactions the activation of leinamycin was 
not a rate limiting factor, t ½ < 8 min compared to its hydrolysis, t1/2, H2O = 5.0 ± 0.3 h and 
DNA-alkylation reaction, t1/2, [DNA]sat  = 0.1 ± 0.01 h (initial rates), t1/2, [DNA]sat = 0.3 ± 0.02 
h (competition kinetics). We measured the rate of alkylation of 2’-deoxyguanosine in a 
mixture of TFE:MOPS buffer (50:50 v/v%, 2.7 ± 0.2 x 10 -4 M -1 s -1), which represented 
the background N7G alkylation reaction. The dielectric constant of this reaction mixture 
was parallel to that of the major-groove of DNA. The rate of thiol-activation of 1 was fast 
under these conditions (t1/2 = 9.3 ± 0.3 min). The alkylation of N7G in ds-DNA is ~ 5650 
times (initial rates) or ~ 3200 times (competition kinetics) faster than alkylation of N7 in 
2’-dG. The effective molarity of leinamycin in the major groove of DNA was found to be 
~ 6.0 M (initial rates) or ~ 3.4 M (competition kinetics). This exceeds the value of 0.8 M 
observed by Taylor and Dervan for guanine alkylation by an α-bromoketone tethered via 
a seven-atom linker to a triple helix-forming oligonucleotide bound in the major groove 
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of DNA. 33 The effective molarity of leinamycin is superior to that achieved by many 
synthetic systems that catalyze bimolecular reactions 48 but is modest compared to the 
effective molarity seen for many unimolecular and enzyme-catalyzed reactions. 49-51 
Finally, the DNA alkylation by activated leinamycin is 5.5 million times  (initial rates) or 
1.1 million times (competition kinetics) faster than its hydrolysis under physiological 
conditions.  
Noncovalent association of activated leinamycin with DNA is not remarkably 
strong, but has profound functional consequences. Noncovalent binding yields a nearly 
5650-fold (initial rates) or 3200-fold (competition kinetics) rate enhancement for the 
alkylation of guanine residues in duplex DNA versus the free 2’-deoxyguanosine 
nucleoside. The apparent second-order rate constant for the reaction of activated 
leinamycin with DNA is 5.5 million times (initial rates) or 1.1 million times (competition 
kinetics) larger than the rate for its reaction with water. Thereby, noncovalent association 
of leinamycin with the duplex drives the natural product predominantly toward the 
formation of the guanine adduct rather than hydrolysis under physiologically-relevant 
conditions.  
Finally, we devised a mathematical description of epoxide-episulfonium 
equilibrium on and off DNA, and its kinetic consequences using the “Rapid Equilibrium 
Assumption Method” 52 (Section 1.9.12.) and the method of “King & Altman” 53 (Section 
1.9.13.). 
 Noncovalent binding can concentrate reactive intermediates near the double helix, 
favoring reactions with DNA over those with water or other biomolecules. There are 
known biologically-active agents that gain their efficient DNA-alkylating properties via 
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noncovalent binding to DNA,26,27 for example aflatoxin B1 epoxide (Figure 4, KB ~ 1400 
M-1) and the “left-half” of azinomycin B (Figure 4, 19, KB ~ 1000 M-1, Chapter 5). Both 
compounds are epoxides, and their DNA alkylation takes place faster than that of a small 
molecular epoxide, glycidol. In addition, the competitive and fast hydrolysis of these 
agents does not result in appreciable yields of the hydrolysis products. The antitumor 
antibiotic CC1065 28 and duocarmycin A29-31,32 possess additional DNA-alkylating 
functional groups, and also show enhanced DNA alkylation via noncovalent DNA 
binding (Figure 4). 
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1.9. Experimental 
1.9.1. Materials and Methods.  
Leinamycin (1) was a gift from researchers at Kyowa Hakko Kogyo Ltd. Additional 
reagents were purchased from the following suppliers and were of the highest purity 
available: MOPS buffer, sodium acetate and sodium phosphate buffers, trifluoroethanol, 
triethylamine, Aldrich Chemical Co. (Milwaukee, WI); HPLC grade solvents (water, 
acetonitrile, ethanol), Fisher (Pittsburgh, PA); herring sperm DNA, Roche Molecular 
Biochemicals (Indianapolis, IN); HPLC vials, National Scientific Corporation; analytical 
HPLC columns, Varian Inc. (Palo Alto, CA). HPLC: Varian Prostar Dynamax, vs. 5.1. 
LC-MS: ThermoFinnigan TSQ7000 triple-quadrupole with API2 source. 
 
1.9.2. DNA Alkylation by Leinamycin in Aqueous Buffer Followed by UV 
Spectroscopy 
The following DNA concentrations were applied: 0.4 mM, 0.6 mM, 0.8 mM, 1.2 mM, 2 
mM, 4 mM, 6 mM and 10 mM. For simplicity, we describe the reaction with 2 mM 
DNA, here. In a 400 µL short-path UV cuvette (0.2 mM) the following components were 
mixed: 284 µL water, 16 µL leinamycin (5 mM in acetonitrile), 40 µL buffer (500 mM 
MOPS, pH 7.4 in water), 40 µL β-mercaptoethanol (10 mM in water) at 7 °C. The 
components were thoroughly mixed with the help of a long plastic pipette tip and the 
cuvette was placed into a thermostated UV cuvette holder for the activation of leinamycin 
(10 min). Finally, 20 µL DNA (40 mM in water) was mixed well into the cuvette (45 sec 
mixing time) and UV scans were carried out over the next 20 min every 5 s. 
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1.9.3. DNA Alkylation by Leinamycin Using Competition Kinetics 
In a typical reaction the following components were mixed in microcentrifuge tubes (500 
µL) in a cold-room at 4 °C: MOPS buffer (10 µL of a 500 mM stock solution), β-
mercaptoethanol (10 µL of 6 mM fresh stock in water), DNA (0-59 µL of a 30 mM 
solution in water), water (72-23 µL). Mixtures were vortexed gently, and the reaction was 
initiated with the addition of leinamycin (8 µL of a 5 mM solution in acetonitrile). The 
final solution was vortexed gently (10 s). The resulting mixtures were incubated at 4°C 
for 6 h. The final concentrations of DNA were: 0 mM, 0.8 mM, 1.6 mM, 3.2 mM, 4.8 
mM, 6.4 mM, 8 mM, 11.2 mM, 14.4 mM and 17.6 mM. After 6 h the mixtures were 
extracted at 4°C with 100 µL butanol (twice) to isolate the hydrolysis product 13 and to 
remove additional small organic molecules (β-mercaptoethanol, 1 and activated 
leinamycin, 10). The butanol extracts were collected, frozen on dry ice and dried in a 
speed-vac instrument. Dried samples were further stored at –20 °C for HPLC analysis. 
The remaining aqueous phase containing our adducted DNA was treated with 200 µL 
DNA precipitating solution (0.3 M sodium acetate in 70% ethanol, pH 5.0). Mixtures 
were vortexed and placed on dry ice for freezing for 10-20 min. The frozen samples were 
centrifuged at 4°C in an Eppendorf 5415 C centrifuge at 10.000 r.p.m. for 30 min to 
assure complete precipitation of the adducted DNA. The supernatant of the centrifuged 
samples was carefully discarded and the remaining white pellets were washed with 100 
µL 80% ethanol in water (twice). Pellets might be invisibly small-sized. The ethanol-
wash was discarded and the samples were dried under a stream of nitrogen gas. Samples 
can be stored at -20 °C before the heat-induced depurination reactions. For the 
depurination reactions, the dried DNA-adduct samples were dissolved in 50 mM MOPS 
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solution at room temperature (150 µL, pH 7.0) and incubated on a heat-block at 70°C for 
1 h to assure complete depurination. After 1 h the mixtures were cooled back to room 
temperature. The guanine adduct (12) was extracted with butanol 150 µL (twice). The 
organic extracts were collected, frozen on dry ice and dried in a speed vacuum instrument 
until complete dryness (~ 2 h). Samples can be stored at -20 °C before HPLC analysis. 
 
1.9.4. HPLC Analysis of the Yields of The Guanine Adduct (12) and The Hydrolysis 
Product (13).  
Dried samples were removed from the freezer (-20 °C) prior to HPLC-injection and 
dissolved into 150 µL of the HPLC-injection mixture (90% A and 10% B, where A, 0.2% 
trifluoroacetic acid, pH 2.0; B, acetonitrile). 25 µL of this mixture was injected onto a 
reversed-phase, narrow-bore analytical HPLC column: 0.2 mm x 250 mm x 5 µm x 120 
Å, C-18, SUPELCO. HPLC separations were done by a gradient elution program shown 
in Table 5. The eluents were: A, 0.2% trifluoroacetic acid, pH 2.0 and B, acetonitrile. 
HPLC was carried out by a VARIAN ProStar 210 HPLC instrument with Star 
Chromatography Workstation vs. 5.1.1. The wavelength of detection was 324 nm. 
Sample HPLC-s are shown in Figure 13. 
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Table 5. HPLC gradient elution solvent system used for the analysis of our reactions. Eluents: A, 0.2% 
trifluoroethanol, pH 2.0; B, acetonitrile. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. HPLC chromatogram of the products of the DNA and of the 2’-deoxyguaosine alkylation 
reactions by leinamycin. Retention times: leinamycin-guanine adduct (12) 26.5 min; leinamycin-2’-
deoxyguanosine adduct, 27.0 min; leinamycin-hydroxide (13), 29.5 min; leinamycin (1) 45.5 min; activated 
leinamycin (10) (thiol conjugate), 53 min. The concentration of DNA shown: 0.8 mM, 1.6 mM, 3.2 mM. 
DNA was incubated in the presence of 10 at 4°C for 2 h, extracted with butanol to isolate 13. Ethanol 
precipitation, heat induced depurination followed by butanol extraction was used to extract 12.  
Time  
(min) 
%A:  
 
%B:  
 
Flow rate 
(ml/min)  
0 90 10 0.2 
46 64 36 0.2 
52 35 65 0.2 
56 35 65 0.2 
62 90 10 0.2 
72 90 10 0.2 
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1.9.5. Calculation of the Relative Yields of Guanine Adduct (12) and Hydrolysis 
Product From HPLC Peak Area (13).  
We assumed that their extinction coefficients at our detection wavelength (324 nm) are 
determined solely by the Z, E-5-(thiazol-4-yl)-penta-2,4-dienone portion of the molecules 
and that their extinction coefficient at 324 nm are the same. Accordingly, the peak sizes 
(P12, P13) were measured at each applied DNA concentration (Figure 13), since only 
these two products are formed in the reactions. The relative percentage yields were 
calculated by calculating the percentage each peak area (P12 or P13) would add to the total 
peak area (P12 + P13) of these two products (Equation 5 and Equation 6). The relative 
yields were then plotted against the concentration of DNA (Figure 7, in Section 1.5.2). 
 
   
Equation 5 
 
 
Equation 6 
 
 
 
1.9.6. Measurement of the Rate of Hydrolysis (kH2o) of Activated Leinamycin (10) in 
the Absence of DNA.  
All reactions were carried out at 4 °C in a cold-room. For every reaction in our present 
studies the following stock solutions were placed in the cold-room for cooling prior to 
reaction: MOPS buffer (500 mM, pH 7.0), β-mercaptoethanol in water (6 mM), 
leinamycin in acetonitrile (5 mM) and a stop mixture (90% A and 10% B where A: 0.2% 
trifluoroacetic acid pH 2.0; B: acetonitrile), TFE, water (HPLC grade). After 30 minutes 
reactions were set up in 500 µL microcentrifuge tubes as follows: MOPS (20 µL, 500 
)(
10012%
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P
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+
=
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mM, pH 7.0), β-mercaptoethanol (20 µL, 6 mM in water), and water (144 µL). This 
solution was gently vortexed (10 s). Reactions were initiated with the addition of 1 (16 
µL of a 5 mM solution in acetonitrile), and after gentle vortexing (10 s), sample 
collection began. At different times (0 min, 1 min, 2 min, 4 min, 8 min, 12 min, 18 min, 
30 min, 50 min, 5 h, 8 h, 24 h) 15 µL aliquots were taken from the mixture and 
immediately mixed with the stop mixture (115 µL), vortexed for 20 s and placed on top 
of dry ice for freezing. Frozen samples were stored in a freezer at -20 °C. Before HPLC 
injection the samples were quickly melted at room temperature, vortexed (5 s) and 25 µL 
of this mixture was immediately injected into the HPLC and analyzed by our method 
shown in Table 5. Alternatively, to confirm our analysis, we also carried out sample 
analyses as was described by Asai et al.17 The appearance of 10 was followed (Figure 14) 
for the calculation of the rate constant of the activation of the natural product (1). The 
activation reaction was fast, a non-rate-limiting reaction: kact = 1.6 ± 0.3 x 10-3 s-1, (t1/2 = 
7.5 ± 0.5 min) (Figure 15; Equation 7). The degradation of the activated leinamycin (10) 
was followed from our HPLCs (Figure 14), and plotted as a semi-logarithmic function 
(Equation 8) vs. time (Figure 16). The slope yields the rate constant of hydrolysis of 10 in 
aqueous buffer kH2O = 4.3 ± 0.1 x 10 -5 s -1, (t1/2 = 5 ± 0.3 h). The measurements were 
carried out twice, independently and the errors were calculated by means of statistical 
analysis using confidence values at the 67% confidence level. 
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Figure 14. Sample HPLCs showing the appearance of activated leinamycin (10) in the reactions between 1 
and β-mercaptoethanol. Conditions are given in experimental. HPLCs are shown for sample collections at 
30 min, 12 h. 
 
 
Equation 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The semi-logarithmic plot for the calculations of the first order rate constant of activation of leinamycin in aqueous 
buffer (left, kact = 1.6 ± 0.3 x 10-3 s-1, t1/2 = 7.5 ± 1.5 min). Errors were calculated using 67% confidence (n=2). 
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Figure 16. The semi-logarithmic plot to calculate the first-order rate constant of the hydrolysis of 10. The 
calculated first-order rate of hydrolysis of 10: kH2O = 4.3 ± 0.05 x 10 -5 s -1, t1/2 = 5 ± 0.3 h. Errors were 
calculated using 67% confidence (n=2). 
 
 
1.9.7. Calculation of the Apparent Rates of DNA Alkylation at Each DNA 
Concentration, K2, KM. 
To calculate the apparent rate of DNA alkylation at each DNA concentration, we applied 
a blend of competition kinetic analysis with Michaelis-Menten enzyme kinetics 
employing the data in (Figure 7), using Equation 1-Equation 1. We measured the rate-
constant for the hydrolysis of 10 (kH2O) in the absence of DNA. The maximum rate 
constant for DNA-alkylation (DNA-alkylation at saturating DNA concentration, k2) was 
calculated using the ratio of the peak sizes: (P12 / P13 = k2 / kH2O ). The apparent rates of 
DNA alkylation at each DNA concentration were calculated similarly using the ratio of 
the guanine-adduct and hydrolysis products formed as shown in Equation 9.  
Equation 9 
 
The calculated apparent rate constants were plotted vs. the concentration of DNA (Figure 
8), and summarized in Table 2.  
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1.9.8. Measurement of the Rate of Hydrolysis of 10 (kH2o) in TFE:Buffer.  
Reactions were carried out at 4 °C in a cold-room. After thermal equilibration of the 
stock solutions the reaction components were mixed in 500 µL microcentrifuge tubes as 
follows: MOPS (20 µL of 500 mM, pH 7.0), β-mercaptoethanol (20 µL, 50 mM) 1 (400 
µM), water (44 µL), TFE (100 µL to a final 50% v/v). Reactions were initiated with the 
addition of leinamycin (16 µL of a 5 mM solution in acetonitrile). The mixture was 
gently vortexed (5 s). Note: [H2O] in this mixture: 27.8 M. Sample collection and 
quenching began as follows: at different times (0 min, 1 min, 2 min, 4 min, 8 min, 12 
min, 18 min, 30 min, 50 min, 5 h, 8 h, 24 h, 48 h, 96 h, 168 h) 15 µL aliquots were taken 
from the mixture and immediately mixed with the stop mixture (115 µL of a 0.2 % v/v 
TFA solution in water, pH = 2.0), vortexed for 20 s and placed on top of dry ice for 
freezing. Frozen samples were stored in a freezer at -20 °C. Before HPLC injection the 
samples were quickly melted at room temperature, vortexed and 25 µL was injected into 
the HPLC. The appearance of activated leinamycin (10) was followed for the calculation 
of the rate constant of activation kact.  We plotted ln([LM*]/[LM*]i) versus time (Figure 
17). The activation reaction was a fast, non-rate-limiting reaction: kact = 1.8 ± 0.1 x 10-3 s-
1
, (t1/2 = 9.3 ± 0.5 min). The degradation of the activated leinamycin (10) was followed 
from our HPLC (Figure 18), and plotted as a semi-logarithmic function (Equation 11) vs. 
time (Figure 19). The slope of this plot yields the rate constant of hydrolysis of 10 in the 
TFE:buffer mixture kH2O,TFE = 6.6 ± 0.2 x 10 -6 s -1, (t1/2 = 29 ± 0.7 h). The measurements 
were carried out twice, independently and the errors were calculated by means of 
statistical analysis using confidence values at the 67% confidence level. Note:HPLC 
analyses of these reactions were confirmed by the method as reported by Asai et.al. 17 
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Equation 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Plot of appearance of activated leinamycin (10) vs. time for the calculation of the rate of 
activation of leinamycin in TFE:MOPS buffer. Conditions are described in the experimental. Sample 
collection times: 2 min, 5 min, 10 min, 30 min. Errors were calculated using 67% confidence (n=2). 
 
 
 
 
 
 
Figure 18. HPLC traces of the hydrolysis reaction of 1 in TFE:buffer mixture. The times of sample 
collection are given in the text above. HPLCs are shown for times: 24 h, 48 h. The disappearance of the 
episulfonium peak at 51 min (10) was followed. 
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Figure 19. Plot of disappearance of 10 vs. time in the hydrolysis of leinamycin in TFE:MOPS buffer. 
Conditions are given in experimental. The slope of the curve yields the rate of hydrolysis: kTFE = 5.3 ± 0.3 x 
10 -6 s -1, t1/2 = 38.5 ± 3.5 h. Errors were calculated using 67% confidence (n=2). 
 
 
1.9.9. Reaction of Activated (10) Leinamycin with 2’-Deoxyguanosine in TFE:Buffer; 
the Formation of 21.  
Reactions were carried out at 4 °C in a cold-room. After stock solutions reached thermal 
equilibrium, reactions mixtures were made up in 500 µL microcentrifuge tubes 
accordingly: MOPS buffer (20 µL of a 500 mM solution, pH 7.0), 2’-deoxyguanosine (0-
100 µL 12 mM solution in TFE), β-mercaptoethanol (20 µL of a 50 mM solution in 
water), water (44 µL), TFE (100-0 µL). The mixture was vortexed gently (5 s), then the 
reactions were started with the addition of 1 (16 µL in acetonitrile). The final 
concentrations of 2’-dG were as follows: 1 mM, 2 mM, 4 mM, 6 mM. The final TFE 
content was 50 % v/v. At different times (2 h, 4 h, 8 h, 24 h, 48 h, 96 h, 168 h) small 
aliquots (15 µL) were immediately injected into the stop mixture at 4 °C (135 µL of a 
0.2% v/v TFA solution in water, pH 2.0) vortexed for 10 s and frozen on dry ice. Frozen 
samples were further stored at -20 °C.  
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Figure 20. Sample HPLCs showing the separation of products in the reaction of leinamycin with 2’-
deoxyguanosine. Peaks: 4 min: buffer, RSH; 24 min: LM-dG (21) + LM-G (12), 27 min, 44 min: 
leinamycin; 52 min: activated leinamycin. Conditions are described in Experimental. HPLCs are shown for 
8 h reaction time at the following 2’-deoxyguanosine concentrations: 1 mM, 2 mM, 4 mM, 6 mM. 
 
1.9.10. HPLC Analysis of The 2’-Deoxyguanosine Reactions.  
Samples were melted prior to HPLC injection, vortexed, and 25 µL was injected to the 
HPLC, onto an RP-C18, narrow-bore analytical HPLC-column, as described in Section 
1.9.10. Sample HPLC-s are shown in Figure 20. The ratios of the peak integrals for the 
peak of the guanine-adduct (21, 27 min) and the hydrolysis product (13, 29 min) were 
calculated from our HPLC-s (Figure 20, Section 1.9.7.), and used for the calculation of 
the pseudo-first-order rate constants and the second order rate of 2’-deoxyguanosine 
alkylation in the TFE:buffer mixture (Section 1.9.11.).  
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1.9.11. Calculation of the First- and Second-Order Rates of 2’-deoxyguanosine 
Alkylation by 10. 
First, the rate of hydrolysis of 10 had been determined in TFE:buffer mixture 
independently (Section 1.9.8.). Then, we calculated the ratios of the guanine vs. 
hydrolysis product peak integrals (P21 / P13) from our HPLC plots in the 2’-dG alkylation 
reactions (Figure 20). The pseudo first order rates of the 2’-dG reactions were calculated 
from this ratio, using Equation 12. To calculate the second order rate of alkylation, the 
pseudo-first order rates were plotted vs. the corresponding concentrations of 2’-
deoxyguanosine (Figure 11) and the slope of this plot gave us the second order rate of 
alkylation (kG = 2.7 ± 0.2 x 10-4 M-1s-1). The alkylation reactions were carried out twice, 
independently, and errors were calculated using 67% confidence. The first and second 
order rates are collected in table 2.  
 
Equation 12 
 
 
1.9.12. Kinetic Description of the Precovalent DNA-Binding and DNA Alkylation by 
Leinamycin Episulfonium in Equilibrium with its Epoxide Form Using The Rapid 
Equilibrium Assumption Method 52  
In Section 1.5.2., Equation 1 shows the Michaelis-Menten kinetic scheme for DNA 
alkylation by leinamycin. We showed that DNA alkylation by leinamycin takes place 
from a pre-equilibrium complex between the DNA and the episulfonium ion. It was 
shown by NMR that the N7-nitrogen of guanine in DNA is attached directly to the C6-
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carbon of the episulfonium ion (10 in Scheme 2). 8 The episulfonium ion exists in 
equilibrium with the epoxide form (11, Scheme 2). 17 With their structural similarities we 
assume that epoxide also binds non-covalently to DNA, and the epoxide-episulfonium 
equilibrium can interconvert these structures to one-another both on DNA and off DNA 
as shown in Scheme 4. In this Section we show the derivation of a kinetic equation for 
the Michaelis-Menten interpretation of this complex equilibrium using the Rapid 
Equilibrium Assumption method. 
 
 
 
 
 
 
Scheme 4. The equilibrium between the epoxide (11) and episufonium (10) of leinamycin, their 
noncovalent DNA binding and interconversion on DNA. 
 
 In the rapid equilibrium assumption method, we assume that k2 is much smaller 
than any of the preceding rates. The formation of the DNA adduct kinetically can be 
described by Equation 13. 
 
Equation 13 
 
The total concentration of activated leinamycin in this system is expressed in Equation 
14. 
 
Equation 14 
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Their ratio (Equation 13/Equation 14 ) is expressed in Equation 15. 
 
Equation 15 
Multiplying by [LM*] will give a more handy form in Equation 16. 
 
  
Equation 16 
 
We may introduce Vmax into this equation by a relationship from enzyme kinetics 
(Equation 17) to yield Equation 18. 
 
Equation 17 
 
 
Equation 18 
 
 
Now, we will divide each term in Equation 18 by [Epi], so that we will be able to use the 
equilibrium constants (KB, K2, K3, K4). 
 
 
Equation 19 
 
 
Equation 19 can be written into Equation 20, which only has the following terms: [DNA] 
and Ki. 
 
 
Equation 20 
 
To further shape this similar to a Michaelis-Menten equation, we divide both the 
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Equation 21 
 
In the general Michaelis-Menten equation the [DNA] term does not have a multiplying 
factor. We can cancel it by dividing both the numerator and the denominator terms with 
(1+K4) to yield Equation 22. 
 
 
 
 
Equation 22 
 
 
The laws of thermodynamics dictate the following relationship: 
 
Equation 23 
 
From the above equation we can express (1+K4) shown in   Equation 24. 
 
  Equation 24 
 
 
Equation 23 and Equation 24 will allow us to rearrange Equation 22 to a format that will 
allow us to apply our final rate equation to  the “open-loop” version of Scheme 4 (shown 
as Scheme 5). The “open-loop” equilibrium is analogous to the one in Scheme 4. “Adding 
or removing a pathway from an equilibrium system in a way that does not change the 
number of equilibrating species will not change or affect the equilibrium.” 52  The open 
loop scheme has the following parameters: k2, KB, K2, K3. 
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Scheme 5. The “open-loop” form of the complex equilibrium between the leinamycin-epoxide and the 
leinamycin episulfonium ion. This is analogous thermodynamically and kinetically to the closed 
equilibrium circle. 
 
 
 
 
 
 
 
Equation 25 
 
 
 
Equation 25 is a clear Michaelis-Menten equation, which can be used to express kcat 
(Equation 26), KM (Equation 27) and the specificity constant: kcat/KM  (Equation 1). 
 
 
Equation 26 
 
 
 
 
Equation 27 
 
 
Equation 28 
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1.9.13. Kinetic Description of Precovalent DNA-Binding and DNA Alkylation by 
Leinamycin Episulfonium in Equilibrium With its Epoxide Form Using the Method 
Of King and Altman 53  
In Scheme 4 we show that both the epoxide and episulfonium ion of leinamycin 
can bind to DNA noncovalently, and their conversion may happen on and off DNA. 
Here, we show the derivation of the Michaelis-Menten parameters using the method of 
King and Altman. For our discussion here, we used the “open-loop” form of the 
equilibrium (Scheme 5). 
In this method, N is the number of enzyme species in equilibrium (N = 4 in our 
case). Each enzyme species will be described with N-1 number of rate equations: E1  
E2 for example has two enzyme species but only one rate equation connects them.  
 
(1) We generate a “master-plan”, which is an equilateral polygon with N sides  
Figure 21. 
 
 
Figure 21. The master-plan for the King and Altman discussion of our open-loop mechanism with four-
“enzyme” species. 
 
(2) We assign each corner of our polygon with the name of the enzyme 
(leinamycin) species in the equilibrium-loop (Figure 22). 
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Figure 22. The master-plan showing the leinamycin (“enzyme”) containing species on the appropriate 
corners. 
 
 
(3) Next, let us assign each side of the master-plan polygon with the 
appropriate rate-constants. Here, the method of King and Altman connects the enzyme 
species that precedes the product formation ([Epi:DNA]) to the first one ([Epo:DNA]) 
with the rate constant of the product formation (kp). This may look misleading in 
chemical sense, but mathematically it is appropriate (Figure 23). 
 
 
 
 
 
 
Figure 23. The master-plan with its sides assigned to the microscopic rate-constants and the rate of DNA-
adduct formation (kp). 
 
(4) We can generate open-loops in four different ways (Figure 24).  
 
 
 
 
Figure 24. The four possible loop equilibrium. 
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(5) We need to generate an N x N matrix (4 x 4 here).  
i. Repeat the row in Figure 24 four times (Figure 25) 
ii. For each pattern in a row assign one of the corners as the final 
product (shown with a ball in Figure 25).  
iii. Make the sides of the open loops into single-direction arrows, and 
label them with first order rate constants. All products with [DNA] 
component will be formed with the first order rate constant 
multiplied by [DNA].  
iv. “Formulate” the assigned product in four different ways, so that 
the corresponding rate constants will be positive.  
v. Discard the matrix members that have a krev factor.  
 
Steps (5.1. – 5.5.) are shown in Figure 25. 
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Figure 25. The 4 x 4 matrix of “open-loops” for the construction of the rate equation of the 
epoxide/episulfonium equilibria off/on DNA. 
 
 
(6) We can start the construction of the rate equation algebraically now. At 
intermediate stages this equation will look complicated, however it will simplify with 
simple mathematical operations. First, we need to realize that the “sum” of all terms in 
the matrix is the total concentration of activated leinamycin [LM*] containing species in 
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the equilibrium. This will be 10 total terms, since there are 6 DISCARD terms containing 
the rate factor: krev. In addition to the six discard terms, we will discard all those having a 
rate factor: kp, since the magnitude of these will be smaller than the rest of the terms, kp 
being the slowest step in the total system. Thereby: 
 
Equation 29 
 
The ratio of the DNA-bound episulfonium to the total activated leinamycin is: 
 
Equation 30 
 
From the third row it is evident that the product forms: 
Equation 31 
 
A combination  of Equation 30 and Equation 31 will form Equation 32: 
Equation 32 
 
 
The Michaelis-Menten equation has a [DNA] term factored by one. We divide both 
numerator and denominator by (k1k2k3+k-1k-2k-3): 
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From Equation 33 we can read out the Michaelis parameters: 
 
Equation 34 
 
 
Equation 35 
 
Simplification of the kcat and the KM expression is simple by dividing both the 
numerator and denominator by k1k2k3: 
 
Equation 36 
 
 
 
 
 
 
Equation 37 
 
This is exactly the same equation that we obtained by the Rapid Equilibrium 
Assumption Method (Equation 26 and Equation 27).  
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Chapter 2. Leinamycin: A Structurally Novel DNA Intercalator 
 
 
2.1. DNA-Intercalators 
It is well known that the preferred reversible, noncovalent DNA binding mode of 
planar polyaromatic ligands (dimethyl acridine, ethidium bromide, Figure 27) is 
intercalation.1 In the process of intercalation, the planar, polyconjugated chromophore of 
the small organic molecule is sandwiched between the DNA base pairs with their pi-
electrons taking part in a stacking interaction (Figure 26). This process will change the 
structure of DNA by increasing the distances and decreasing the winding angle between 
the DNA-bases flanking the intercalators. Numerous results have suggested that a 
minimum of two fused-rings (as in naphthalene, Figure 27) are necessary for intercalative 
binding, 2,3 and intercalating drugs with two fused-rings have been classified as “minimal 
intercalators” (Figure 28, Section 2.2.).4 Intercalation can be a strong interaction (KB ~ 
104 – 106 M-1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Physical changes in the structure of duplex-DNA upon intercalation. With intercalators stacked 
in between the DNA base-pairs, the DNA molecule elongates along its long axis. At the same time, the 
winding angle between the “sandwiching” base-pairs will decrease causing the unwinding of the DNA 
duplex. Furthermore, these structural alterations will change the physical and spectroscopic properties of its 
solutions. 
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Figure 27. Classical DNA intercalators (dimethyl acridine, ethidium bromide). Finally, the structure of 
pluramycin, an anti-tumor antibiotic is presented. 
 
 
2.2. Non-Classical DNA-Intercalators 
There are small organic molecules with only one aromatic ring or non-fused ring-
structures that have been recognized to intercalate DNA (Figure 28). Such is the 
anticancer drug esperamicin A1 (Figure 28). This molecule binds the major groove of 
DNA with its methoxyanthranilate ring intercalated.5 Amiloride is an interesting non-
classical intercalator.6 The non-fused bi-thiazole component of the complex antitumor 
antibiotic bleomycin is an intercalating agent.7 Finally, the newly discovered antibiotic, 
nitrofurantoin, used in the treatment of urinary tract inflammations, has two isolated five-
membered rings that have shown DNA-intercalation. 8 
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Figure 28. Nonclassical DNA intercalators structures. Esperamycin, amiloride, bleomycin, nitrofurantoin 
and neocarzinostatin. 
 
 
2.3. Biological Consequences of DNA-Intercalation 
There are biological consequences of DNA-intercalation.9-11  Intercalators can cause 
inhibition of cell-growth, induction of cell death and cell transformation, changes in the 
chromatin structure, and inhibition of virtually any DNA or RNA dependent enzymes 
(polymerases, nucleases, helicases).12,13 Several intercalating molecules can induce single 
strand breaks in the DNA of mammalian cells.14,15 This usually happens via 
topoisomerase poisoning.16 Topoisomerases are responsible for the separation of DNA 
strands in replication and transcription. Photochemical induction of DNA nicks in the 
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presence of ethidium bromide (a widely used laboratory reagent!) has been noted. 17,18 
DNA intercalation can also have medicinally useful properties. For example, there are 
known antitumor agents that are DNA-intercalators, like pluramycin (Figure 27)19 or the 
anticancer aza-anthrapyrazoles.20 
 
2.4. Changes in DNA Structure and the Detection of Intercalation 
Intercalation causes changes in the structure of duplex DNA as discussed above.21 
This binding causes changes in the physical and spectral properties of DNA solutions, 
which can be followed to identify the intercalative binding mode of organic molecules. 
2.4.1. Biophysical Tools for Detecting Intercalation 
Viscosity:  
The lengthening and stiffening of DNA caused by intercalation (Figure 26) causes 
a characteristic increase in the viscosity of DNA-containing solutions. 1,22 Hydrodynamic 
methods such as viscosity or sedimentation measurements thus can provide evidence of 
intercalation.23 To date there have not been published reports that show that other DNA-
binding modes could give a positive response in these assays. Changes in viscosity can be 
measured in an Oswald-type flow viscometer by measuring changes in flow-time of the 
solution through the viscometer. Normally, the relative viscosities are calculated as η = 
(t/to), where t is the flow time of DNA containing solution with the intercalators, and to is 
the flow time of DNA solution without the intercalators. From this measurement, the 
DNA fragment length (L/Lo) is usually calculated as (η/ηo)1/3 and plotted versus r, where  
ηo represents the viscosity of DNA solution alone,  r represents the ratio of ligand to DNA 
base pairs. In our current work (Chapter 2 and 4), we used this assay to monitor changes 
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in viscosity as a consequence of DNA-alkylation. Alkylation of DNA by small organic 
molecules incapable of DNA intercalation does not show increases in viscosity. 24 
DNA-unwinding:  
Intercalation unwinds supercoiled plasmid DNA (Figure 26).25,26 Most groove 
binders do not cause DNA unwinding, 23 although a few do,27 so this phenomenon is 
generally used an evidence of intercalation. The unwinding of the DNA-helix can be 
studied by various experimental tools like sedimentation,28 viscometry,29 electron 
microscopy,30 and electrophoretic methods.31 We used DNA agarose-gel electrophoresis 
of plasmid DNA to monitor leinamycin-induced DNA winding effects (Section 2.7.). For 
noncovalent DNA intercalators, where the DNA topoisomers cannot be separated by 
electrophoresis due to their equilibrium exchange, unwinding usually is studied on 
linearized plasmid DNA, which is ligated into a supercoiled form after the addition of the 
suspected intercalator. 32 Depending on the degree of original unwinding, the supercoiled 
form will have different number of supercoils. The resulting different topoisomers can be 
separated and visualized on agarose gel. It is important to note here that the 
electrophoretic mobility of these topoisomers decreases with fewer numbers of 
supercoils, reaching the lowest mobility for the open-circular form of DNA (see gel 
image in Figure 33). Once rewinding takes place in the opposite direction (Figure 29), the 
electrophoretic mobility increases again. Since the agarose-gel is a chiral medium, the 
mirror-image topoisomers (topoisomers with opposite direction of superhelical structures 
but the same number of supercoils) will show different electrophoretic mobility. Overall, 
an agarose gel separation of these results is a tilted Gaussian distribution of topoisomers 
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(Figure 29 and Figure 33) along the direction of electric current versus a linear increase 
in the concentration of the intercalator.  
 
 
 
 
 
Figure 29. Plasmid DNA unwinding by increasing concentration of the intercalators. IC: intercalators. 
 
Changes in the Melting Point of DNA:  
Finally, it is worth mentioning that an increase in thermal stability of the DNA-
duplex accompanies intercalation. This is evidenced in the increase in the melting 
temperature (Tm) of the DNA. 33 Note that this effect is by no means unique to 
intercalation and is seen for any DNA-binding ligand. 
 
2.4.2. Spectroscopic Analysis of Intercalation 
Drug-DNA intercalation changes the diffraction (X-ray)34, optical (fluorescence 35 
and UV-vis23) and magnetic (NMR)34 properties of DNA and that of the intercalator. 
Accordingly, Fluorescence Contact Energy Transfer (FCET) and NMR experiments have 
been utilized in our research. These methods are introduced below.  
Fluorescence Contact Energy Transfer experiment:  
The FCET phenomenon involves transfer of energy from the donor (DNA) to the 
acceptor (intercalators) as pictured in Figure 30. 23,36 DNA is photoexcited in the range of 
200-300 nm. In the absence of intercalators, DNA will relax this excess energy in 
unwinding open circular rewinding opposite
direction (chirality)
IC IC IC IC
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molecular motions, which ultimately means that DNA shows no observable fluorescence 
under normal conditions. However, when an intercalator is stacked in between the base-
pairs of DNA, this excitation energy can be quenched by energy transfer to the 
intercalators (Figure 30). Finally, the energy obtained from DNA can be emitted from the 
intercalator molecule as light at a wavelength of its normal emission peak.  This energy 
transfer is highly sensitive to the proximity and orientation of the donor and acceptor; 
thereby, this technique can differentiate between binding modes reliably. 35 If we excite 
the system at a variety of wavelengths in the range of 220-280 nm, in the presence of 
intercalators with detection at the emission wavelength of the intercalators, we expect to 
obtain an emission intensity spectrum that resembles the UV-spectrum of DNA (Chapter 
4, Section 4.9.)  
 
 
 
 
 
 
Figure 30. The theory of the FCET experiment. UV excitation of DNA will not result in fluorescence (left 
side), since molecular motions will quench the excitation energy. An intercalator, however, can pick up 
some of the excitation energy and emit it as its own resonance energy (right side) yielding fluorescence. 
IC: DNA-intercalator. 
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NMR Experiments:  
i., The protons that are stacked in DNA suffer an upfield chemical-shift 
perturbation as a result of magneticity from ring currents induced in the DNA bases by 
the NMR magnetic field.34,37 Protons that do not take part in the intercalation will not 
suffer similar changes in their chemical shifts.  
ii., Upon intercalation, the NOE interactions between the neighboring base pairs 
at the intercalation sites will be disrupted. This can be visualized as a breaking of the 
sequential NOE-NOE connectivities in 2D-NOESY experiments. 
iii., Finally, the protons of the intercalators are expected to interact with the 
protons of the sandwiching base-pairs magnetically, resulting in ligand-DNA NOE 
signals. 
 
2.5. Leinamycin Does not Have any Structural Motifs Suggesting DNA-Intercalation  
Typical noncovalent DNA-binding structural motifs (Figure 31) are absent from the 
molecular framework of leinamycin (1) and the leinamycin episulfonium ion (10). For 
example, these agents do not have an overall positive charge that would make it bind 
DNA electrostatically, as seen in polyamines, spermidine for example. In addition 1 and 
10 do not have an extended concave curved “backbone” which would suggest that it may 
act as a groove-binder similar to distamycin (Figure 31). Finally, an aromatic ring 
structure capable of intercalation (Sections 2.1. and 2.2.) is not evident in leinamycin. 
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Figure 31. Typical noncovalent DNA-binders. Spermine: electrostatic-binder; Distamycin: groove-binder; 
ethidium bromide: DNA-intercalator and leinamycin (1), leinamycin episulfonium ion (10). Elements of 
regular DNA-binding structural motifs (overall positive charge, curved molecule, polyaromatic 
intercalator) are absent from the structure of leinamycin. 
 
 
 
2.6.  Hypothesis: Leinamycin is a Novel, Nonclassical DNA-Intercalator 
Leinamycin does not possess any structurally classical DNA binding elements 
(electrostatic binding groups, groove binding or intercalating moieties), and still it has 
been shown to bind DNA noncovalently, which is absolutely critical to efficient DNA 
alkylation.  
An initial molecular model of the N7G-leinamycin-oligonucleotide adduct 
revealed very interesting information about the DNA-adduct of leinamycin. The model 
showed that the natural product perfectly fits between the base pairs in duplex DNA. 
Additionally, the DNA-alkylating episulfonium electrophile is placed in a restricted 
trajectory in front of the N7-nitrogen of the guanine base. The natural product can only 
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approach the N7 of guanine with a limited number of trajectories (Section 2.10, Figure 
43) supporting the eventual intercalation of the Z,E-5-(thiazol-4-yl)-penta-2,4-dienone 
macrocycle in between the DNA base-pairs on top of the 3’-side of the alkylated guanine 
residue (Figure 32).  
The observed asymmetry of our model is supported by our earlier sequencing 
studies 38 showing the effect of the 3’-base neighbor on the efficiency of N7G-alkylation 
by leinamycin. Consequently, intercalation of 1 is structurally possible, and this initial 
model even shows that sufficient surface area of the natural product is available for DNA 
intercalation (Figure 32) This highlights the idea of studying DNA-intercalation by our 
natural product. Finally, it is important to realize that there are valuable cancer treating 
drugs amongst intercalators. 39,40 
 
 
 
 
 
 
 
 
Figure 32. Model building showing the positioning of leinamycin in duplex DNA attached to N7G in the 
DNA-adduct, frontal view (22), top view (23). Limited trajectories are available for leinamycin to approach 
N7G, all suggesting the eventual intercalation of Z,E-5-(thiazol-4-yl)-penta-2,4-dienone portion on the 
3’side of the alkylated guanine residue. Modeling procedures: the episulfonium.pdb file was constructed by 
ChemDraw 3D vs. 9.0. This model was energy minimized using the MM2 package of the software. The 
model was docked with into a DNA-duplex.pdb model with distance restraints between episulfonium and 
N7G. The validity of the computer model was confirmed by manual model building using plastic model 
building kit. 
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2.7. Covalent Association of Leinamycin Unwinds Plasmid DNA 
We examined whether adduct formation unwinds DNA (see introduction in Section 
2.4.1.). We alkylated plasmid DNA (PGL2BASIC) under conditions to minimize the 
depurination of the LM-DNA adduct (4 °C, 50 min). In the presence of constant DNA 
concentration (35 µM bp), an increasing concentration of leinamycin (0-1 mM) was 
applied. Samples were then mixed with stain and loaded to 0.9% agarose at 4 °C. After 
visualization of the gel, we observed that increasing equivalents of leinamycin adduct on 
DNA unwound DNA as described Section 2.4.1. (Figure 29 and Figure 33). Plasmid 
DNA alkylation by small N7G alkylators that are incapable of DNA-intercalation do not 
result in unwinding of DNA. We demonstrated this in the alkylation and electrophoresis 
of plasmid DNA by glycidol under identical conditions (Figure 34). 
This result is consistent with our intercalation model, though in rare cases it remains 
possible that groove binding could yield unwinding. 
 
 
 
 
 
 
Figure 33. The unwinding of plasmid DNA (PGL2BASIC) by increasing concentrations of 10. The 
following concentrations of 10 were used: lane 1: 0 mM, 2: 0.02 mM, 3: 0.04 mM, 4: 0.08 mM, 5: 0.1 mM, 
6: 0.15 mM, 7: 0.2 mM, 8: 0.3 mM, 9: 0.4 mM, 10: 0.5 mM, 11: 0.6 mM, 12: 0.7 mM, 13: 0.8 mM, 14: 0.9 
mM, 15: 1.0 mM, 16: 1.1 mM. 
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Figure 34. The unwinding of plasmid DNA (PGL2BASIC) by increasing concentrations of glycidol. The 
following concentrations were used: lane 1: 0 mM, 2: 0.02 mM, 3: 0.04 mM, 4: 0.08 mM, 5: 0.1 mM, 6: 
0.15 mM, 7: 0.2 mM, 8: 0.3 mM, 9: 0.4 mM, 10: 0.5 mM, 11: 0.6 mM, 12: 0.7 mM, 13: 0.8 mM, 14: 0.9 
mM. Reaction conditions and incubation times were identical to that of the unwinding experiment by 
leinamycin. 
 
 
2.8. A Transitory Fluorescence Contact Energy Transfer (FCET) Supports 
Intercalated Leinamycin 
 We alkylated CT DNA (0.8 mM) with leinamycin (200 µM) in the presence of β-
mercaptoethanol (240 µM) in 10 mM sodium-phosphate buffer at 4 °C for 2 h to 
synthesize the DNA-adduct of leinamycin (44). The adduct was diluted to 1 µM 
concentration into a quartz fluorescence cuvette and fluorescence readings were taken. 
FCET signal was calculated as described in Section 2.4.2. and in Chapter 4 for the left-
half of azinomycin. A transitory existing FCET signal was observed (Figure 35), which is 
difficult to reproduce. We think that at this low concentration, the DNA-adduct of 
leinamycin degrades quickly due to reversion (Chapter 3) to the hydrolysis product (13) 
and depurination (43, Chapter 3). 
 
 
O
OH
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Figure 35. Transitory FCET signal of a 1 uM leinamycin-DNA adduct (44). 
 
 
2.9. Viscometric Monitoring of the DNA-alkylation Reaction Demonstrates that the 
Leinamycin-DNA Adduct is Intercalated 40 
As was described above, it is possible to detect DNA intercalation by the 
accompanying change in the viscosity of DNA solutions. Based upon the adduct model 
structure (Figure 32) we suggested that the adduct should be intercalated. Thereby, we 
designed a viscometric monitoring system to follow adduct formation by viscosity 
changes in time. Similarly, time-dependent changes in vivo and in vitro have been studied 
by viscometric methods in the past. Classically, for example, the cellular degradation of 
DNA can be followed by viscosity measurements,41,42 and other cellular events, like the 
unpacking of chromosomes, have also been analyzed by kinetic viscometry.43 
Incubation of calf-thymus DNA (1 mM) with activated leinamycin (10) resulted in a 
time-dependent change in viscosity. The viscosity increased in an exponential fashion, 
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consistent with the idea that changes in viscosity parallel the chemical modification of 
DNA (Figure 36). Increasing the equivalents of leinamycin linearly increases the final 
relative viscosity, which further substantiates this idea. The half-lives were calculated by 
a non-linear regression, using an exponential rising curve fit to our experimental data. We 
found that the half-life of the increase in viscosity matched that of the DNA alkylation 
calculated from the rate of DNA alkylation (k2) earlier (Chapter 1). This data 
conclusively shows that the leinamycin-DNA adduct is intercalated into the double helix. 
On the basis of our hypothesis that the increased viscosity is the result of an 
intercalated adduct, the degradation of the adduct via depurination should reduce the 
gained viscosity. This was observed by bringing the solution to room temperature, where 
depurination is pronounced, and studying the changes of solution viscosity. A gradual 
decrease in viscosity was observed (Figure 37), eventually going below the viscosity of 
intact DNA solution. The changes in the viscosity of the DNA solution are exclusively 
characteristic of DNA-intercalation. Groove binders (distamycin in our control 
experiment) do not increase the viscosity of DNA-containing solution.23 We 
demonstrated this by titrating 1 mM CT DNA with distamycin (Figure 31). No changes 
in viscosity were observed  (Figure 38). 
It is interesting to investigate if activated leinamycin itself (10) is intercalated in DNA 
before the alkylation is accomplished. We tested this by pre-activating the natural product 
outside the DNA reaction, and transferring it to the CT DNA followed by viscometry. 
Since similar half-lives were observed for the changes in the relative viscosity, we 
concluded that activated leinamycin itself did not intercalate to a measurable extent, but 
associates with the DNA-helix by some other noncovalent binding-mode. With the 
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known binding constant of activated leinamycin to duplex DNA (KB ~ 2500 M-1, Chapter 
1), under these conditions, a minimum of 75% of activated leinamycin (10) is associated 
to DNA noncovalently. 
Finally, we tested if covalent bond formation by non-intercalating N7G-DNA-
alkylators produce increased viscosity of DNA solutions. We incubated C.T.DNA in the 
presence of dimethyl sulfate under identical conditions, and followed changes in its 
viscosity.  There was no increase in viscosity. Rather a slight reduction in viscosity was 
observed (Figure 38), probably as a result of depurination and strand cleavage.44  
Our viscosity experiments demonstrated that the natural product is intercalated in the 
DNA-adduct (Figure 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Time dependent changes in the relative viscosity of 1 mM C.T.DNA solution in the presence of 
10. Higher equivalents of the natural products produces linearly larger changes in viscosities. 
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Figure 37. Changes in the viscosity of alkylated C.T.DNA solution after it had been warmed up to room 
temperature. The decreased viscosity is the result of the depurination of the leinamycin-DNA adduct and 
the fragmentation of the DNA chains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Effect of added groove-binder distamycin (Figure 31) and small DNA-alkylator: Me2SO4 on the 
viscosity of 1 mM C.T. DNA solution. Groove binding and DNA alkylation by small molecular DNA-
alkylators do not generate extra viscosity to the DNA-solution. 
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2.10. Where Does Leinamycin Contact the Duplex During the Alkylation Reaction? 
The Harris-Stone Experiment 37,45 
We have reported that the efficiency of alkylation of a guanine base in duplex DNA 
depends on the 3’-neigboring base, which was reflected in our molecular model of the 
leinamycin-DNA adduct (Figure 32). As we have seen above, the only way that the 
intercalated leinamycin-DNA adduct can be formed from the noncovalently bound 
episulfonium (10) is to arrange its polyene moiety on the 3’-top of the alkylated guanine. 
We wished to examine where leinamycin makes any contact with the duplex during the 
alkylation reaction. We believed that this information would reveal some of the structural 
features of the transition state of the alkylation reaction. 
 
2.10.1. Quantitative Alkylation of Self Complementary Oligonucleotides can Reveal 
Which Surface of Guanine is Contacted by the Natural Product 
We alkylated self complementary sequences of DNA (24 and 25, Figure 39) with one 
guanine residue on each strand. Six-mer sequences were used, and the guanine residues 
were nearest neighbors in the middle of the strands so that either their 3’-surfaces (24, 25) 
or their 5’-surfaces (26, 27) faced one another. If alkylation requires a contact between 
leinamycin and the 3’- guanine, then the duplex with guanines facing each other with 
their 3’-surfaces (24, 25) will get alkylated only once, because one alkylation event will 
block the accessibility of the 3’-surface of the guanine on the opposite strand. On the 
other hand, the alkylation of the duplex with guanines facing with their 5’-faces will 
allow both the strands to be alkylated, because after one alkylation event the 3’-surface of 
the remaining guanine is still accessible by leinamycin. Based on our model (Figure 32) 
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and sequencing data, 38 we predicted that leinamycin should contact the 3’-surface of the 
alkylated guanine base in the process of alkylation. Note that complete alkylation 
(essentially a 100% yield in alkylation) is required for this experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. The self complementary oligonucleotides used in the leinamycin-G contact experiments. 6-mer 
self complementary sequences with one G base in each strand were designed. The guanines are nearest 
neighbors, so either their 3’-surface or 5’-surface will face one another. 
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2.10.2. Alkylation of Self Complementary Oligonucleotides and their HPLC 
Analysis 
Our initial attempts to alkylate our oligonucleotides in aqueous buffers failed 
to provide us with quantitative yield (67% per strand after multiple re-alkylation attempts 
and requiring high excess of the natural product). Since in this assay we analyze the 
yields of alkylated vs. non-alkylated strands, quantitative alkylation is essential. 
Eventually, we used a biphasic alkylation system to sequester the thiol-activated natural 
product against hydrolysis in a methylene chloride layer. On top of this we layered a 
mixture of our oligonucleotide in a buffered solution. Reactions were done at 4 °C to 
suppress depurination and the reversion of the DNA adduct. After routine purification the 
adducted oligonucleotides were studied by HPLC separation of the adducted and intact 
chain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. The HPLC of the oligonucleotides used in the Harris-Stone experiment. The humps in the 
HPLCs in the region of 27-32 min is a fluctuation of the baseline due to a quick-change in the elution 
gradient. Solvents used: A: 50 mM ammonium formate, pH 7.0, B: acetonitrile, gradient elution at 45 °C. 
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HPLC analysis reveals (Figure 41) that alkylation of the oligonucleotide 
5’…GC…3’ (24) results in 50% yield in strand alkylation, suggesting that the first 
alkylation event blocks the second guanine from alkylation. In contrast, duplex with 
sequence 5’…CG…3’ (26) undergoes double alkylation as expected. This appears as 
complete alkylation of the oligonucleotide. 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. HPLCs of the alkylated oligonucleotides in the Harris-Stone reactions. 
 
For identification of the adducts, we treated the oligonucleotide adducts (25 
and 27) with 1M piperidine at 80 °C for 1 h and analyzed their degradation products by 
HPLC (Figure 42). As expected, the HPLC peaks for the putative adducted 
oligonucleotide disappear to yield two peaks with shorter retention times (12 min 13 
min), characteristic of the cleaved degradation products of this workup. 
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Figure 42. HPLCs of the adducted oligonucleotides after their treatment with piperidine 1M, 80 °C, 1 h). 
 
In conclusion, the results show that leinamycin must make contacts on the 3’-
side of the targeted guanine in order for alkylation to occur. Based upon our additional 
data, we suspect that this contact is most probably intercalation, though the Harris-Stone 
experiment does not speak to binding mode. The results presented in this Section are in 
perfect agreement with our earlier observation that the sequence specificity of DNA-
alkylation by leinamycin is determined only by the nearest 3’-neighbor base to the 
alkylation point.38  
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Figure 43. The position of the episulfonium ion over the 3’-surface of the guanine base in the approach of 
the N7G nitrogen. The approach from the 5’-side of guanine would place the episulfonium and the N7G in 
distant locations in the context of duplex DNA. 
 
 
 
 
2.11. Effect of DNA Bulges in the DNA-alkylation by Leinamycin 
2.11.1. Occurrence of DNA-Bulges In Vivo and their Structure 
Bulged DNA structures46-53 typically cause a bend in the DNA-backbone and 
contain a base either flipped away (out) from the DNA axis51 or stacked between the 
DNA bases50 (Figure 44) . Such structures present in nucleic acids are biologically 
interesting and can be targets for therapeutics. 48 Studies show that bulged DNA 
sequences are preferential alkylation sites for numerous DNA intercalating DNA-
damaging natural products, for example neocarzinostatin (Figure 45), bleomycin, 9-
aminoacridine and Altromycin B (structures of intercalators: Figure 28).48,49,53,54 Bulged 
structures are also mutational hot-spots for frameshift mutations (insertion or deletion),55 
and their lifetime is stabilized with intercalators.54 
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Figure 44. Image of a DNA bulge. 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. Binding of neocarzinostatin in the DNA-bulge 56 
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2.11.2. Alkylation of Oligonucleotides with Bulges near the Targeted Guanine 
Bulged DNA structures can be used in the identification of DNA-intercalation.49  
We investigated the effect of DNA bulges on the efficiency of alkylation at nearby 
guanines by 10 (Figure 46). We studied the effect of one-base bulges positioned 3’ or 5’ 
to the alkylation spot on the efficiency of DNA-alkylation by leinamycin. Using 32P-
labelled oligonucleotides (28,-32,Figure 46) we found that if a bulge is present 3’ from 
the alkylation site the efficiency of alkylation increases no matter if the bulge is on the 
strand of the alkylation site (30) or the opposite strand (32). However, a bulge at the 5’ 
side of alkylation (viewed along the strand of alkylation) does not affect the efficiency of 
alkylation. The efficiency of alkylation is considerable enhanced when the bulge is on the 
3’-side of the alkylation spot (average 3.1 times), independent of whether it is on the 
strand of alkylation or the opposite strand. A smaller increase in the alkylation efficiency 
is seen when the alkylated G is in the bulge (average 1.9 times). A very slight increase is 
seen when the alkylation spot is 5’-to the bulge (average 1.4 times). The increase in the 
efficiency of alkylation of bulged sequences follow the order: bulge 3’ > bulge at 
alkylation spot > bulge 5’. In conclusion, a bulge in the DNA-structure “pre-opens” an 
intercalation site. The yields of these alkylations at the bulge Gs are tabulated in Table 6. 
The preferential binding of leinamycin to bulged-DNA sequences in a sequence 
specific manner supports the idea of its intercalation, because a bulge opens a space in the 
core of the DNA-duplex. Additional binding modes may no be affected by this opening. 
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Table 6. The increases in G-alkylation in bulged DNA sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. The sequencing gel of oligonucleotide bulged-oligonucleotides alkylated by 10 and the 
sequences. 
Sequence kbulge/kTGT POSITION kbulge/kTGT 
28 1.9 bulge 3’ to G 3.1 
29 2.8 G in bulge 1.9 
30 1.4 bulge 5’ to G 1.4 
31 1.3 
32 3.4 
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2.12. Chapter Conclusions 
We demonstrated that the leinamycin-DNA adduct is intercalated. Initial 
molecular modeling (Section 2.6., Figure 32) showed that intercalation is possible and in 
fact is the only way to place the natural product in the DNA-adduct. The features of this 
model were also supported by earlier sequencing data. 38  
The intercalation of leinamycin in the DNA adduct was supported by DNA 
unwinding (Section 2.7). A short-lived FCET signal also supports an intercalated DNA-
adduct (Section 2.8). Our viscosity studies (Section 2.9.) conclusively showed that the 
natural product is intercalated in the DNA-duplex. Alkylation of self complementary 
oligonucleotides (Section 2.10.) showed that leinamycin requires a contact with the 3’-
side of the target guanine during the DNA alkylation reaction. Finally, increased yields of 
guanine alkylations in bulged DNA-sequences, preferentially 3’-to the target guanine 
suggested that a “pre-opened” intercalation site 3’ from the target guanine increases the 
efficiency of alkylation at that site (Section 2.11.). 
Leinamycin is a structurally novel minimal DNA intercalating agent. 
 
 
 
 
 
 
 
Figure 47. The position of leinamycin in duplex DNA. 
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2.13. Experimental 
2.13.1. Materials and Methods.  
Leinamycin (1) was a gift from researchers at Kyowa Hakko Kogyo Ltd. Additional 
reagents were purchased from the following suppliers and were of the highest purity 
available: MOPS buffer, sodium acetate and sodium phosphate buffers, trifluoroethanol, 
triethylamine, Aldrich Chemical Co. (Milwaukee, WI); HPLC grade solvents (water, 
acetonitrile, ethanol), Fisher (Pittsburgh, PA); herring sperm DNA, Roche Molecular 
Biochemicals (Indianapolis, IN); HPLC vials, National Scientific Corporation; analytical 
HPLC columns, Varian Inc. (Palo Alto, CA). HPLC: Varian Prostar Dynamax, vs. 5.1. 
LC-MS: ThermoFinnigan TSQ7000 triple-quadrupole with API2 source. 
2.13.2. Plasmid DNA Unwinding by 10 
In 500 µL microcentrifuge tubes the following components were added together at 4 °C: 
2.5 µL of sodium-phosphate buffer (500 mM, pH 7.0) 3 µL of PGL2BASIC plasmid-
DNA (1 µg/mL solution), 2.5 µL β-mercaptoethanol (20 mM in HPLC water), then 11 µL 
HPLC water, followed by the following leinamycin stock solutions together with  
acetonitrile to make the total acetonitrile content of the reactions 6 µL: 1 µL or 2 µL (500 
µM leinamycin in acetonitrile), 2 µL or 2.5 µL (1 mM leinamycin in acetonitrile), 0.74 
µL or 1 µL or 1.5 µL or 2 µL or 2.5 µL (5 mM leinamycin in acetonitrile), 1.5 µL or 1.75 
µL or 2 µL or 2.25 µL or 2.5 µL (10 mM leinamycin in acetonitrile). Samples were gently 
vortexed and incubated for 50 min at 4 °C in a cold room. After incubation samples were 
treated with 6 µL of glycerol loading buffer (7 µL) containing 0.25% bromophenol blue 
and 40% sucrose, and the mixtures were vortexed gently (5 s). Samples were loaded on a 
Chapter 2 
Leinamycin: A Structurally Novel DNA Intercalator 
______________________________________________________________________________________ 
 82 
2% (m/m%) agarose-gel and electrophoresed vs. 40 V for approximately 16 h in a 4 °C-
cold-room. 
 
2.13.3. Viscometric Monitoring of DNA-alkylation by 10 And the Spontaneous 
Depurination Reaction 
 These studies were carried out in a custom-made flow viscometer (ACE Glass) 
with a 1 mL-volume sample size with a 100 s flow-time for distilled water at room-
temperature. The reactions and viscosity studies were done at 4 °C in a cold-room. 
Samples were composed of 100 mL sodium phosphate buffer (100 mM, pH 6.5), 285 µL 
calf thymus DNA solution (3.5 mM in water), 415 µL water, 100 µL β-mercaptoethanol 
(7.2 mM in water), followed by 24 µL or 48 µL or 100 µL leinamycin stock solution (5 
mM in acetonitrile) respectively, and 76 µL or 52 µL or no acetonitrile respectively. 
Samples were placed in the flow-viscometer with the help of a glass Pasteur pipette and 
bubbled. The flow times were recorded and the relative viscosity of the solution at a 
given time-point was calculated as: (t-t0)/t0 where t is the flow time of the actual data 
point, t0 is the flow time of the solution without leinamycin. The calculated relative 
viscosities were plotted vs. time (Figure 36). 
 
2.13.4. Viscometric Monitoring of DNA-Titration by Distamycin.  
For this experiment the same flow-viscometer (1 mL sample size, 100 s flow time for 
water at room temperature) was used. Titration was done at 4 °C. The initial DNA 
solution was made as follows: 100 µL sodium phosphate buffer (100 mM, pH 7.0), 100 
µL β-mercaptoethanol (7.2 mM), 285 µL calf thymus DNA solution (3.5 mM in water),  
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415 µL water. The flow time of this DNA solution was recorded and taken as t0. Aliquots 
of concentrated acetonitrile solution of distamycin (4 µL of a 25 mM solution in 
acetonitrile) were added. The resulting mixture was bubbled intensively for mixing (10-
20 s), and the flow-time was recorded. The relative viscosity was calculated and plotted 
vs. the added equivalents of distamycin (Figure 38). 
 
2.13.5. Viscometric Monitoring of the DNA-alkylation by Small-Molecular DNA 
Alkylator Dimethyl Sulfate.  
In a custom-made flow-viscometer (1 mL sample, 100 s for water at room temperature) 
the following DNA solutions was made: 100 µL sodium phosphate buffer (100 mM, pH 
7.0), 100 µL β-mercaptoethanol (7.2 mM), 285 µL calf thymus DNA solution (3.5 mM in 
water),  415 µL water. The flow time of this DNA solution was recorded and taken as t0. 
Then, a fresh stock solution of dimethyl-sulfate was prepared (100 mM in water) and 25 
µL of this solution was added to the flow-viscometer with the DNA solution. The mixture 
was bubbled for 10 s and the flow time was recorded periodically. The relative viscosity 
was calculated and plotted vs. reaction time (Figure 38). 
 
2.13.6. Alkylation of Self Complementary Oligonucleotides 24 and 26 by 10 and 
their Purification.  
Oligonucleotides 24, 26 were custom made by Integrated DNA Technologies. To 
approximately 700 nmol (for strands) oligonucleotide was added 120 µL sodium chloride 
solution (500 mM NaCl) and 90 µL sodium phosphate buffer (100 mM, pH 7.0) and 90 
µL of HPLC water. This provides a solution of ~ 2.3 mM oligonucleotide (single-strand 
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concentration, 1.15 mM for duplex concentration), 200 mM sodium chloride, 30 mM 
sodium phosphate. The mixture was vortexed well (1-2 min) to solubilize the 
oligonucleotide and placed on an 80°C-heat-block for 10 minutes. The heat-block was 
placed together with the samples in a pyrofoam box into a 4°C-cold-rooom for slow-
cooling to anneal the oligo strands over the next 12-16 h. The exact concentration was 
determined after the annealing by U.V. absorbance reading of the diluted oligonucleotide 
solution in HPLC water (A260nm = 1 of a 75 µM b.p. DNA solution which is 50 µg/mL).  
DNA alkylation was carried out in a biphasic system as reported by Stone and Harris. 37,57 
Accordingly, the 40 µL of the aqueous oligonucleotide solution (~1.15 mM for duplex 
that can be higher, 200 mM NaCl, 30 mM NaPi) was treated with 4 µL β-
mercaptoethanol solution (130 mM) in a 500 µL eppendorf tube. 100 µL leinamycin (5 
mM in acetonitrile) was evaporated to dryness under a stream of nitrogen gas, and 
redissolved into 50 µL of methylene chloride (yields a 10 mM solution of leinamycin). 
This organic solution was placed in a 4-degree cold-room for thermal equilibration. The 
cold oligonucleotide solution was placed on top of the methylene-chloride solution and 
intensive vortexing begun in a centrifuge-tube vortex mixer over the next 4 h. After the 
DNA-alkylation reaction vortexing stopped and the sample was centrifuged in a bench 
top centrifuge (1000 r.p.m., 20 s) to separate the organic and aqueous layers. The bottom 
phase was carefully removed and discarded with the help of a pipette tip. To the 
remaining aqueous DNA-adduct mixture 60 µL water (HPLC) and 100 µL cold butanol 
were added. The mixture was intensively vortexed and the top layer (butanol) was 
removed and discarded. Another portion of butanol (100 µL) was layered on the aqueous 
phase, vortexed and the butanol layer was discarded again. The aqueous layer can now be 
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analyzed by HPLC or furthered purified by DNA precipitation. For DNA precipitation 
200 µL of a precipitating stock solution (0.3 M for sodium acetate and 70% ethanol) was 
mixed with the solution and the mixture vortexed and placed on dry ice for precipitation 
for 30 min. Then, the frozen samples were centrifuged in a bench-top centrifuge 10.000 
r.p.m. fro 30 min. The DNA-pellets were washed with 50 µL of 80% ethanol twice, and 
then stored at minus 20 °C before the HPLC analysis. 
 
2.13.7. HPLC Separation and Analysis of the Oligonucleotides 24, 25, 26 and 27.  
For the HPLC separation of oligonucleotides and alkylated oligonucleotides we used 50 
mM ammonium formate pH 7.0 (solvent A) and acetonitrile (solvent B) in a gradient 
elution method (Table 7) with a flow rate of 1.5 mL/min and a RP-HPLC C18 4.6 x 250 
column heated to 45 °C in a thermostated-water bath. 
 
Time (min) B (%) 
0 1 
20 9 
26 56 
29 56 
30 80 
32 80 
37 1 
39 1 
 
Table 7. HPLC method used for the elution of our oligonucleotides 24-27. Column: RP-HPLC C18 4.6 x 
250. Temperature: 45 °C. 
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2.13.8. Polyacrylamide Gel Electrophoresis of Bulged-DNA-Sequences (28-32) after 
Alkylation with 10.  
Oligonucleotides shown in Figure 46 (Section 2.11.) were labeled using T4 
polynucleotide kinase and γ-32P ATP. The radiolabelled oligonucleotides (28-32) were 
annealed with the complementary strand by heating to 90 °C for 5 min, and slow cooling. 
The duplexes were reacted with 20 µM leinamycin in the presence of 200 µM β-
mercaptoethanol and 50 mM MOPS pH 7.0 buffer and 200 µM Herring Sperm DNA and 
100 mM sodium chloride for 2 h. Samples were extracted with equivolume butanol 
(twice). DNA was further purified by precipitation using 0.3 M sodium acetate in 70% 
ethanol. The precipitated DNA was placed on top of dry ice (30 min) and was centrifuged 
at 10.000 r.p.m. for 30 min. The supernatant was discarded, and the DNA pellets were 
further washed with 80% chilled ethanol. The DNA pellets were redissolved into 200 
mM piperidine solution and were kept at 95 °C for 30 min. After cooling samples were 
loaded onto a polyacrylamide-gel (16%) and were electrophoresed for 3h at 1200 V in 
TAE buffer. Radioactivity was visualized by phosphoimager. The Maxam-Gilbert 
G/A+G were performed following standard protocols. 58 
 
2.13.9. Fluorescence Contact Energy Transfer Experiments 
The DNA adduct of leinamycin (44) was synthesized accordingly: In a 500 µL 
microcentrifuge tube the following solutions were mixed at 4 °C: 10 µL sodium 
phosphate buffer (100 mM, pH 7.0), 10 µL CT DNA solution (8 mM in water), 10 µL β-
mercaptoethanol (2.4 mM in water) and 62 µL water. The alkylation reaction was 
initiated by the addition of 8 µL leinamycin (5 mM in acetonitrile). After 2 h 15 µL of 
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this mixture was diluted by 10 mM sodium phosphate buffer (pH 7.0) to 3 mL and placed 
into a quartz fluorescence cuvette. Fluorescence readings were taken with the following 
instrumental settings: lamp power: 75 Watts, detector: 1000 V, slots: 8 nm, integration: 
0.1 s. 
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Chapter 3. Reversible DNA Alkylation by Leinamycin and Related 
DNA-Alkylators 
 
3.1. Introduction to Reversible DNA Alkylators and their Importance 
3.1.1. Reversible DNA Intercalators 
DNA alkylation has been most commonly thought of as an irreversible covalent 
reaction between a DNA-alkylator and DNA. In only a few recent reports has it been 
shown that DNA adducts of natural products or small organic molecules can reverse with 
the release of intact DNA and either the original DNA-alkylator (CC1065,1,2 
duocarmycin A and SA,3,4 ecteinascidin 743,5 quinone methides, 6 leinamycin, 7,8, 
Scheme 6)  or their modified forms (Cyclopropyl Quinone Methides,9 base propenals,10,11 
metabolites of tobacco carcinogens: NNK or NNNAL 12,13, Scheme 7). 
3.1.2. Chemical and Experimental Considerations of Reversible DNA Alkylations 
In the chemistry presented in Scheme 6 and Scheme 7, DNA acts a leaving group. For 
N9-substituted purines (guanine, adenine) alkylated at the N7 position, the leaving group 
ability of DNA under physiological conditions can be estimated by the pKa of the 
corresponding protonated forms of the base-nitrogens (pKa N7H+: 2.1; pKa N1H+: 9.2).14  In 
addition to the leaving group ability of DNA, the ease with which the alkylating agent is 
regenerated also determines reversion. In the structure of CC-1065 and duocarmycin, for 
example, the closure of the cyclopropyl ring takes place unusually easily.2 The leaving 
group ability of the DNA-bases (G, A, C) attached to the C3-carbon of base-propenals 
correlates well with the ease of reversion.11  
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Scheme 6. Reversible DNA alkylators that are regenerated in their intact form from their DNA adducts 
during reversion. 
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Scheme 7. Reversible DNA alkylators that are regenerated from the DNA adduct in their modified form 
during reversion. 
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In cases where reversible DNA alkylation generates a small molecular species 
different from the original DNA alkylator (Scheme 7) DNA can be thought of as a 
catalyst for the transformation of the DNA-alkylating agent, 9-13 although one that acts at 
a very poor rate and yields.  
The mechanism of reversion deserves some consideration. In cases where DNA is 
attached via a tertiary carbon to the DNA-alkylator, a direct displacement of DNA in an 
SN2 attack at the carbon attached to the base by an external nucleophile is highly 
improbable for steric reasons. 15 In these situations, usually intramolecular neighboring 
group participation must promote the reversion step. This can take place in a direct 
displacement (ecteinascidin 743, leinamycin, NNK metabolite) or with the help of a β-
elimination reaction (cyclopropyl quinone methides). Another mechanism is observed in 
a deprotonation induced quinone-formation reaction (CC-1065, duocarmycin A). In a few 
cases intramolecular displacement by water was observed (NNNAL metabolite). This 
latter process only takes place when DNA is attached to a primary or secondary carbon as 
SN2 reactions do not take place readily on tertiary carbons. 15 
Reversion of DNA-adducts elongates the life time of the DNA-damaging agent in the 
proximity of DNA. Reversible DNA alkylation may allow “shuffling” of the kinetic 
alkylation products to thermodynamically more favorable sites. For example, quinone 
methides are known to alkylate the most nucleophilic (N1) nitrogen in adenine, and then 
is transferred to the thermodynamically more favorable (N6) nitrogen. 6 Migration along 
the DNA-chain is possible this way. For example, the rates of reversion of the 
Ecteinascidin 743 adduct show sequence dependence, occurring faster from 5’-AGT than 
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5’-AGC.5 This also means that the kinetic product of DNA alkylation might not 
necessarily reveal the ultimate target sequence in DNA.1 This would be revealed by a 
change in the sequence specificity of DNA-alkylation with time. 
The conformation of DNA varies in cells, which can have an impact on the 
reversibility of adduct formation. The reversion of the duocarmycin adduct, for example, 
is facile from duplex DNA, whereas in single-stranded DNA it is slow.4 On the other 
hand, as discussed below, leinamycin is released from single-stranded DNA at a higher 
rate than from the DNA-duplex.  
Rates and yields of reversion steps for some reversible DNA-alkylators have been 
reported. Some, relevant to physiological conditions, will be reiterated here. The DNA 
adduct of CC-1065 (adenine N3) was incubated in a mixture of butanol and 25 mM 
sodium phosphate buffer at 37°C at pH 7.4 for 5 days. This resulted in 20% extraction of 
the alkylator into the butanol phase.1 In this report, an essentially quantitative reversion 
of the DNA-adduct was reported at pH 8.4 under otherwise similar conditions. Reversion 
of duocarmycin-DNA adduct (adenine N3) above 50% was observed during a 4 day 
incubation at 37 °C in a butanol / 270 mM sodium phosphate buffer mixture at pH 8.0. 
This yield increased to 80% during a 6 day incubation time.4 The reversal of the 
ecteinascidin 743-DNA adduct (guanine N2) was studied 5 from 22-mer oligonucleotides 
with a single modification site. The rates of the reverse reaction from 5’-AGC, kr-1: 2.8 x 
10-4 s-1 (t1/2 = 41 min, 0.7 h) and from 5’-AGT, kr-2: 1.2 x 10-3s-1 (t1/2 = 9 min, 0.15 h) are 
clearly sequence dependent. Finally, the kinetic adduct of a quinone methide (adenine N1) 
was studied.6 This derivative hydrolyzed to 95% extent within 4 h. This work showed 
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that the released quinone methide can be transferred to additional nucleophilic alkylation 
sites in DNA (adenine N6, guanine N2, cytosine N3), which are the major adducts formed 
with this alkylating agent. 
 
3.1.3. Biological and Medicinal Consequences of Reversible DNA Alkylations 
Reversal of a bioactive natural product from its DNA adduct can elongate its life-
time as a DNA-damaging agent and may increase its mutagenic potential. The lipid 
peroxidation product malondialdehyde (MDA), for example, forms a mutagenic DNA-
adduct (M1G, shown in Scheme 7).10,16 A similar DNA-adduct formed formed under 
oxidative stress in cells with adenine can “carry” malondialdehyde to guanines to form 
M1G. This way, the life-time of MDA is increased in cells, and it is also spread further 
along the DNA strand. Additionally, it was also observed that the adenine-MDA adduct 
is more mutagenic than MDA itself.10  
Since DNA adducts are generally cytotoxic and mutagenic lesions17-21 the relative 
rates of reversion of intact DNA and that of depurination or repair of the DNA-adduct 
can determine the magnitude of their toxicity and mutagenicity.9 Along these lines it has 
been expressed that if higher reversibility was achieved in normal cells than in tumor 
cells, these alkylating agents would be selectively cytotoxic to tumor cells. 4  
Successful DNA repair might depend upon the reversibility of a DNA adduct. 
DNA-repair induced cell toxicity was reported for ecteinascidin 743.22 The ease of 
reversal of this drug depends on the sequence context of DNA. It was shown that this 
adduct induces nucleotide excision repair (NER). The repair protein assembly associates 
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the DNA adduct irreversibly, and leads to mutations and apoptosis. Using mammalian 
cell lines it was shown that ET 743-DNA adducts at different sequences with different 
inherent adduct stabilities are repaired at different efficiencies. The more stable ET 743-
lesions are repaired to lesser extent. 
Our understanding of reversible DNA alkylation by natural products is at an early 
stage. This fact itself speaks to exploring a novel reversible DNA alkylator, leinamycin. 
 
 
3.2. Initial Discovery of Reversibility in the DNA-alkylation by Leinamycin 8,23 
Our research group observed the release of the hydrolysis product of leinamycin (1) 
from highly purified DNA-adduct. This reversion probably takes place in an SN1 (first-
order) reaction with the neighboring group effect of the ring sulfur in the DNA adduct. 
With the information that SN2 reactions do not take place readily on tertiary centers,15 we 
hypothesize that the highly reactive episulfonium-ion (10) is regenerated first and then 
undergoes hydrolysis to 13. 
 
 
 
 
 
Scheme 8. The release of the hydrolysis product of activated leinamycin (10) from its purified DNA adduct 
(33). In the mechanism above, we hypothesize that the displacement of DNA happens with the help of the 
ring sulfur. 
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Suggestively, we demonstrated that leinamycin-modified DNA could “carry” 
active alkylating agent to an unmodified DNA duplex. Similarly a 2’-deoxyguanosine 
adduct of leinamycin can alkylate plasmid DNA.7 We suspected this involved the release 
of a free episulfonium ion (10) from these adducts. 
 
3.3. Goals of this Work 
The natural product leinamycin (1) has revealed novel chemistry in its DNA 
damaging reactions, 23 and it employs unique DNA binding strategies (Chapter 1, Chapter 
2) to facilitate this chemistry. With the possibility that this natural product is also a 
reversible DNA-alkylating agent, additional unexpected chemical activities are expected 
to be found in leinamycin. Additionally, leinamycin would be the first reversible DNA-
alkylating natural products that targets the N7 nitrogen in guanine. 
- We set out to measure the rates of reversion from the DNA-duplex and from single-
stranded DNA under physiological conditions. With this information we can 
calculate the relative yields of reversion/depurination, which would be important in 
evaluating what determines the cellular fate of the natural product. We will also 
learn here if the DNA-duplex promotes or inhibits the reversion. 4  
- We investigated whether the small N7G alkylator antitumor agent chlorambucil (34, 
Scheme 9) and a sulfur-mustard (CEES, 37, Scheme 9) 24 similarly alkylate DNA 
reversibly. These compounds are important as drugs and war gases. Our work 
stands to reveal an important, unrecognized property of these drugs and toxins. 
These molecules alkylate DNA via aziridinium or episulfonium intermediates, 
Chapter 3 
Reversible DNA Alkylation by Leinamycin and Related DNA-Alkylators 
______________________________________________________________________________________ 
 103 
respectively, and at a fundamental level, their adducts are structurally analogous to 
leinamycin’s.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9. The structures and DNA-alkylating forms of the nitrogen-sulfur: chlorambucil (34) and CEES 
(37). 
 
 
 
- Finally, we examined whether thiols of different leaving-group ability (β-
mercaptoethanol: pKa = 9.5; glutathione: pKa = 8.5 and thiophenol: pKa = 6) and the 
biologically abundant chloride ion (Cl-: pKa = - 4) would reversibly add to activated 
leinamycin. Reversible addition of these or related thiol molecules to activated 
leinamycin could effectively extend the cellular life-time of this DNA-alkylating 
agent, and help “carry” the natural product to its target in the cell nucleus. 
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3.4. Proposing a Tentative Mechanism for the Reversion of 10 from the DNA 
Adduct (33) 
 
A kinetic mechanism for reversible DNA alkylation by LM can be proposed (Scheme 
10). 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. Release of activated leinamycin (10) from the DNA adduct (33) and its further hydrolysis to 
yield the leinamycin-hydroxide (13) with simultaneous depurination to 43. The structures of 13 and 33 and 
43 are shown. In the mechanism above we used results from earlier studies 23 that showed 
disproportionation of 10 between hydrolysis and depurination to yield 13 and 43, respectively. 
 
 
 
A simple inspection of this mechanism suggests that the relative yields of LM-OH and 
LM-G should depend on the concentration of DNA in the reaction. Low DNA 
concentration disfavors the formation of the noncovalent complex: [10 • DNA], thus 
disfavoring alkylation versus hydrolysis to 13. We derived a kinetic equation for this 
mechanism (Section 3.5.). We examined the yields of 13 and 43 (Section 3.6.). We 
measured the rate of decomposition of the leinamycin-DNA-adduct and calculated krev 
under different conditions (Sections 3.8. and 3.9.). 
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3.5. Steady State Analysis to Derive a Rate Equation for our Hypothesized 
Mechanism 
We derived a rate equation from our proposed mechanism (Scheme 10 and Scheme 
11 below). The concentration of the DNA adduct gradually will decrease in time by the 
two terminal reactions in a competitive fashion (Equation 39). These reactions are the 
depurination of the leinamycin-DNA adduct (kG) and the hydrolysis of the released 
episulfonium ion (10).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Mechanism of reversion of the leinamycin episulfonium ion (10) from the leinamycin-DNA 
adduct (33), with the equilibrium constant Kx. 
 
The newly introduced “equilibrium constant”: 
 
Equation 38 
 
The degradation of the adduct in time: 
Equation 39 
 
 
To eliminate the factor: [10] from the equation we expressed it using the equilibrium 
constant (Equation 38): 
kcat / krev = Ke
KB x Ke = Kx
13 10  +  DNA [10]   [DNA] 33
koh kgKb kcat
krev
H2O
43
"Ke"
hydrolysis 
product
DNA-adduct depurination
product
]][10[
]33[
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K x =
]10[]33[]33[ OHg kkdt
d
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Equation 40 
 
 
…this rewrites Equation 39 to Equation 41 below: 
Equation 41 
 
Rearranging Equation 41 to express the time dependence of its concentration change will 
give us Equation 42. 
 
Equation 42 
 
Integration of Equation 42 will result in Equation 43: 
 
Equation 43 
 
This equation above describes the actual concentration of the leinamycin-DNA adduct 
[33] at any given time point in the incubation reactions. 
From Equation 42 and Equation 43 the rate of the degradation of the leinamycin-DNA 
adduct (33) can be expressed, Equation 44. 
 
Equation 44 
 
Since DNA was fully converted to the adduct, the following is true: [DNA] ≈ [33], 
thereby: 
 
Equation 45 
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Equation 45 shows that the degradation of the leinamycin-DNA is the result of two 
reactions, the apparent rate of depurination (kg, :rate of appearance of the depurination 
product in the incubation of the DNA-adduct ) and apparent hydrolysis (Equation 46: rate 
of appearance of the hydrolysis product in the incubation of the DNA-adduct). 
Equation 46 
 
 
Please, note that the apparent rate constant of hydrolysis here (k(OH)app, the rate at which 
the appearance of the LM-OH product is observed in the incubation of pure DNA-adduct) 
is different from the rate of the pure hydrolysis of leinamycin (kOH). Also, note that the 
apparent rate of depurination (kg) is the observed rate of appearance of the depurination 
product in the incubation of the leinamycin-DNA adduct. As shown by Equation 46 and 
later confirmed by our results, k(OH)app and the final yield of 13 (Figure 49) will depend on 
the concentration of the adduct in the incubation. At the same time, kg is independent of 
the concentration of the DNA-adduct incubated at a given temperature. However, the 
yield of the depurination product will change with the concentration of the DNA-adduct, 
since the k(OH)app is changing with the concentration of the adduct [33]. 
Measuring the rate of the disappearance of the leinamycin-DNA adduct (kLM-DNA) and 
measuring  the apparent rate of depurination (kg) and the rate of the appearance of the 
hydrolysis product (k(OH)app) in the same experiment, allows us to calculate the rate of the 
reversal step (krev). Note that a measurement of the noncovalent association constant (KB), 
the maximum rate of DNA alkylation (kalk) and the “inherent” rate of hydrolysis of the 
leinamycin episulfonium ion (kOH) needs to be done in independent experiments.  
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The yield of the hydrolysis product in the incubation of pure leinamycin-DNA adduct 
(from reversal Chemistry) can be expressed as the ratio of the rates of the terminal 
reactions: 100 x k(OH)app / kg. This ratio is expressed in Equation 47. 
Equation 47 
 
 
Accordingly, the yield of the hydrolysis product will decrease in a hyperbolic fashion 
with increasing adduct concentration. Accordingly, the yield of the depurination product 
should increase. 
Our data for the yields of LM-G and LM-OH at various DNA adduct concentrations 
perfectly fits this equation. At higher concentrations of the DNA-adduct, we see a 
decrease in the yield of the hydrolysis product (13).  
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An alternative mechanism for the formation of the hydrolysis product (13) would be the 
direct displacement of the LM-OH from duplex DNA by water as shown in Scheme 12.  
 
 
 
 
 
 
Scheme 12. Mechanism of reversion via direct displacement of hydrolysis product (13) by water from the 
DNA adduct (33) with the competitive depurination to the leinamycin-guanine molecule (43). 
 
An analysis by Steady-State theory and derivation shows that the yield of the hydrolyzes 
product (13) would not depend on the concentration of the incubated DNA-adduct, 33 
(Equation 48) 
Equation 48 
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3.6. The Yields of 13 and 43 Confirm our Reversion Mechanism 
We incubated LM-DNA at 37 °C in 50 mM sodium phosphate buffer at pH 7.0 for 48 
h at different adduct concentrations, and followed the production of 13 and 43 in time 
(Figure 48). Upon accomplishment of the degradation of the DNA-adduct, the yield of 13 
(Figure 50) and the yield of 43 (Figure 49) were calculated at each adduct concentration. 
Our observed yields followed that proposed by our kinetic mechanism (Section 3.5.). 
Dilution of the DNA-adduct dilutes each reaction component, which will eventually help 
the disintegration of the DNA-adduct, and result in increased yields of reversion (the 
hydrolysis product, 13). This has been predicted by the kinetic description of our 
mechanism (Section 3.5., Scheme 10, Equation 47).  
 
 
 
 
 
 
 
 
 
Figure 48. The appearance of the hydrolysis product (13) and the depurination product (43) from the DNA-
adduct (33) of leinamycin (1) versus time. 
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Figure 49. The yield of the hydrolysis product (13) from the DNA-adduct (33) via reversion. Conditions: 
Incubation at 37 °C in 50 mM sodium phosphate buffer (pH 7.0) for 48 h. Concentrations of the purified 
DNA adduct (33): 0.1 mM, 0.2 mM, 1 mM, 2 mM, 5 mM, 10 mM.  
 
 
 
 
 
  
 
 
 
 
Figure 50. The yields of the depurination product (43) in the reversion chemistry. 
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3.7. How do we Exclude “Carry Over”?  
In the case of carry over, the hydrolysis of the released episulfonium ion (kOH) and 
the depurination of the DNA-adduct (kG) would be independent of each other. Assuming 
an initial n% carry over and 100-n% adducted leinamycin, upon the accomplishment of 
hydrolysis and depurination, the n% episulfonium would be converted to n% hydrolysis 
product and the 100-n% adduct would be converted to 100-n% depurination product, and 
would be independent of the concentration of the DNA in the degradation studies. 
 
 
 
 
 
 
Scheme 13. Mechanism of the generation of the hydrolysis product of leinamycin (13) via noncovalently 
bound “carry over” episulfonium. 
 
 
 
Such is not the case for reversal. As we have shown in our kinetic description 
(Section 3.5.), the release of the hydrolysis product should follow a hyperbolic 
dependence on the DNA-adduct concentration (Equation 47). This will consequently 
force a concentration dependence of the final yield of the depurination product in the 
reversal Chemistry. 
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3.8. Calculation of the Rate of Reversion (krev) 
We incubated our DNA-adduct at 2 mM concentration in 50 mM sodium phosphate 
buffer (pH 7.0) at 37 °C, and followed the time appearance of the hydrolysis product (13) 
and the depurination product versus time (43). Non-linear regression of the products 
versus time curve (Figure 48) to a rising exponential allowed us the calculation of the rate 
of degradation of the adduct (kLM-DNA). Using Equation 45 (repeated below), with an 
independent measurement of kOH, (4.3 ± 0.5 x 10 -5 s-1, t1/2 = 4.5 h), KB, (1000 M-1) and 
kalk (9.1 x 10-4 s-1, t1/2= 13 min ) (Chapter 1), we were able to calculate krev = 1.5 x 10-4 s-1, 
t1/2 = 1.3 h. Please note that in Equation 45, the rate of depurination (kg = 4.0 x 10-5 s-1, t1/2 
= 4.8 h) is the apparent/observed rate of appearance of the depurination product from the 
adduct in our incubation calculated from Figure 48, using non-linear regression. 
 
Equation 45 
From the data above we can conclude that the DNA adduct is more prone to reversion 
than to depurination (krev/kg = 3.7). This simply means that reversion is favored 
kinetically over depurination. 
The yields of 13 and 43 (Section 3.6) show us that eventually the winner of these 
reactions will be the depurination reaction. This is the consequence of the binding forces 
(KB ~ 1000 M-1 and Ke = 6, KB x Ke ~ 6000 M-1, Ke = kalk/krev) that holds the reversed 
natural product in the major-groove of DNA until the adduct bleeds out to depurination. 
Please, notice that the equilibrium between the non-covalently bound episulfonium (10 • 
DNA) and the covalent DNA-adduct (33) is in the direction of the adduct formation: Ke = 
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“kalk/krev = 6” (∆G° ~ 1 kcal/mol). This equilibrium constant shows that leinamycin is 
more stable in the form of the covalent DNA-adduct than in the noncovalent complex [10 
• DNA]. 
 
3.9. The DNA Duplex Stabilizes the Leinamycin DNA-Adduct (33) 
To compare the rates of reversal from duplex DNA to that of single-stranded DNA, 
we incubated the ss-DNA adduct of leinamycin (5’-TATATGCATATA-3’) at 2 mM 
adduct concentration at 37 °C, in 50 mM sodium phosphate buffer. We followed the 
appearance of the products in time by HPLC. Nonlinear-regression allowed us to measure 
the rate of degradation of the single-stranded DNA-adduct (kTOTss). We calculated the rate 
of reversion similarly to the situation for the duplex-DNA-adduct (Section 3.7). This, 
however, required us to use the same binding constant (KB) and rate of DNA alkylation 
(kalk) originally found for the alkylation of duplex-DNA. Finally, the rate of reversion for 
this system is: krev, ss-DNA =  3.2 x 10 -4 s-1 (t ½ = 0.6 h). Please, note that leinamycin 
would bind to single-stranded DNA less efficiently than to duplex DNA (KBss < KBds) and 
would alkylate single-stranded DNA at a lower rate (kalk-ss < kalk-ds). With our measured 
kTOT, using a lower KB and lower kalk in Equation 45, the “real” krev for the reversal 
Chemistry of the single-stranded DNA-adduct would be somewhat different. 
Nevertheless, the measurement of reversion from single-stranded DNA should give us the 
true krev. The real rate of reversal (krev-ssREAL) would be smaller.  
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Physically, the faster reversion from the single-stranded DNA in comparison to the 
duplex-DNA-adduct is the consequence of decreased adduct stabilization in the single 
stranded DNA. Interestingly, even the measured rate of depurination was faster from the 
single-stranded DNA-adduct (kgss > kgds), suggesting that the leinamycin-DNA-adduct 
enjoys stabilization in the context of duplex-DNA. Note: The depurination of the single-
stranded DNA adduct of leinamycin (kgss) was directly measured in these experiments.  
We compared the rates of reversion (Figure 52) and the rates of depurination (Figure 
52) and the yields of the final products (Figure 53) in bar graphs, below. A closer 
inspection of these bar-graphs helped us understand that the DNA-adduct of leinamycin 
is stabilized by duplex-DNA (Figure 51). The ratio: kalk / krev is greater than 1 in both 
cases, which shows that the equilibrium between the noncovalently associated adduct of 
activated leinamycin (10•DNA) and the covalently bound LM-DNA adduct (33) favors 
the covalent adduct (33), shown in Figure 51.  
 
 
 
 
 
 
 
Figure 51. The Equilibrium between the 10•DNA complex and its covalent adduct (33) favors the covalent 
DNA-adduct (33) of leinamycin in both single-stranded and duplex-DNA. 
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Figure 52. Comparison of the rate constants of reversion (left), rate constants of depurination (right) in the 
degradation of the DNA-adduct (33) in single-stranded and in duplex-DNA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 53. The yields of end products 13 and 43 = LM-G (left) and the ratio: kcat/krev in the degradation of 
the DNA-adduct (33) in single-stranded and in duplex-DNA. 
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3.10. Reversible Guanosine Alkylation by Structural Analogs of the Leinamycin-
DNA Adduct 
We set out to examine if the regeneration of the intact guanine base is possible from 
the N7-guanosine adduct of the anti-tumor agent chlorambucil (34) and that of CEES 
(37) under physiological conditions. Such reaction would involve the neighboring group 
attack of the heteroatom (N or S, respectively) on the carbon bound to the N7-nitrogen 
with a transient formation of an aziridinium or episulfonium ion (Scheme 14). We looked 
for the appearance of the hydrolysis products and the regeneration of intact guanosine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 14. Proposed mechanism of reversion of guanosine from the N7-guanosine adduct of chlorambucil 
(44) and that of CEES (47) 
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3.10.1. Synthesis of The N7-Guanosine-Chlorambucil (44) and N7-Guanosine CEES 
(47) Adducts 
First, we developed a synthesis of the N7 adducts (44, 47). Our attempt in using flash-
chromatographic or preparative-TLC purification of the products failed. The starting 
materials, the expected products and the impurities turned out to be inseparable using 
either silica or reversed-phase-based separation methods. Our attempts for their 
recrystallizations failed, too. We anticipated that the HPLC purification of the adducts 
would be tedious, requiring high loads of HPLC solvents and desalting at the end, so 
eventually, we decided to synthesize 44 and 47 in stochiometrically controlled fashion in 
2,2,2-trifluoroethanol solvent. DMF, DMSO, and THF solvents did not give us 
acceptable yields. Reactions were run at room temperature until the total disappearance 
of the starting materials and were followed using RP-HPLC (Figure 55 and Figure 58). 
Since CEES is undetectable by HPLC, the synthesis of the N7-GUO-CEES adduct was 
finished by evaporating the excess CEES from the mixture under high vacuum. LC-MS 
(Figure 56 and Figure 60) and NMR characterization revealed the regiochemistry of the 
adducts and concluded that they formed on the N7 nitrogen of guanosine in both 44 and 
47. The regiochemistry (N7 vs. N2 or O6 adducts) is confirmed by the chemical shift of 
the C8-H, 25 the presence of the N2 chemical shifts and the effect of added deuterium-
oxide (D2O) on the exchangeable protons of guanosine in the adduct. 8 
 
 
Chapter 3 
Reversible DNA Alkylation by Leinamycin and Related DNA-Alkylators 
______________________________________________________________________________________ 
 119 
3.10.2. Reversal of Sulfur Mustard and Nitrogen Mustard Guanosine-N7 Adducts of 
Chlorambucil and CEES 
Guanosine adducts (44, 47) were incubated in buffered solutions at 4°C and 37 °C 
for 3 days, and analyzed by HPLC. In the case of 44, the reappearance of the hydrolysis 
product of chlorambucil (18 min peak in Figure 54 and Figure 57) and in the case of 47 
the reappearance of intact guanosine (13 min peak in Figure 58, and Figure 59) were 
taken as signs of reversion. The percentage reversion was calculated from these product 
peaks. The adducts were found fairly stable, with 85% remaining intact. In both cases a 
minor reversion (total yield x < 2.9%) was observed (Table 8). Corrected for the 
remaining starting material this change is more significant: (~15%). The percentage 
reversion found for 44 and 47 was less than that of leinamycin (up to 20%). We explain 
this by the pre-organized nature of the natural product leinamycin for the intramolecular 
displacement reaction compared to the rather flexible adducts in 44 and 47 (Table 8).  
 
 
 
 
 
 
 
 
 
 
Table 8. Percentage reversible decomposition of 33, 44 and 47 and their structures. 
Adduct 4 °C (3 days) 37 °C (3 days) 
33 ~ 12% N.A. 
44 0.3% 2.3% 
47 2.3% 2.9% 
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Figure 54. HPLC-trace of the hydrolysis products of chlorambucil (34) 
 
 
 
 
 
 
 
 
Figure 55. HPLC-trace of the N7-guanosine adduct of chlorambucil (44) 
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Figure 56. Mass Spectrum of the N7-guanosine adduct of chlorambucil (44)  
 
 
 
 
 
 
 
 
 
 
Figure 57. The HPLC-trace of N7-guanosine adduct of chlorambucil (44) after exposure to aqueous buffer 
(50 mM MOPS, pH 7.4, 3 days). 
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Figure 58. HPLC trace of the N7-guanosine-CEES adduct (47) 
 
 
 
 
 
 
 
 
 
 
Figure 59. HPLC-trace of the N7-guanosine-CEES adduct (47) after exposure to aqueous buffer (50 mM 
MOPS, pH 7.4, 7 days) 
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Figure 60. Mass spectrum of the N7-guanosine-CEES adduct (47) 
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3.11. Reversible Addition of Chloride Ion and Thiols to Activated Leinamycin and 
its Potential Role in Stabilizing and Carrying the Leinamycin Episulfonium Ion. 
 We set out to study if nucleophiles, other than the N7-nitrogen of guanine can add 
to the episulfonium ion in a reversible fashion. Such studies are interesting, because cells 
contain thiols and negatively charged species at considerable concentrations (thiols: 0-10 
mM,26 chloride ion ~ 200 mM27). The leaving group abilities of these nucleophiles cover 
a wide range from glutathione (pKa = 8.5), protein thiols (5 < pKa < 9), chloride (pKa = -
4).  
We hypothesized that reversible thiol or chloride adduct may be able to “carry” 
the leinamycin episulfonium ion in cells and protect it from nonproductive hydrolytic 
decomposition (Scheme 15). It is known that hydrolytic instability can limit the DNA-
alkylating efficiency (and the biological activity) of other agents such as nitrogen 
mustards.28 
 We expect that soft thiols (β-mercaptoethanol, pKa = 9.0; glutathione, pKa = 8.5) 
would add in a Michael-Fashion to the conjugated thiazole-dienone portion (the “left-
half”) of leinamycin (42). Consequently, harder thiols, like thiophenol (pKa = 6.5) would 
rather favor adduct formation with the harder electrophile, the three-membered-ring of 
the episulfonium (41). Similarly, we expect chloride ion to add directly to the 
episulfonium-ring (40, Scheme 15). 
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Scheme 15. Hypothesized thiol/chloride adducts of the alkylating form of leinamycin (10). Such adduct 
may “carry” and “protect” the episulfonium ion in cells. 
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3.11.1. Soft Thiols: β-Mercaptoethanol (pKa = 9.5) and Glutathione (pKa = 8.5) May 
Carry Leinamycin in the Form of Michael-Adducts on The Thiazole-Dienone 
Moiety of Leinamycin (42) 
 We hypothesized that activated leinamycin (10) will reversibly react with thiols as 
shown in Scheme 15. Accordingly, in the presence of increasing concentrations of thiols, 
the apparent concentration of the free episulfonium ion will decrease, and so will its rate 
of hydrolysis to 13. We aimed to study the rate of hydrolysis of 400 µM leinamycin in the 
presence of increasing concentration of thiols (1-6 mM), in 50 mM MOPS buffer at room 
temperature, using HPLC. We followed the disappearance of activated leinamycin (10) 
and the appearance of the hydrolysis product (13) at 324 nm (Figure 61).  
 
 
 
 
 
 
 
 
 
 
Figure 61. General HPLC trace of the hydrolysis products and activated leinamycin (10) after exposure to 
different thiols or the sodium chloride. Note: the shown retention times are 15 minutes less from the actual, 
as the trace above was recorded with 15 minutes delay in acquisition. 
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We noticed that the rate of degradation of the activated leinamycin (10) increases 
with increasing thiol concentrations (Figure 62), consistent with our hypothesized 
mechanism (Scheme 15).  
 
 
 
 
 
 
 
 
Figure 62. The rate of consumption of the leinamycin episulfonium ion (10) versus the applied thiol 
concentrations. 
 
 
We followed the hydrolysis of leinamycin (200 µM) in 50 M MOPS buffer (pH 
7.4) in the presence of two different concentrations of β-mercaptoethanol (1 mM, Figure 
63 and 8 mM, Figure 64) at 37 °C. At lower β-mercaptoethanol concentration (1 mM) 
activated leinamycin was quantitatively converted to its hydrolysis product (13). 
According to our UV-data, the hydrolysis of 10 to 13 in the presence of 1 mM β-
mercaptoethanol takes place with the direct conversion of 10 to 13 (isosbestic point, 
Figure 63) and without much final loss of absorbance at 350 nm. At 8 mM β-
mercaptoethanol concentration, however, the yield of the hydrolysis product (13) was 
found to decrease gradually with time. These reactions were also followed by UV, and 
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the “loss” of leinamycin in the presence of 8 mM β-mercaptoethanol was accounted for 
by the loss of the conjugated chromophore in the leinamycin-macrocyle. This takes place, 
probably in a Michael-Addition reaction of the thiol to the conjugated dienone 
functionality of the episulfonium ion (10) (42, Scheme 15), and also to the molecule of 
the hydrolysis product, 13 (Scheme 16). This is supported by the absence of isosbestic 
points in the UV of the hydrolysis reaction at 8 mM β-mercaptoethanol (Figure 64).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. Changes in the UV of 200 µM activated leinamycin (10) in 50 mM MOPS buffer (pH 7.4) at 37 
°C in the presence of 1 mM β-mercaptoethanol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64. Changes in the UV of 200 uM activated leinamycin (10) in 50 mM MOPS buffer (pH 7.4) at 37 
°C in the presence of 8 mM β-mercaptoethanol. 
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Scheme 16. Hypothesized Michael-Addition of soft-thiols to the leinamycin chromophore in the molecule 
of the hydrolysis product (13). 
 
Further investigations are required to find the thiol-adducts in HPLC and identify 
their composition by LC-MS methods. It would also be interesting to study the fate of the 
purified hydrolysis product of leinamycin (10) in the presence of 8 mM β-
mercaptoethanol or glutathione. These studies are in progress now. 
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appearance of four new peaks was found in our HPLC-s (A1-A4, Figure 65). These new 
peaks interconverted into each other, and eventually were converted to the HPLC-peak of 
the hydrolysis product (13). 
The slow conversion of the new adduct peaks (A1-A4) to that of 13 allowed us to 
calculate a rate constant for the alkylation reaction, using non-linear regression. The rates 
of hydrolysis of leinamycin were plotted vs. the concentration of thiophenol (Figure 66), 
and found to decrease with increasing concentration of thiophenol. 
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Figure 65. HPLC traces of the hydrolysis reaction of activated leinamycin (10) in the presence of 
thiophenol at room temperature, in 50 mM MOPS, pH 7.0 buffer after 1h incubation. The retention times 
shown here are 15 min less than the actual retention times due to delayed data acquisition. [thiophenol]: 
top, 400 µM; middle, 800 µM; bottom, 2 mM 
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Figure 66. The rates of hydrolysis of activated leinamycin (10) versus the concentration of thiophenol. 
Leinamycin (200 µM) was hydrolyzed in 50 mM MOPS buffer (pH 7.4) in the presence of thiophenol (1-3 
mM). 
 
 The pattern of peaks in our HPLC (Figure 65) and the retained absorptivity of the 
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Figure 67. The hypothesized thiophenol adducts of the leinamycin episulfonium ion (10) 
 
 
 
 
 
 
 
 
N
S
N
H
O
H
O
H
HO
S CO2
OH
10
N
S
N
H
O
H
O
H
HO
S CO2
OH
OH
13
N
S
N
H
O
H
O
H
HO
S CO2
OH
S
N
S
N
H
O
H
O
H
HO
S
S
CO2
OH
N
S
N
H
O
H
O
H
HO
S
CO2
OH
H2O
PhPh
S
Ph
N
S
N
H
O
H
O
H
HO
S
CO2
OH
S Ph
A1
A2
A3 A4
Ph-SH
Ph-SH
Ph-SH
Ph-SH
Chapter 3 
Reversible DNA Alkylation by Leinamycin and Related DNA-Alkylators 
______________________________________________________________________________________ 
 134 
3.11.3. Chloride Ion is a Carrier of Leinamycin (40) 
 Finally, we initiated studies to examine whether the physiologically profuse 
chloride ion27 is able to “carry” the leinamycin episulfonium and protect it against 
hydrolysis (Scheme 17). We incubated 400 µM leinamycin in 50 mM MOPS buffer (pH 
7.4) at room temperature, and followed the appearance of the leinamycin hydrolysis 
product (13) by HPLC. Rates of hydrolysis were calculated by non-linear regression 
analysis of the appearance of 13, and plotted versus time (Figure 68). Very interestingly, 
the rate of hydrolysis of 10 dramatically decreases (~ 10 times) in the presence of the 
physiological concentration (200 mM) of sodium chloride. For a comparison, 500 mM 
sodium chloride was shown to increase the half-life of chlorambucil 3.5 fold.29 This data 
is in line with our proposed mechanism (Scheme 17).  
 
 
 
 
Scheme 17. The hypothetical chloride-adduct of the leinamycin episufonium ion (10). 
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Figure 68. The rates of the disappearance of the episulfonium ion (here also the rate of hydrolysis) in the 
presence of various concentrations of sodium chloride. 
 
 
Since we did not find an “adduct-peak” characteristic for the chloride adduct in our 
HPLC, probably doe to the quick disintegration of the adduct in HPLC eluent, this 
experiment was confirmed by following the hydrolysis of 200 µM 10 in the presence of 
200 mM sodium chloride by UV absorbance measurements (Figure 69). 
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recorded during the hydrolysis of 10 in the presence of 13 does not show the clear 
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the conversion between more than two species, supporting our mechanism for the 
episulfonium-chloride adduct (Scheme 17). The retained chromopore at 350 nm suggests 
that chloride adds to the episulfonium ring (40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69. UV spectra recorded in the hydrolysis of 200 µM 10 in 50 mM MOPS buffer (pH 7.4) in the 
presence of 200 mM sodium chloride. 
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3.12. Discussion 
3.12.1. Reversal of Leinamycin From DNA 
We investigated the reversibility of DNA alkylation by the leinamycin episulfonium 
ion (10). In this process, the regeneration of intact DNA and the episulfonium ion (10) is 
expected. Our data is consistent with a unimolecular regeneration of activated leinamycin 
(10). We also showed that if the product of this reversion Chemistry arose by a direct 
attack of water on the DNA-adduct, the relative yields of 13 and 43 would not be 
dependent on the DNA concentration (Section 3.5.). We also explained that the 
appearance of 13 from the DNA adduct cannot be “carry over” (Section 3.7), because, in 
this case, the final yields of 10 and 43 had been already determined in the relative 
amounts of the leinamycin-DNA adduct and the activated leinamycin “impurity” on 
DNA, before the degradation reaction. Noticeably, the yields of the hydrolysis product 
(10) are very high (x > 22 %) at lower physiological  DNA concentrations. This parallels 
those found for CC-1065 1,3 and for duocarmycin,4 though smaller than in case of the 
readily reversible DNA-adduct of ectenaiscidin.5 This helps us appreciate that reversal of 
activated leinamycin may occur to an important extent in cells. The yield of the reversion 
product becomes invisible at higher DNA concentration. Higher DNA concentrations 
favor the formation of the noncovalent complex: [10 • DNA]. Under such conditions, 10 
simply “back-reacts” with DNA and will ultimately be found in the depurination product, 
rather than the hydrolysis product. Indeed, in single-stranded DNA, where noncovalent 
binding of 10 to a duplex structure obviously cannot occur, we observe that loss of adduct 
and conversion to 13 is fast (Section 3.9). Kinetic analysis of the reaction at 2 mM adduct 
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concentration indicated a rate of reversion from duplex DNA:  krev = 1.5 x 10-4 s-1, (t1/2 = 
1.3 h), and rate of reversion from single-stranded DNA:   krev, ss-DNA =  3.2 x 10 -4 s-1 (t ½ 
= 0.6 h). Interestingly, these measured rates of reversion are very close to those found for 
the readily reversible DNA-adduct of ecteinascidin.5 The rate of reversion from single-
stranded DNA should provide a clean measure of the krev step. Gratifyingly, we observed 
that this rate is similar to that calculated for the duplex DNA-adduct. 
Overall, our data indicates that reversal of the leinamycin-DNA adduct in duplex 
DNA is facile and may allow the migration between kinetic and thermodynamic 
alkylation sites in DNA.6 A further study would be interesting to find out whether the 
sequence preference of DNA alkylation by leinamycin changes in time. At this point, it is 
interesting to note that DNA-damaging agents preferentially alkylate the more accessible 
inter-nucleosome linker DNA regions of the chromosomes (Figure 70).30 Reversal of the 
natural product would help the spreading of the DNA-damaging agent to other, less 
accessible surfaces of the genomic DNA (Figure 70) for a more extensive DNA damage. 
 
 
 
 
 
 
Figure 70. Alkylation of DNA in the chromosome structure takes place preferentially in inter-nucleosome 
Sections of DNA. Reversible DNA alkylators have the capacity to spread to other parts of the genome with 
time. 
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3.12.2. Reversal of Sulfur Mustard and Nitrogen Mustard DNA Adducts 
 It is intriguing to see the product of reversion of the guanine adducts of nitrogen 
mustards and sulfur mustards (Section 3.10.2.). It remains unclear now, if the reversal 
appears as the result of direct hydrolysis or reversal of the adduct. A kinetic analysis 
could be employed to find out the mechanism. For example, if reversal is responsible for 
the observed products, then trapping of the adduct with thiocyanate would be 
independent of the concentration of thiocyanate: [SCN-]. We could also examine whether 
mustard-nucleoside adduct could act as a transporter to carry alkylating agent to 
unmodified DNA fragment. We expect to observe the characteristic aziridinium ion or 
episulfonium ion sequence specificity if reversal occurs. 
 
3.12.3. Reversible Addition of Chloride and Thiols to Activated Leinamycin 
 We have shown that thiols (β-mercaptoethanol, glutathione and thiophenol) can add 
to activated leinamycin. Using a combination of HPLC and UV analyses (Section 3.11.1., 
Figure 63 and Figure 64), we can propose that softer-thiols (β-mercaptoethanol, pKa = 9; 
glutathione, pKa = 8.5) presumably add to the conjugated thiazole-dienone moiety of 
activated leinamycin (10) or the leinamycin hydrolysis product (13), presumably in a 
Michael-Addition reaction (42, Scheme 16). Further studies are needed to find and 
identify these adducts in HPLC, LC-MS experiments. Using a similar experimental 
setting, we suggest that the hard-thiol: thiophenol (pKa = 6.0) adds to the small 3-
membered episulfonium ring in the activated leinamycin molecule (41, Section 3.11.2., 
Figure 67).  
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We also showed that the presence of chloride ion slows the hydrolysis of 10 dramatically 
(Section 3.11.3). We suggested that this might happen via an adduct formation between 
the chloride ion and activated leinamycin. This adduct formation probably takes place in 
the 3-membered ring of the episulfonium ion (40, Scheme 17), which is concluded from 
our UV experiments (Figure 69). It is very intriguing to realize that the chloride-
concentration should be much decreased in the hydrophobic DNA-grooves, where DNA-
damage takes place. Thereby, in proximity to DNA, the salt adduct is disintegrated and 
activated leinamycin is released. 
 It is interesting to note here that the leinamycin producing species of Streptomyces 
does not contain glutathione in its cells. These species bio-synthesize a small gluco-thiol: 
mycothiol (Figure 71). It is interesting to think about the role of mycothiol as a “carrier” 
of leinamycin, to protect Streptomyces from suicide by its own drug. 
 
 
 
 
 
Figure 71. The structure of mycothiol, found in the leinamycin-producing Streptomyces species. 
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3.13. Conclusions 
3.13.1. DNA Damaging Strategies of Leinamycin 
With our experiments presented in Chapter 1, Chapter 2 and this Chapter, we can propose 
a map of the strategic reactions of leinamycin in facilitating the DNA-damaging 
Chemistry in host cells, while protecting the producing organism at the same time 
(Scheme 18). Accordingly, when leinamycin is produced by Streptomyces, the natural 
product might be sequestered in a thiol or chloride adduct to protect it from unproductive 
hydrolysis and to save the cell from suicide. In host cells, similar chemistries work in 
concert to save the DNA-damaging potential of the natural product, and to “carry” it to 
DNA for an effective DNA-damaging reaction. 
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Scheme 18. The map of the strategic reactions of leinamycin  (1) to protect the producing organism and to 
facilitate its DNA-damaging Chemistry in host cells. 
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3.13.2. Reversal of Activated Leinamycin from DNA Makes DNA-Repair an Energy 
Wasting Process 
Finally, it is interesting to imagine how reversal wastes the energy of the cell in its 
attempt to repair the DNA-adduct of leinamycin by nucleotide excision repair (NER). 
Accordingly, nucleotide excision repair excises a short piece of the adducted DNA, 
containing the DNA-adduct (Scheme 19).31 The reversion of activated leinamycin takes 
place from this piece of single-stranded DNA-adduct. The activated leinamycin (10) 
alkylates DNA again. This cycling is simply a vain utilization of cellular energy. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 19. Nucleotide excision repair of the leinamycin-DNA-adduct (33) shown as an “energy-wasting” 
process, only to elongate the cellular life-time of the activated leinamycin. 
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3.14. Experimental 
3.14.1. Materials and Methods 
Leinamycin (1) was a gift from researchers at Kyowa Hakko Kogyo Ltd. Additional 
reagents were purchased from the following suppliers and were of the highest purity 
available: MOPS buffer, sodium acetate and sodium phosphate buffers, trifluoroethanol, 
triethylamine, Aldrich Chemical Co. (Milwaukee, WI); HPLC grade solvents (water, 
acetonitrile, ethanol), Fisher (Pittsburgh, PA); herring sperm DNA, Roche Molecular 
Biochemicals (Indianapolis, IN); HPLC vials, National Scientific Corporation; analytical 
HPLC columns, Varian Inc. (Palo Alto, CA). HPLC: Varian Prostar Dynamax, vs. 5.1. 
LC-MS: ThermoFinnigan TSQ7000 triple-quadrupole with API2 source. 
3.14.2. Preparation of The Leinamycin DNA-Adduct 
In a 500 µL microcentrifuge tube 100 µL of 20 mM calf thymus DNA was added as well 
as 20 µL of 100 mM sodium phosphate buffer (pH 7.0), 20 µL of β-mercaptoethanol (in 
water) and 44 µL of HPLC water. The mixture was vortexed gently (5 s) and the DNA 
alkylation reaction was initiated with the addition of 16 µL leinamycin (5 mM in 
acetonitrile). The sample was incubated for 4 h at 4 °C. Under these conditions DNA 
alkylation proceeds with a minimum of 75% yield and the available alkylation sites are in 
excess. After the incubation samples were extracted using 200 µL butanol (twice) to 
purify the DNA adduct from small-molecular impurities and unbound 10 (activated 
leinamycin), the remaining aqueous phase was treated with 400 µL DNA precipitating 
solution (0.3 M sodium acetate in 70% ethanol), vortexed and kept on dry ice for 30 min. 
The frozen samples were centrifuged at 10,000 r.p.m. in a 4 °C for 30 min. The 
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supernatant was carefully discarded and the remaining DNA pellets were washed with 
200 µL chilled 80% ethanol at 4 °C (twice). The pellets were dried under a stream of 
nitrogen gas, and kept at minus 20 °C before incubation for reversion studies.  
 
3.14.3. Incubation of the leinamycin DNA-Adduct (33) at Varying Concentrations 
To study the fate of the DNA adduct (depurination to the  leinamycin guanine adduct 43 
and reversion to 13) we incubated 33 at six different concentrations (0.1 mM, 0.2 mM, 1 
mM, 2 mM, 5 mM, 10 mM). The DNA adduct pellets were redissolved into water to 
make a 15 mM stock solution. The exact concentration was determined by U.V. 
absorbance measurements (A260nm = 1 is 75 µM for base pairs or 50 µg/mL). The 
reactions were mixed in 500 µL microcentrifuge tubes to a final volume of 100 µL. In 
these samples the following components were mixed: DNA-adduct (0.7 µL, 1.4 µL, 6.7 
µL, 13.3 µL, 33 µL, 66 µL), 10 µL sodium phosphate buffer (100 mM, pH 7.0), HPLC 
water (89.3 µL, 88.6 µL, 83.3 µL, 76.7 µL, 57 µL, 24 µL). Samples were vortexed gently 
and incubated at 37 °C for 48 h. Afterwards incubation samples were extracted with 100 
µL butanol (three times) for their contents of 13 and 43. The extracts were frozen on dry 
ice and dried in a speed-vac centrifuge. The dried samples can be stored at minus 20 °C 
before HPLC analysis.  
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3.14.4. HPLC Analyses 
HPLCs were run on a Varian-Prostar instrument with 210 solvent delivery system and 
Star Chromatography vs. 5.1.1. Column: RP-C18 (ODS), Supelco: 2.1 mm diameter x 
250 mm, 5 µm. Applied flow rate: 0.2 mL/min, using A: 0.2 % TFA + 0.1 % TEA, B: 
acetonitrile in a gradient elution method (Table 9). 
 
 
 
 
 
 
Table 9. The gradient HPLC-method used for the analysis of products in the work presented in chapter 3. 
Solvent system: A: 0.2% TFA + 0.1% TEA, B: acetonitrile. Column: ODS Supelco (RP-HPLC, C18) 2.1 x 
250 x 5 µm. Flow rate: 0.2 mL/min. 
 
 
3.14.5. Calculation of the Yields of 13 and 43 in the Complete Degradation of the 
DNA-Adduct via Depurination and Reversion.  
The yields of reversion / depurination at the complete degradation of 33 (37 °C, 2 days) 
were calculated as is given in equations 12 and 13. P13 is the peak size for the hydrolysis 
product (13), P43 is the peak size for the depurination product (43). 
 
Equation 49 
 
 
Equation 50 
 
 
Time (min) %B 
Start 10 
0-42 10-34 
42-52 34-65 
52-56 65 
56-62 65-10 
62-72 10 
4313
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PP
P
+
4313
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PP
P
+
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3.14.6. Measurements of the Rate of Product (13, 43) Formation at 0.5 and 2 mM 
DNA-Adduct Concentrations for the Calculation of the Rate of Reversion: krev.  
The synthesized DNA adduct pellet (synthesis described above) was removed from the 
minus 20 degree refrigerator and dissolved into water to make a stock solution (10 mM). 
The exact concentration was adjusted with the help of UV-absorbance measurement 
(A260nm = 1 is 75 µM for base pairs or 50 µg/mL). The incubation mixtures for the 0.5 
mM and the 2 mM reactions were composed as follows: 10 µL sodium phosphate (100 
mM pH 7.0) and 5 µL or 20 µL DNA (10 mM in water) and 85 µL or 70 µL water 
(HPLC). Samples were gently vortexed for 5 s and placed into a 37 °C oven for 
incubation. At different times (1 h, 5 h, 12 h, 24 h, 44 h, 98 h) 10 µL was removed from 
the solution and diluted to 100 µL with 10 mM sodium phosphate buffer (pH 7.0). This 
diluted solution was extracted with 100 µL butanol (twice). The butanol phases were 
collected, frozen on dry ice and dried in a speed-vac instrument. The dried samples can 
be stored at minus 20 °C before HPLC analyses. At the time of HPLC analyses sample 
was redissolved into the HPLC injection mixture (90%A and 10% acetonitrile, where A 
is: 0.2% TFA). Samples were immediately injected into the HPLC as described above. 
The peak size for the sum of hydrolysis product and depurination product (P13 + P43) 
were plotted vs. time (Figure 48). An exponential rising curve was fitted to these plots 
and the time factor of this curve was used as the rate constant for the given reaction. For 
the calculation of the rate of reversion (krev) in each case, the kinetic rate equation 
(Equation 45) devised in Section 3.5. was used. 
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3.14.7. Degradation of the Leinamycin-DNA-Adduct from ss-DNA.  
In a 4 °C cold-room in a 500 µL eppendorf tube (microcentrifuge tube) was added 100 
µL of a 20 mM 12-mer oligonucleotide (5’-TATATGCATATA-3’, annealed earlier to 
duplex form) solution in water, 20 µL of sodium phosphate buffer (pH 7.0) and 20 µL β-
mercaptoethanol (in water) and 44 µL of HPLC water. This mixture was vortexed gently, 
and the DNA alkylation reaction was initiated with the addition of 16 µL of leinamycin 
stock solution (5 mM in acetonitrile). The mixture was incubated at 4 °C for 4 h.  After 
incubation, the samples were extracted with 200 µL butanol (twice). The remaining 
aqueous phase was treated with 400 µL DNA precipitating solution (0.3 M sodium 
acetate in 70% ethanol), vortexed gently and kept in dry ice for 30 min. The frozen 
samples were centrifuged at 10,000 r.p.m. in a 4°C for 30 min. The supernatant was 
carefully discarded and the remaining DNA pellets were washed with 200 µL chilled 
80% ethanol at 4 °C (twice). The pellets were dried under a stream of nitrogen gas, and 
kept at minus 20 °C before incubation for reversion studies.  
At the time of incubating the ss-DNA adduct for reversion studies, the dried 12-mer 
oligonucleotide-adduct was removed from the refrigerator and was dissolved using 10 
mM sodium phosphate buffer. The final concentration was adjusted with the help of U.V. 
absorbance measurements (A260nm = 1 is 75 µM for base pairs or 50 µg/mL). Incubation 
started in a 37°C-oven (12-mer melts to single-stranded) and at different times, aliquots 
of 10 µL were removed from the mixture, diluted to a final volume of 100 µL with water, 
and extracted with 100 µL of butanol (twice). The organic layer was collected, and dried 
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in a speed-vac instrument. The dried samples can be stored at minus 20 °C. At the time of 
HPLC analyses samples were analyzed as described before. 
 
3.14.8. Synthesis of the N7-GUO Adducts of Chlorambucil (44) and CEES (47).  
In a small vial (5 mL) 5.0 mg of guanosine (0.018 mmol) was dissolved in 1.5 mL TFE. 
The solution was sonicated for 20 min to disperse guanosine. This resulted in the 
formation of a blurred solution. To this solution 0.014 mmol chlorambucil was added 
from a 500 mM stock solution in acetonitrile (29 µL). Stirring began and continued for 
approximately 4 days. The disappearance of chlorambucil was followed by RP-HPLC. 
After the completion of the reaction, the mixture was stored at minus 20 °C. The 
synthesis of the N7-GUO-CEES adduct (47) was carried out similarly. After 4 days, 
however, the mixture containing the CEES adduct was evaporated to dryness under high-
vacuum, to evaporate the unreacted CEES, as this species cannot be detected in HPLC. 
The dried material was dissolved in TFE (1.5 mL) and stored at minus 20 °C. The 
concentration of these solutions is 10 mM.  
 
3.14.9. The fate of 44 and 47 in Aqueous Buffers.  
The incubation mixtures were made of 500 mM MOPS buffer (pH 7.4, 40 µL) and 320 
µL of HPLC water and 40 µL of the N7-GUO-chlorambucil adduct (10 mM) or the N7-
GUO-CEES adduct (in TFE, 10 mM). Solutions were mixed well and incubated at 37 °C. 
At selected times, 35 µL of the mixture was added to 105 µL of 50 mM ammonium-
acetate buffer (pH 6.5), and injected to the HPLC for analysis. Samples were studied for 
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the reappearance of intact guanosine for both the chlorambucil and CEES adducts, and 
for the appearance of the hydrolysis product of chlorambucil. 
 
3.14.10. HPLC Analyses used to Study the Reactions of Chlorambucil (34) and 
CEES (37). 
HPLC samples were made as described above and 25 µL was injected onto an RP-HPLC, 
C18, Varian 4.6 mm x 250 mm x 5 Å column. Gradient elution program was used with 
the following eluents: A: 50 mM ammonium-acetate (pH 6.5) and B: 50 mM ammonium 
acetate (pH 6.5) in 50% acetonitrile. The gradient used was: 0% B for 5 min, 0%-100% B 
in the next 30 min, 100% B for the next 9 min, 100%-0% B in the next 2 min, 0% B for 2 
min. Detection: 265 nm.  
 
3.14.11. Hydrolysis of Leinamycin (1) in the Presence of Increasing Amounts of 
Sodium Chloride.  
The preparation of the reaction mixture with 1 M sodium chloride is explained: in a 500-
µL microcentrifuge tube we placed 44 µL of water, 20 µL MOPS buffer (500 mM, pH 
7.0), 20 µL of β-mercaptoethanol in water (4.8 mM), 16 µL of leinamycin in acetonitrile 
(5 mM) and 100 µL sodium chloride (1 M in water). Mixture was vortexed well (5 s) and 
reactions were incubated at room temperature. At selected times 20 µl of the samples 
were injected to 220 µL of a stop mixture (0.2 % TFA at pH 2.0). This mixture was 
vortexed quickly (5 s) and placed on dry ice. This sample was melted prior to HPLC 
injection, and 25 µL was injected onto an RP-C18 (ODS) HPLC column, Supelco: 2.1 
Chapter 3 
Reversible DNA Alkylation by Leinamycin and Related DNA-Alkylators 
______________________________________________________________________________________ 
 151 
mm diameter x 250 mm, 5 µm. Applied flow rate: 0.2 mL/min, using A: 0.2 % TFA + 0.1 
% TEA, B: acetonitrile in a gradient elution method (Chapter 1, Experimental). 
 
3.14.12. Hydrolysis of Leinamycin in the Presence of Increasing Concentrations of 
β-mercaptoethanol, Glutathione and Thiophenol.  
The preparation of the reaction mixture containing 5 equivalents of added thiol is 
explained here. Into a microcentrifuge tube (500 µL) we added 69 µL HPLC water and 
20 µL MOPS buffer (500 mM, pH 7.0) followed by 50 µL of thiol (8 mM in 
acetonitrile:water 30:70 v/v%) and 45 µL acetonitrile and finally 16 µL of leinamycin (5 
mM in acetonitrile). Mixture was vortexed well (5s) and incubated at room temperature. 
Please, note that the reaction mixtures consist of 30% acetonitrile. At selected times 20 µl 
of the samples were injected to 220 µL of a stop mixture (0.2 % TFA at pH 2.0). This 
mixture was vortexed quickly (5 s) and placed on dry ice. This sample was melted prior 
to HPLC injection, and 25 µL was injected onto an RP-C18 (ODS) HPLC column, 
Supelco: 2.1 mm diameter x 250 mm, 5 µm. Applied flow rate: 0.2 mL/min, using A: 0.2 
% TFA + 0.1 % TEA, B: acetonitrile in a gradient elution method (Chapter 1, 
Experimental). 
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Figure 72. NMR of the N7-guanosine adduct of chlroambucil. 
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Figure 73. NMR of the N7-guanosine adduct of CEES.
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Chapter 4. DNA Alkylation and DNA-Binding by Analogs of the Left-
Half of Azinomycin: A Minimal DNA-Intercalating Structure 
 
 
4.1. The Chemistry and Biology of Azinomycins and the Left-Half of Azinomycin 
 
Carzinophilin (Azinomycin B, 49, Figure 74) was first reported in 1954 when it 
was found in the screening of soil anaerobes for antitumor activity. Azinomycin B was 
isolated from the fermentation broth of Streptomyces sachachiroi. 1 In addition, a 
structural analog (Azinomycin A, 50, Figure 74) and Azinomycin B were independently 
isolated from Streptmyces grizeofuscus. 2 They show similar antitumor activities. 3,4 
Azinomycin B was shown to increase the life-span of rodents with leukemia (P388) and 
provided up to a four times increase in the life expectancy in rodents with Ehrlich 
carcinoma and Yoshida carcinoma. 4 These compounds may decompose physiologically 
to the truncated analogs, the “left-halves” (Figure 75), which have been shown to retain 
most of the biological activity of the original natural product. 5 Studies on the left-half 
analogs showed that the epoxide functionality is essential for the biological activity of 
these molecules 4,6,7 
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Structural analyses of Azinomycin B later revealed that it is identical to 
Carzinophilin (49). 5 The total synthesis of these molecules 7-12 and their truncated 
analogs6,10,13-16  have been carried out by a variety of routes. 
 
 
 
 
 
 
Figure 74. Carzinophilin (Azinomycin B) and Azinomycin A. 
 
 
The Azinomycins were shown to associate with the major groove of duplex DNA 
sequence specifically (5’GNT3’ and 5’GNC3’ sequences).17 These natural products are 
bifunctional DNA alkylating agents. They form interstrand crosslinks at the N-7 position 
of purine bases. In the crosslinking reaction, these molecules sequentially alkylate the N7 
nitrogen of adenine in a ring opening of the aziridine moiety followed by the N7 nitrogen 
of guanine with the epoxide functionality (Scheme 20). 
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Figure 75. The analogs of the Left-Half of Azinomycin 
 
 
 
Scheme 20. DNA Alkylation and Crosslinking by the Azinomycins. 
 
 
Our research group showed that the neutral naphthoate unit of 49 and 50 
intercalates DNA. 18 This is noteworthy, because such functionalities only show DNA 
intercalation if they are in a bis-intercalating system or have a positive-charge that helps 
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their DNA-binding. 19-22 The contribution of intercalation by the aromatic rings to the 
biological efficiency of these compounds was also demonstrated in cytotoxicity assays 
with analogs of azinomycins devoid of this functional group. 6  
The left-half of azinomycin binds to DNA noncovalently 18 and retains DNA-
alkylating abilities (Figure 75). Our group showed that this DNA-alkylation is sequence 
specific. 23 The DNA-binding mode of 51 and its analog 52 (Figure 78 and Figure 79) has 
been a topic of debates, thus our goal was to carefully characterize mechanisms of non-
covalent DNA binding and DNA-alkylation by the left-half of azinomycin. 18,24,25  
 
 
4.2. Goals of this Work 
 
1. We wanted to confirm the structure of the azinomycin-epoxide guanine-adduct 
using characteristic reactions and LC-MS methods (Section 4.3.).  
2. We carried out model building experiments to determine whether intercalation of 
the Azinomycin-guanine adduct is structurally reasonable. 
3. We set out to examine whether the naphthoate ring of the azinomycin DNA-
adduct is intercalated, using a variety of biophysical and spectroscopic methods. We also 
addressed the question of whether neutral naphthoates intercalate DNA without covalent 
association. 
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4.3. Identification of the DNA Alkylation Product by LC-MS 
We alkylated CT DNA (1 mM) with 51 (250 µM) in MOPS buffer (50 mM, pH 
7.0). We isolated the guanine adduct of 51 by quantitative depurination of the DNA-
adduct. The guanine adduct was dissolved in HPLC water, and the mixture was injected 
into a Thermo-Finnigan TSQ7000 triple-quadrupole mass spectrometer with the API2 
source (ThermoFinnigan, San Jose, CA). Similar identifications of N7-purine adducts 
have been reported earlier. 26,27 The Total Ion Current and the spectra are shown in Figure 
76. The guanine adduct of 51 (Figure 77) was identified at the m/z value of 480.3. The 
regiochemistry of 51 on guanine in DNA was identified as N7-guanine adduct, in its 
characteristic depurination reactions, which are followed using HPLC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 76. The TIC (a) and the LC-MS of the guanine adduct (b) of the left-half of Azinomycin (51). The 
guanine adduct of 51 is suggested by the m/z value at 480.3. 
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Figure 77. The guanine adduct of 51. 
 
 
 
4.4. Initial Chemical Model of the Left-Half-Oligonucleotide Adduct 
We constructed a molecular model of the DNA adduct of 51. (Figure 78 and 
Figure 79). This model revealed that intercalation of the aromatic naphthoate ring-system 
onto the 3’-surface of the alkylated guanine can happen without disruption of the B-DNA 
helix (Figure 78). On the other hand, the reorganization of the model to put the aromatic 
rings in a stacking position over the 5’-surface of the alkylated DNA-base seemed to 
cause steric clashes between the phosphate backbone of DNA and that of the 5-atom-
linker connecting the naphthoate to guanine (Figure 79). The distinction between these 
two possibilities is not so well pronounced in the models, although overall they are in 
close agreement with the sequence specificity observed by Dr. Hong Zang earlier in our 
laboratory (Ph.D. thesis, University of Missouri-Columbia).28  
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Figure 78. Chemical model showing 51 intercalated into a short oligonucleotide on the 3’-surface of the 
alkylated guanine residue. This model suggests efficient intercalation and a comfortable placement of the 5-
atom-linker in the duplex without any obvious distortion of the B-DNA helix structure. 
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Figure 79. Chemical model showing 51 intercalated on the 5’-surface of the alkylated guanine residue. 
This model suggests an efficient intercalation but only with a simultaneous steric congestion of the 5-atom-
linker with the backbone of DNA, which would distort the B-DNA helix. 
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4.5. Kinetics of DNA Alkylation by 51 and its Rate Acceleration by Noncovalent 
Binding 
 
We set out to characterize the noncovalent DNA-binding and DNA-alkylation by 
the left-half of azinomycin using kinetic tools, similar to our work with leinamycin 
(Chapter 1). As a part of this work we hoped to estimate the rate acceleration and 
equivalent molarity provided by noncovalent binding of the natural product’s naphthoate 
residue.  
4.5.1. DNA-alkylation by 51 Follows Michaelis-Menten Kinetics 
Using a constant concentration of 51 (250 µM), we alkylated different 
concentrations of duplex DNA with a mixed sequence (600 µM, 2.4 equiv; 1200 µM, 4.8 
equiv; 4000 µM, 16 equiv) in MOPS buffer (50 mM, pH 7.0) at room temperature. At 
different times the reaction mixture was extracted to remove unreacted 51 and heated to 
depurinate the DNA-adduct quantitatively. The depurination product (52) was isolated by 
extraction and studied by HPLC. The guanine adduct of 51 in this method shows up at 23 
min, the hydrolysis product of 51 elutes at 27 min (Figure 80). Formation of the DNA 
adduct was followed by the gradual appearance of the guanine adduct peak of 51 and was 
plotted versus time (Figure 81).  
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Figure 80. The products of DNA alkylation and hydrolysis of 51 separated by RP-HPLC. Buffers: 4 min, 
guanine adduct: 24 min; hydrolysis product: 28 min, 51: 32 min. 
 
 
 
 
 
 
 
 
Figure 81. The appearance of the guanine adduct in the DNA alkylation reaction by 51 (250 µM) versus 
time and the applied DNA concentrations. 
 
 
Since the only product of this reaction is the guanine adduct, a nonlinear 
regression was used to fit exponential curves to the data and the initial rates were 
calculated from the first derivatives at x  t0 condition. 29 The initial rates and the half-
lives of DNA alkylations are summarized in Table 10. 
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[DNA] in (mM) Initial rate of 
alk. by 51 in (s-1) 
Half-life in (h) 
0 0 n.a. 
0.6 10.2 x 10-5 1.9 
1.2 13.9 x 10-5 1.3 
4.0 17.9 x 10-5 1.1 
 
Table 10. The initial rates and initial half-lives of DNA alkylation by 51 (250 µM). Applied concentrations 
of DNA (600 µM; 1200 µM; 4000 µM) 
 
 
We realized that the rates of DNA alkylation follow a saturation curve when 
plotted against the concentration of DNA (Figure 82). This information suggested that we 
apply a pseudo-Michaelis-Menten model (Equation 51) to fit these rates of adduct 
formation vs. the applied DNA concentrations. The Michaelis-Menten plot and additional 
linearized forms of the initial rates versus DNA concentration data (Eadie-Hofstee, 
Hanes-Woolf,  Lineweaver-Burk; Figure 83) were used to calculate the maximum rate of 
DNA alkylation (VMAX), the Michaelis constant (KM), the binding constant (KB). These 
values are tabulated in Table 11. 
 
 
Equation 51 
 
 
 
 
 
 
 
 
 
 
 
[51] [DNA] [51]  [DNA] [51-DNA]+
noncovalent coomplex adduct
k1
k
-1
k2
Chapter 4 
DNA Alkylation and DNA-Binding by Analogs of the Left-Half of Azinomycin: a Minimal 
DNA-Intercalating Structure 
______________________________________________________________________________________ 
 169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82. Michaelis-Menten plot of the initial rate constants of DNA alkylation by 51 vs. the applied 
DNA concentrations. The calculated Michaelis-parameters: The averaged values from the different 
graphical analysis: KM = 4.5 x 10 -4 M; KB =2200 M-1; maximum rate of DNA alkylation: k2 = 18 x 10-5 s-1 
(t1/2 = 1.1 h) 
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Figure 83. Linear representations of the initial rates of DNA alkylation by 51, Eadie-Hoostee plot (top); 
Hanes-Woolf plot (middle), Lineaweaver-Burk plot (bottom). The averaged values from the different 
graphical analysis: KM = 5.89 x 10 -4 M M; KB =1697 M-1; maximum rate of DNA alkylation: k2 = 14.34 x 
10-5 s-1 
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Table 11. Tabulated maximum rate (VMAX) and half-life of DNA-alkylation by 51, the Michaelis parameter 
(KM) and the noncovalent binding constant (KB).  
 
 
 
DNA alkylation by 51 follows Michaelis-Menten kinetics (Equation 51). Effective 
DNA alkylation is facilitated by a pre-covalent association of the drug to the duplex-
DNA molecule. Our measured binding constant is in good agreement with earlier 
measurements using biophysical methods.28 
 
 
 
4.5.2. The rate of Hydrolysis of 51 
We measured the rate of hydrolysis of 51 (250 µM) under conditions identical to 
our DNA alkylation reactions. HPLC analysis of the hydrolysis mixture was carried out 
and the appearance of the hydrolysis product together with the disappearance of 51 was 
followed (Figure 86). Linear regression analysis of these time-curves was used to 
calculate kH2O,3 = 4.14.x 10-6 s-1, (t1/2 = 46.5 h).  
 
 
 
Method VMAX (s-1) t1/2 (h) KM (M) KB (M-1) 
Michaelis plot 1.8 x 10-4 1.1 4.5 x 10-4 2 200 
Eadie-Hofstee 2.0 x 10-4 1.0 6.1 x 10-4 1 600 
Hanes-Woolf 2.0 x 10-4 1.0 5.9 x 10-4 1 680 
Lineweaver-Burk 2.1 x 10-4 1.0 6.2 x 10-4 1 600 
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Figure 84. The appearance of the hydrolysis product of 51 (left) and the disappearance of 51 (right) in the 
hydrolysis reaction for the calculation of the rate of hydrolysis: kH2O,3 = 4.14 x 10-6 s-1, t1/2 = 46.5 h. 
 
 
 
The hydrolysis reaction of 51 is much slower (t1/2 = 46.5 h) than its DNA-alkylation (1 
h). We can conclude that 51 is hydrolytically fairly stable. We compared these rates 
(Equation 52) and conclude that noncovalent DNA binding provides a 4.5 million times 
faster rate of DNA-alkylation than hydrolysis under identical conditions. 
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       4.5 million times 
 
 
 
 
 
 
 
time (h)
0 50 100 150
A
re
a
 
u
n
its
 
(H
PL
C)
0
2e+5
4e+5
6e+5
8e+5
Time (h)
0 50 100 150
A
re
a
 
u
n
its
 
(H
PL
C)
0
1e+6
2e+6
3e+6
==
−
−
M
s
M
s
M
k
K
k
OH
M
alk
1
1
2
]55[
Chapter 4 
DNA Alkylation and DNA-Binding by Analogs of the Left-Half of Azinomycin: a Minimal 
DNA-Intercalating Structure 
______________________________________________________________________________________ 
 173 
 
4.5.3. The Rate of Alkylation of 2’-Deoxyguanosine by 51 
Finally, we wanted to study alkylation of 2’-deoxyguanosine by the left-half of 
Azinomycin, to understand if N7G alkylation is accelerated by noncovalent association. 
A comparison of the rates of 2’-deoxyguanosine and DNA alkylations under identical 
conditions will allow us to calculate the equivalent molarity and the rate acceleration 
provided by such weak binding events to DNA.  
Accordingly, we measured the rate of degradation of 51 in 50%:50% TFE:buffer 
with a dielectric constant that mimics the dielectric environment of the major-groove of 
DNA, where N7 of guanine resides (Chapter 1).30-32 The identification of the 2’-
deoxyguanosine adduct of 51 was unachievable due to its short retention time, thereby, 
we followed the degradation of 51 in this reaction mixture. The only product formed in 
this reaction is the N7-2’dG adduct of 51. Minimal amount of hydrolysis product (3% 
yield) was observed in these reactions. Due to the limited supply of 51 we measured the 
rate of 2’-deoxyguanosine alkylation at a single concentration (5 mM). We followed the 
appearance of the product by HPLC, calculated the first order rate of 2’-deoxyguanosine 
alkylation by non-linear regression of this data versus time, kdG,3, 5mM = 1.20 x 10-6 s-1, (t1/2 
= 160 h). We calculated the second order rate of alkylation with respect to the 
concentration of 2’-deoxyguanosine : kdG,3, 5mM /0.005 = ksec,2’dG,3 = 2.4 x 10-4 s-1M-1.  
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4.5.4. Rate Acceleration and Effective Molarity Provided by Noncovalent Binding 
of 51 to Duplex DNA 
To appreciate the rate acceleration provided by the noncovalent association of 51 
to duplex-DNA, we compared the rate of N7-G alkylation in DNA to that in 2’-dG 
(Equation 53), and found that the duplex provides 1411 times rate acceleration. The 
effective concentration of 51 on the surface of duplex-DNA was also calculated 
(Equation 54) to be 0.9 M.  
 
Equation 53 
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4.6. The Intercalation of the Left-Half of Azinomycin and its Significance 
Studying the intercalation of the left-half of azinomycin (51) turned out to be 
interesting for two reasons. First, the minimum structural requirement for a small 
molecule to intercalate DNA has been suggested to be two annealed aromatic rings 
together with a functional group that is positively charged under physiological conditions. 
33,34
 We would like to see if this neutral system (51) intercalates as a result of covalent 
attachment to DNA. After the recognition of the cancer therapeutic advances of minimal 
DNA-intercalators, 35-37 such small molecules have been used in drug development. 
Interestingly, it was recognized early that classical intercalators with more than two 
aromatic rings could not penetrate cells appropriately.37 The two-ring intercalators 
systems have been referred to as: minimal intercalators.37  
A second motive to learn about intercalation by 51 and its analog 52 comes from 
debates about the intercalation of these analogs under different conditions,24 which we 
will address in the conclusions Section. 
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4.7. Plasmid DNA Unwinding by 51 and 52 and the Absence of Unwinding by 53 
Supports DNA-Intercalation as a Result of DNA-alkylation 
The phenomenon of plasmid DNA unwinding via DNA-intercalation has been 
discussed in detail in Chapter 2, Section 2.4.1, thereby we narrow our discussion to our 
results here. Since viscometric experiments showed that the DNA alkylating analogs of 
the left-half of azinomycin (51, 52) intercalate DNA upon alkylation, we alkylated 
Plasmid-DNA (PGL2BASIC, 35 µM/bp) by increasing equivalents of these molecules. 
After alkylation, electrophoretic separation and visualization of the topoisomers we 
observed that the epoxide analogs 51 and 52 unwound the plasmid DNA (Figure 85). 
Unwinding was not observed by the cyclopropene analog (53), which is unable to 
alkylate DNA (Figure 85).  
Our data presented here suggests that the naphthoate ring of our analogs (51, 52) is 
capable of DNA-intercalation in the DNA-adduct. As evidenced by the absence of 
unwinding by 53 we can conclude that the neutral naphthalene ring does not intercalate 
DNA without covalent “linkage” to DNA bases. Control experiments were carried out to 
show that DNA alkylation by a small molecular epoxide glycidol does not result in 
plasmid unwinding (Figure 85). 
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Figure 85. Plasmid-DNA unwinding (PGL2BASIC) by the epoxide analogs 51 (top), 52 (middle) and the 
cyclopropyl analog 53 (bottom). Conditions: MOPS (50 mM, pH 7.0), PGL2BASIC (70 µM/bp), 
Concentrations of drug in lanes: 1: DNA alone, 2: 20 µM 3: 40 µM, 4: 80 µM, 5: 100 µM, 6: 200 µM, 7: 
300 µM, 8: 400 µM, 9: 500 µM, 10: 600 µM, 11: 700 µM, 12: 800 µM, 13: 900 µM, 14: 1 mM. 
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4.8. Viscosity Studies Demonstrate that 51 is Intercalated in the DNA-Adduct 
We discussed the physical changes in the solution structure 38 and viscosity of 
DNA solutions 39,40 upon intercalation earlier (Chapter 2., Section 2.4.). We also talked 
about the biological consequences 41-43 that intercalation lends to a small organic 
molecule (Section 2.3.). We also outlined the classical structural requirements 33,34 for 
DNA-intercalation (Section 2.1. and 2.2.). This information will not be repeated here.  
As we discussed in Chapter 2, increases in the viscosity of a DNA-solution in the 
presence of a small organic molecule can demonstrate its intercalation into DNA. 44 In 
our experiments  calf thymus (CT) DNA (450 µM) was exposed to a DNA-alkylating 
epoxide analog (51) at different concentrations (15 µM, 30 µM, 45 µM) at room 
temperature and the viscosity of the reaction mixture was followed. The observed time 
dependent increases in the relative viscosity of the solution (Figure 86) suggested that the 
DNA-alkylation results in an intercalated structure. This idea was also supported by the 
observation that increasing equivalents of 51 in the alkylation reaction results in 
increasing absolute changes in the viscosity. In this experimental setup the viscometer 
responds linearly to increasing equivalents of a well known intercalator, ethidium 
bromide. This is observed at a range of DNA concentrations (Figure 87). This suggests 
that our experimental setup is capable of detecting intercalation. 
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Figure 86. Changes in the relative viscosity of C.T. DNA solutions vs. time in the presence of 51. The 
applied concentrations: [DNA]: 450 µM, 3: 15 µM, 30 µM, 45 µM. Buffer: MOPS (50 mM, pH 7.0). 
 
 
 
 
 
 
 
Figure 87. Changes in the relative viscosity of a CT DNA solution during the titration with the classical 
intercalator: ethidium bromide. 
 
The observed exponential time dependence of the changes in the relative viscosity 
of our DNA solutions suggest that these changes are induced by chemical processes, 
reasonably the formation of the DNA-adduct of 51. This experiment demonstrated that 
the DNA adduct of 51 is intercalated. We did not see any observable changes in the 
solution viscosity upon addition of 51 to the DNA-solution at zero time. This suggests 
that the naphthoate system is not intercalated before DNA-alkylation.  
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4.9. Fluorescence Contact Energy Transfer Experiments Demonstrate the Stacking 
of the Naphthoate Ring of 3 into DNA 
 
We have discussed the changes in the spectral properties of DNA complexes upon 
intercalation earlier (Chapter 2. Section 2.4.2.). The fluorescence properties of duplex 
DNA and a free DNA-intercalator markedly differ from that of their intercalated 
complexes.44,45 Intercalation brings the intercalators into such proximity to the DNA base 
that photon excitation of the otherwise non-fluorescent DNA will result in fluorescence at 
the emission wavelength of the intercalators (Figure 88). This phenomenon is termed: 
Fluorescence Contact Energy Transfer.44-46 The excitation energy (200-300 nm) taken up 
by DNA will be transferred directly to excite the intercalator, which will then fluoresce at 
its characteristic wavelength. This type of energy transfer can only happen when the 
proximity of the organic molecule is as small as the distance between stacking molecules. 
Consequently, this method is capable of differentiating intercalation from other DNA-
binding modes.46 It is important to realize that by themselves the intercalators do not 
fluoresce when excited at this wavelength range (200-300 nm). 
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Figure 88. The theory of the FCET experiment. UV excitation of DNA will not result in fluorescence (a), 
since molecular motions will quench the excitation energy. Intercalators pick up some of the excitation 
energy and emit it as their own resonance energy (b) yielding fluorescence. 
 
 
In an FCET experiment the samples are excited in the wavelength range (200-300 
nm) and the fluorescence signal is collected at the emission wavelength of the suspected 
intercalators. The FCET spectrum is calculated by Equation 55, and plotted versus the 
excitation wavelength.44 A positive FCET spectrum (evidence for intercalation) looks 
like the UV-spectrum of DNA, and the value of the calculated FCET should be largen 
than one (x > 1).  
Equation 55 
 
 
In the equation above, Q(λ)/Q(310) is the FCET function, I is fluorescence intensity, b – 
data for the bound ligand, f – data for the free ligand.  
 First, we recorded the emission fluorescence spectrum of our analogs (51, 52) and 
found that there is a strong emission centered at 435 nm when the analogs were excited at 
260 nm (the UV-absorption peak of DNA), data not shown. We used 435 nm as our 
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detection wavelength. The excitation fluorescence of 51 and 52 were recorded during 
DNA-alkylation at zero time and after 11 h (Figure 89). An increase in fluorescence was 
observed in the excitation spectrum as the DNA-alkylation reaction progressed. This was 
a sign of energy transfer from the DNA to the alkylating agents (51, 52). 
  
 
 
 
 
 
 
 
Figure 89. The fluorescence excitation spectrum of 51 before and after DNA-alkylation. Conditions: 
[DNA]: 400 µM, [51]: 8 µM. Incubation at 37 °C. 
 
 
Reading the fluorescence of the DNA-alkylating solution at different times and 
calculating the FCET values over the range of excitation wavelengths resulted in the 
FCET spectra (51: Figure 90, 53: Figure 91). The appearance of the FCET signal strongly 
supports the intercalation of the naphthoate ring as DNA-alkylation proceeds. The 
cyclopropyl analog (53) did not yield an FCET signal under the same conditions. The 
absence of the FCET signal for 53 tells us that intercalation happens as a consequence of 
DNA alkylation.  
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Figure 90. The FCET spectra calculated from fluorescence spectra recorded as DNA alkylation progressed 
in the presence of 51. CT DNA (500 µM) was alkylated with 51 (100 µM) at 37 °C in 50 mM sodium 
phosphate buffer (pH 7.0). At selected times, solution was diluted 100 times into HPLC water and 
fluorescence readings were taken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 91. The FCET spectra calculated from fluorescence spectra recorded as DNA alkylation progressed 
in the presence of 52. CT DNA (500 µM) was alkylated with 52 (100 µM) at 37 °C in 50 mM sodium 
phosphate buffer (pH 7.0). At selected times, solution was diluted 100 times into HPLC water and 
fluorescence readings were taken. 
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Reading the FCET signal vs. time at a selected excitation wavelength (Figure 92) 
shows exponential time-dependence, suggesting that the FCET signal is the result of a 
chemical process. The calculated pseudo-first-order rates of DNA alkylation match the 
magnitudes of the DNA-alkylation rates measured earlier (Section 4.5.), 1.2 x 10-4 s-1 < k 
< 8.6 x 10-4 s-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 92. The appearance of the FCET signal at its corresponding maximum in the DNA-alkylation 
reaction by 51 and 52. General conditions: [DNA]: 400 µM, [51]: 4 µM, incubation at 37 °C. 
 
 
 
As expected, the FCET signal disappears after exposing the mixture to a heat 
shock at 80 °C for half an hour, presumably due to the depurination process. 
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4.10. Chapter Conclusions 
 
 
The DNA adduct of the left-half of azinomycin (51) was isolated and studied by 
LC-MS and identified as an N7-G adduct by its m/z value and its characteristic 
depurination reaction. A chemical model of the adduct was constructed, which revealed 
that intercalation of the aromatic naphthoate ring-system of 51 on the 3’-surface of the 
alkylated guanine is easily accomplished, whereas stacking over the 5’-surface of the 
alkylated DNA-base would probably result in steric clashes between the phosphate 
backbone of DNA and that of the 5-atom-linker attaching the naphthoate ring to the 
guanine base. This suggests that alkylation is more favored sterically when 51 can stack 
over the 3’-surface of the target guanine. This modeling showed agreement with the 
sequencing data collected by Dr. Hong Zang in our laboratory (Ph.D. Dissertation, 
University of Missouri-Columbia, 2001.).  
The rate of DNA alkylation appears to follow Michaelis-Menten type saturation 
kinetics vs. increasing concentrations of DNA, which parallels with our earlier 
experiments suggesting that a noncovalent pre-equilibrium is required (Equation 51, 
Figure 82) before the alkylation step and this facilitates DNA alkylation (Section 4.5.1.). 
Graphical analysis of our data results in the following averaged kinetic and 
thermodynamic parameters for the DNA alkylation reactions: Vmax: 2.1 x 10-4 s-1, KM = 
6.2 x 10-4 M, KB = 1600 M-1. The rate of the hydrolysis reaction of 51 was also measured 
(kH2O,3 = 4.14 x 10-6 s-1, t1/2 = 46.5 h).  
To estimate the rate acceleration provided by the noncovalent binding of 51 to 
duplex DNA we measured the rate of alkylation of 2’-deoxyguanosine by 51 in a 50:50% 
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(v/v): kdG,3, 5mM = 1.20 x 10-6 s-1. We calculated the second order rate constant for the 2’-
deoxyguanosine alkylation reaction for our condition: ksec,2’dG,3 = 2.4 x 10-4 s-1M-1. We 
calculated that the alkylation of N7G in DNA goes 1411 times faster than that in 2’-
deoxyguanosine. This corresponds to a 0.9 M effective molarity on the surface of duplex-
DNA. DNA-alkylation is 4.5 million times faster than the hydrolysis of 51 under 
comparable conditions. In conclusion, noncovalent binding of 51 facilitates DNA 
alkylation, similar to other small molecular DNA-alkylating agents. 47,48 
We studied plasmid-DNA unwinding by the epoxide analogs (51 and 52) and the 
cyclopropyl analog (53). Plasmid DNA unwinding by the epoxide analogs was observed, 
but not with that of the cyclopropyl analog. This supports our model that the naphthoate 
ring is intercalated into DNA in the DNA-adduct, but not before alkylation is 
accomplished. 
Next, we followed changes in the viscosity of CT DNA solution in the presence 
of our epoxide (51, 52) and cyclopropyl (53) analogs. We observed time-dependent 
increases in the viscosity of DNA solution in the presence of the epoxide analogs. This 
demonstrated that a chemical process results in an intercalated DNA-adduct with these 
alkylating agents, and reinforced the idea that the DNA-adducts of 51 and 52 are 
intercalated. Such increases in viscosity were not observed in the presence of the 
cyclopropyl analog (53). This suggests that the neutral naphthoate ring is not intercalated 
unless the molecule is adducted to DNA. 
Finally, we recorded the fluorescence of DNA solution in the presence of our 
analogs (51-53). A development of increasing fluorescence was observed in the presence 
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of our epoxides (51, 52) as time progressed. In the presence of the cyclopropyl analog 
(53), we did not see any change in fluorescence.  From the fluorescence signals, we 
calculated the Fluorescence Contact Energy Transfer from DNA to our chromophores 
(51, 52), and gratifyingly, we found excellent FCET signals. The presence of the FCET 
signal demonstrated the formation of intercalated DNA adducts of 51 and 52 as a result 
of DNA-alkylation. The absence of the fluorescence enhancement and the absence of the 
FCET signal in the presence of the cyclopropyl analog showed us that the neutral 
naphthoate ring is not intercalated before DNA-alkylation. Overall, our experiments 
demonstrate that 51 and 52 are intercalated in the DNA-adduct. 
It is interesting to correlate our data to the literature. It is reported that such small 
aromatic systems only intercalate DNA if they hold functional groups that are positively 
charged in solutions.19-22 The positive charge facilitates their binding to DNA 
electrostatically. In our analog (51) there is no charge; however, covalent binding can 
concentrate the naphthoate ring close to the DNA-bases for intercalation. Interestingly, 
we do not see any change in the viscosity of DNA-solution in the presence of 53. This 
analog contains the cyclopropyl ring, which does not act as an alkylating agent. 
An earlier controversy between data from our laboratory18 and the laboratory of 
Professor Robert Coleman requires discussion here.24 We found that an analog of the left-
half of Azinomycin (54) intercalated DNA. This analog does not alkylate DNA. The 
research group of Prof. Coleman found that such analogs do not intercalate DNA. This 
difference can be explained by our earlier belief that 54 was not able to alkylate DNA, 
and interpretation that intercalation simply takes places as the result of non-covalent 
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association between 54 and DNA. A careful control, however, needs to be carried out to 
test if 54 is capable covalent adduct formation. Based on the work presented in this 
Chapter, we suggest that 54 might be a DNA-alkylating agent. Our earlier examination of 
the intercalation of analog 54 did not test its DNA alkylating property. Based on its 
structural features, it might be possible that 54 forms a DNA-alkylating epoxide in 
solutions, with displacement of a chloride with the help of neighboring group 
participation of the hydroxyl functionality (Scheme 21). Eventually, both our group and 
the group of Dr. Colemann correctly concluded the available experimental data. In a 
fundamental view, intercalation on neutral naphthoate ring is only possible if the 
molecule is concentrated in the proximity of DNA. This can happen via electrostatic or 
covalent adduct formation.  
 
 
 
 
 
Scheme 21. Hypothesized regeneration of the DNA-alkylating epoxide in the hydroxyl-chloro analog (54). 
 
 
Finally, it is interesting to know that a mimimum 30% of 51 is bound to DNA (KB 
= 1500 M-1) at an initial concentrations of 250 µM and 500 µM DNA. We should have 
seen increases in viscosity or FCET signal if 51 intercalated DNA before alkylation. The 
neutral naphthoate ring, consequently is not intercalated before DNA-alkylation. 
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4.11. Experimental 
 
4.11.1. Materials and Methods 
 
The analogs 51-54 were gifted to us by the research group of Professor Michael Shipman 
from the Department of Chemistry, Warwick University, London. Additional reagents 
were purchased from the following suppliers and were of the highest purity available: 
MOPS buffer, sodium acetate and sodium phosphate buffers, trifluoroethanol, 
triethylamine, Aldrich Chemical Co. (Milwaukee, WI); HPLC grade solvents (water, 
acetonitrile, ethanol), Fisher (Pittsburgh, PA); herring sperm DNA, Roche Molecular 
Biochemicals (Indianapolis, IN); HPLC vials, National Scientific Corporation; analytical 
HPLC columns, Varian Inc. (Palo Alto, CA). The plasmid PGL2BASIC was prepared 
and purified in our laboratory by expression in genetically engineered E.Coli. bacteria. 49 
HPLC: Varian Prostar Dynamax, vs. 5.1. LC-MS: ThermoFinnigan TSQ7000 triple-
quadrupole with API2 source. 
 
4.11.2. Mass Spectrometric Analysis of the 51-DNA Adduct 
The DNA adducts were synthesized as detailed below. The isolated guanine adduct was 
injected into LC-MS, and analized by a Thermo-Finnigan TSQ7000 triple-quadrupole 
mass spectrometer using electrospray ionization (ESI) in positive(+)ion mode, with an 
inlet capillary at 250 °C and an electrospray needle voltage at 4.5 kV. Nitrogen sheath 
gas was used at 80 psi. The LC-MS system is equipped with a Thermo-Finnigan LC 
system consisting of a P4000 quaternary LC pump and SCM1000 vacuum degasser, an 
AS3000 autosampler and a UV6000LP diode array detector. 
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4.11.3. Computer Model of 51 in ds-DNA 5’-AGG-3’ Sequence 
 A protein database coordinate file of a short 10-mer oligonucleotide-bleomycin 
DNA adduct was downloaded from the protein database. The bleomycin molecule was 
erased from this structure and the oligonucleotide was truncated to the 5’-AGG-3’ 
sequence. The middle guanine (underlined) was attached to a 3D chemical model of 51. 
The naphthoate ring of 51 was positioned into a stacking position with either the 3’- or 
the 5’-surface of the alkylated guanine residue. The resulting structure was energy 
minimized by the MM2 package of ChemDraw 3D Ultra Software. The final coordinate 
file (*.pdb) was transferred to X-Seed 50 (software used for supramolecular 
crystallography). This software provides interactive tools of atom coloring and 
light/shadow effects. PovRay (Mathematical Modelling) 51,52 was used to render the 
image (*.jpg) of the molecules. 
 
4.11.4. DNA Alkylation by 51 
At 37 °C the following components were mixed: 50 µL of 51 (2.5 mM in acetonitrile), 50 
µL of MOPS buffer (500 mM in water, pH 7.0), 6 – 40 µL of herring DNA (10 mM in 
water) and water (394 µL to 360 µL) in small 500 uL centrifuge-tubes. Samples were 
vortexed gently (10 s). At different times 50 µL-aliquots were removed from the reaction 
mixture and mixed with 150 µL water. This sample was extracted with butanol (200 µL) 
twice. The remaining aqueous phase was kept on a heat-block for depurination (85 °C, 
1.5 h). The depurination times were optimized via additional experiments making sure of 
complete depurination without the degradation of the guanine-adduct of 51. Samples 
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were cooled to room temperature and were further extracted for their guanine-adduct 
content by butanol (200 µL) twice. The butanol samples were dried in a speed-vacuum 
instrument and stored at -20°C before HPLC analyses. HPLC analyses were carried out 
as described later. 
 
4.11.5. HPLC Analyses of DNA-Adducts and Hydrolysis Samples 
The dried samples from the DNA reactions were redissolved into an HPLC 
injection mixture (150 µL of 60% A and 40% B, where A: 0.5% formic acid in water, B: 
acetonitrile). 20 µL of the reaction samples was injected onto a C18 RP-HPLC 100 Å 
column, 4.6 x 250 (Varian), and was eluted isocratically with 60% A and 40% B (A: 
0.5% formic acid in water; B: acetonitrile) at a flow rate of 0.8 mL/min. The wavelength 
of detection was 260 nm. The guanine adduct of 51 in this method elutes at 23 min, 
followed by the hydrolysis product of 51 at 27 min (Figure 80). 
 
4.11.6. Hydrolysis of 51 
 The following components were mixed together at 37 °C: 25 µL MOPS buffer 
(500 mM in water pH 7.0), 25 µL 51 (2.5 mM in acetonitrile), 200 µL water (HPLC 
grade). The mixture was vortexed gently, and at different times small aliquots (25 µL) 
were removed and were immediately frozen on liquid nitrogen. This frozen sample was 
stored at -20°C before HPLC analyses. HPLC analyses were carried out as described 
above.  
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4.11.7. Degradation of 51 in its Reaction with 2’-Deoxyguanosine 
 The following components were mixed and incubated at 37 °C: 100 µL of 2’-
deoxyguanosine in TFE (10 mM), 20 µL of MOPS (500 mM, pH 7.0 in water), 20 µL of 
51 (2.5 mM in acetonitrile). This mixture was mixed gently (10 s) and incubation begun. 
At different times, small aliquots of the sample (15 µL) were taken from the mixture and 
mixed with 85 µL water (HPLC grade), then frozen on liquid nitrogen, and dried in a 
speed-vacuum instrument. The dried samples were stored at minus 20°C. At the time of 
HPLC analysis, the dried samples were dissolved into 150 µL of HPLC injection mixture 
(60% A and 40% B, where A: 0.5 % formic acid in water, B: acetonitrile). HPLC analysis 
was performed as described above. 
 
4.11.8. Plasmid DNA-Unwinding by 51, 52 and 53 
 Dilutions of the analogs in acetonitrile were carried out to 5 x of their final 
concentration (100 µM, 200 µM, 400 µM, 0.5 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 
mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM). The reaction mixtures were mixed at 4 °C 
accordingly: 2.5 µL of sodium phosphate buffer (500 mM, pH 6.5), 15.5 µL water (HPLC 
grade), 2 µL of PGL2BASIC (1 mg/mL stock solution), 5 µL of the acetonitrile stock 
solution of our analogs. Samples were vortexed gently (5 s), then incubated at 4 °C for 24 
h. Then, samples were treated with 6 µL of glycerol loading buffer (7 µL) containing 
0.25% bromophenol blue and 40% sucrose, and the mixtures were vortexed gently (5 s). 
Samples were loaded on a 2% (m/m%) agarose-gel and electrophoresed at 40 V for 
approximately 16 h in a 4°C cold-room. 
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4.11.9. Plasmid DNA-unwinding by Glycidol  
 Dilutions of glycidol in acetonitrile were carried out to 5 x of its final 
concentration (10 µM, 20 µM, 40 µM, 0.05 mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.25 mM, 
0.3 mM, 0.35 mM, 0.4 mM, 0.45 mM, 0.5 mM). The reaction mixtures were mixed at 
room temperature accordingly: 2.5 µL of sodium phosphate buffer (500 mM, pH 6.5), 
15.5 µL water (HPLC grade), 2 µL of PGL2BASIC (1 mg/mL stock solution), 5 µL of 
the acetonitrile stock solution of glycidol. Samples were vortexed gently (5 s), then 
incubated at 37 °C for 24 h. Then, samples were treated with 6 µL of glycerol loading 
buffer (7 µL) containing 0.25% bromophenol blue and 40% sucrose, and the mixtures 
were vortexed gently (5 s). Samples were loaded on a 2% (m/m%) agarose-gel and 
electrophoresed vs. 40 V for approximately 16 h in a 4 °C-cold-room. The outcome of 
alkylation by glycidol was checked in separate experiments, using base workup 
(DMEDA). These experiments were set up exactly the same way as the glycidol 
experiments above, however, after incubation samples were treated with 3 µL of 
DMEDA solution (1 M in HPLC water) and further incubated at 37 °C for 1 h. Then 
glycerol loading buffer (7 µL) was added to the samples and they were loaded to a 2% 
agarose gel for electrophoresis at 40 V for 16 h at 4 °C.  
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4.11.10. Viscometric Monitoring of DNA Alkylation by 51 
For this experiment a custom made flow-viscometer was used (Ace Glass Co.) 
with a room temperature flow rate of 100 s for water and a sample volume of 1mL. The 
samples were prepared using 100 µL of DNA (4.5 mM in HPLC water), 100 µL NaPi 
buffer (100 mM, pH 7.0), 700 µL of HPLC-water. At this point the sample was mixed 
with bubbling (5-10 s). With the help of a Pasteur-pipette 100 µL of the 10 x stock 
solution 51 (150 µM or 300 µM or 450 µM) mixed into the viscometer and bubbled. Flow 
times were collected until their increase reached saturation. The flow time of the actual 
time-point: t and the flow time of the buffer solution t0 was used to calculate the relative 
viscosity by the equation: (t-t0)/t0. Here t0 is the flow time of the buffered DNA-solution 
without 51. The calculated relative viscosities were plotted versus the reaction time 
(Figure 86) and fitted to a rising exponential using SigmaPlot 2001. 
 
4.11.11. Viscometric Monitoring of DNA Titration by Ethidium Bromide (Control) 
As a control we followed the changes in relative viscosity of C.T.DNA solutions (400-
800 µM concentrations) as we titrated it with a classical intercalator ethidium bromide 
(Figure 85). A flow viscometer with a room temperature flow time of 100 s (for water) 
was used with 1 mL sample volume. The sample was made of 100 µL of C.T.DNA 
solution (10 times the final concentration), 100 µL of MOPS buffer (500 mM, pH 7.0), 
700 µL of HPLC water. This solution was mixed by bubbling the flow-viscometer (10-15 
s). The viscosity of this background solution was measured (t0) as described above. After 
each reading, an aliquot of ethidium bromide solution (10 x the concentration of DNA 
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solution, containing C.T.DNA at the applied concentration to avoid the dilution) was 
mixed into the solution in the viscometer. Flow time was measured and relative viscosity 
was calculated. The relative viscosity was plotted versus the applied equivalents of 
ethidium bromide (Figure 85) to demonstrate that our experimental setup is applicable to 
detect DNA-intercalation and its “end-point”.  
 
4.11.12. Fluorescence Contact Energy Transfer (FCET) to follow DNA-alkylation by 
51 and 52 
 For these fluorescence studies the following instrumental settings were applied: 
lamp power: 750 watts, optical slots 12 nm, multiplier voltage: 950 V, chopper: 51 Hz, 
automatic shutter control and 0.1 s integration time. 1 mL DNA-alkylation sample was 
made accordingly: 20 µL of acetonitrile solution of 51 or 52 (500 µM) was mixed with 
100 µL sodium phosphate buffer (500 mM, pH 6.5) and 100 µL of C.T. DNA solution (5 
mM in HPLC water) and finally 780 µL of HPLC water was added. The mixture was 
vortexed gently over a period of 5-10 s, then placed into a 4 °C refrigerator. At different 
times 10 µL-aliquots were taken from this sample and diluted into 990 µL of fluorescence 
solution (10 mM sodium phosphate, pH 6.5). A fluorescence excitation spectrum was 
recorded in the excitation range of 220-300 nm and at an emission wavelength of 435 nm. 
The fluorescence excitation spectrum was analized by means of Equation 55 (Section 
4.9.), and FCET plots were calculated (Figure 89). The appearance of the FCET signal 
was also plotted vs. time at an excitation wavelength of 275 nm (Figure 92). 
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Chapter 5. A Collaborative Study Toward Engineered Biosynthesis of 
Leinamycin Analogues 
 
 
5.1. Introduction to the Biosynthesis and Combinatorial Biosynthesis of Natural 
Poducts in the Example of Leinamycin 1,2 
 
Microorganisms make a wide variety of Natural Products with a broad range of 
pharmacological activities. 3 Novel bioactive natural products can turn out to be directly 
interesting to Medicine or Industry, or may, as well, promote research to understand the 
action behind the novel chemical structure. The natural products are constructed with the 
help of enzymes in microorganisms. The enzymes responsible for building or tailoring 
the natural product, regulatory proteins and many proteins of unknown function, are 
coded by genes (Scheme 22), which are either in clusters or isolated sporadically in the 
genome of the synthesizing organism. 2 These enzymes are either multifunctional or are 
in the form of enzyme clusters (modules) that carry out a few modifications before 
releasing the intermediate or the final product. A recombination of the order of genes or 
attempts to feed the biosynthetic enzymes with substrate analogs might be useful in the 
preparation of natural product analogs. 4 
 In our simplified representation of the leinamycin biosynthetic machinery 
(Scheme 22) for our current discussion, it is important to recognize the presence of a 
cyclizing/condensing/oxidizing module (module-2) that forms the thiazole ring of 
leinamycin. This module eventually produces a PCP (peptidyl carrier protein) conjugate 
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of our target (56, Scheme 22, boxed). This protein conjugate is a substrate for further 
elongation of the carbon skeleton in the macrocycle of leinamycin (from module-3). 
Chain elongation, dehydration and methyl transfer steps follow in this biosyntesis. 
Finally a “thioesterase” (TE) accomplishes the macrocyclization of the 18-member 
lactam ring and a separate enzyme cluster (Post NRPS-PKS, nonribosomal-
polyketidesynthase) attaches the dithiolenone-S-oxide ring in a spiro-fashion to the 
macrocycle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. Simplified hypothetical scheme for the biosynthesis of leinamycin (re-constructed with 
alterations from figure 1 in Yi-Qiang Cheng, Gong-Li Tang, and en Shen, PNAS, 100 (6), 2003. p.3149.). 
Abbreviations: A: adenilase, PCP: peptidyl carrier protein, Cy: cyclization, Ox: oxidase, KS: ketide 
synthase, KR: ketoreductase, AC: acyl carrier protein, TE: thioesterase, SAM: S-adenosyl-methionine 
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5.2. Design of Precursors for the Biosynthesis of Leinamycin 
 
In a broad view, preparation of natural product analogs via combinatorial 
biosynthesis may offer useful tools to prepare biologically active and medicinally useful 
agents. 4 Such attempts have been approached by either reconstructing the gene-clusters 
of natural product producing species or by replacing substrates of enzymes in a 
biosynthetic machinery with analogs recognizable as substrates by these enzymes. Here 
we hypothesize that in place of the PCP-conjugate of our target (56 in module 2) other S-
Nac species (57, 59, 61, 63 Figure 93) might be applicable for the biosynthetic generation 
of leinamycin analogs. 
To understand the role of the functional groups in leinamycin (1), their 
replacement with rationally designed functional groups can be useful. Drug development 
has also proven that the modification of natural products can yield agents which are 
biologically more potent than the original compound.5 The synthesis of analogs can be 
achieved by means of total-synthesis or biosynthesis. 
To prove that synthetic pre-cursors can be utilized by the biosynthetic machinery, 
we synthesized the natural substrate 56 of the enzyme system (module-3,Scheme 22). 
The research group of prof. Ben Shen (University of Wisconsin, Madison) has developed 
leinamycin producing strains with mutations which would allow the uptake of our 
synthetic substrate. In such mutants the biosynthesis of PCP-conjugate of 56 would be 
turned off.  
We hypothesize that analogs of 56 might turn out to be useful for the biosynthesis 
of leinamycin analogs if they are accepted by the biosynthetic machinery (Figure 93). To 
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reveal the role of the aromatic thiazole ring in the activity of leinamycin its replacement 
with an aliphatic chain is suggested. For this, an aliphatic-S-NAc precursor (57) may be 
employed. 6 Additionally, extension of the aromatic surface area in place of the thiazole 
ring using rationally designed quinoline (59, 61) 7-9 or indole (63) 10-12 analogs would be 
taken into consideration. 
 
Figure 93. Design of S-Nac analogs as potential precursors for the biosynthesis of alternative leinamycin 
structures. 
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5.3. Synthesis of 2-R(1-Amino-ethyl)-thiazole-4-carbothioic acid S-(2-acetylamino-
ethyl) ester 
 
5.3.1. Retrosynthetic Analysis 
The synthetic building blocks of our target molecule (56) are shown in Figure 94. 
Our laboratory has explored the synthesis of amino-thiazole carboxylic acid (a) analogs, 
13
 thereby it was sensible to build on the structure of a. The Thiol compound: N-acetyl 
cysteamide (b) is a commercially available molecule, and esterification of carboxylic 
acids under mild conditions has been reported exclusively with a variety of different 
reagents. 14-18 In addition, it is important to realize, amide formation between an aliphatic 
amine and acetic acid to provide building block c would have been a difficult and low 
yield process due to the potential simultaneous trans-esterification of the thioester. In 
conclusion, we planned to make the amino-thiazole carboxylic-acid and thioesterify it 
using S-acetyl cysteamide (Scheme 23, section 5.3.2.). 
 
 
 
 
 
 
Figure 94. The building blocks of our target molecule (56). (a): amino-thiazole carboxylic acid, (b): N-
acetyl cysteamide, (c): acetamide 
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Scheme 23. Simplified retro-synthetic analysis of our synthesis. 
 
 
 
 
 
5.3.2. Synthesis of biosynthetic precursor (56) and its metabolite (72) 
In our synthesis (Scheme 24, below) we used steps from the work of Pattenden19 
and Fukuyama20 for the construction of the leinamycin macrocycle. Our synthesis started 
from (R)-N-Boc alanine (65). The starting material was converted to an amide 66 
(isobutyl chloroformate, N-methylmorpholine, then conc. NH4OH) and then to a 
thioamide 67 (Lawesson’s reagent, CH2Cl2, RT, 24 h). 21,22 This thioamide 67 was 
subjected to the modified Hantsch cyclization23  using ethyl bromopyruvate to form the 
thiazole ring 68 (K2CO3; ethyl bromopyruvate, then TFAA and pyridine). At this point, 
earlier reports of applying low temperatures for the composition of the thiazole ring did 
not result in product formation. The resulting ester 68 was exposed to basic hydrolysis 
(Na, methanol), which after acidic workup results in an acid 69.  
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Scheme 24. The synthesis of our target molecule (precursor for the biosynthesis of leinamycin): 2-R(1-
Amino-ethyl)-thiazole-4-carbothioic acid S-(2-acetylamino-ethyl) ester, (56) and its in vitro degradation 
product (72) 
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This acid was (69) converted to the thioester of S-acetyl-cysteamide 70 (diphenyl 
phosphorylazide, triethyl-amine). Additionally, the thioesterification had been attempted 
with the use of isobutyl-chloroformate hydroxyl-activating agent, which resulted in 
impurities that co-eluted with the product and were not removable with recrystallization 
either.  
For the deprotection of the exocyclic amine-nitrogen atom, we attempted a few different 
methods. Of these, in situ decarboxylation using mild oxygen silylating agent (trimethyl-
silyl triflate) in the presence of a weak base (2,6-lutidine, pKa of acid form: 5.0) proved to 
be useful. This reaction resulted in our amine-thiazole-cysteamide analog 71. For 
purification of 71 we bubbled dry hydrogen-chloride gas into a THF solution of 71 and 
after trituration in diethyl-ether we obtained a highly pure HCl-form of our target (56). 
Under in vitro/in vivo conditions 56 was noticed to degrade via hydrolysis of the 
labile thioester bond. To follow this process by HPLC, Prof. Ben Shen’s group required 
an authentic standard of the degradation product (72), the exocyclic carboxylic-acid 
derivative. This molecule (72) was synthesized from 69 via deprotection of the exocyclic 
amine and precipitation of 72 in dry THF by HCl gas. The average yield of these 
synthetic steps were 70% and the overall yield of the 7-step-synthesis is 20%. 
 
 
5.4. Results of Biosynthesis using our precursor (56) 
The work outlined in this section have been carried out by the research group of 
Dr. Ben Shen, (Currently, Department of Chemistry, University of Wisconsin, Madison, 
WI 53705. ). Dr. Ben Shen et al. developed reliable fermentation of leinamycin and its 
isolation and HPLC-detection from wild-type and mutant S. atroolivaceus strains. The 
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mutant strain has a dysfunctional protein up-stream from the adenilase (A) in module-2, 
with inhibited biosynthesis of the thiazol ring in leinamycin. Once 56 is transferred to the 
peptidyl carrier protein (PCP, module-2), hypothetically, it will be incorporated into the 
biosynthesized leinamycin molecule. 56 is the natural substrate for proteins in module-2 
and module-3. 
Our thiazole-SNAc analog (56) was fermented with LnmQ mutant which misses 
the ability to synthesize the thiazole ring. The detection of leinamycin from this ferment 
proved unsuccessful, presumably because of the low yield in the uptake of the analog by 
the cells, and apparently due to its hydrolysis in the broth. On the other hand in the 
presence of an LnmQ/LnmE mutant, the generation of a leinamycin analog (TG-25) in 
the cells was observed, which only can form if our thiazole-S-NAc analog is incorporated 
into the biosynthetic machinery. The detection of TG-25 is possible because it is more 
stable than leinamycin.  
In conclusion the incorporation of our analog 56 was successful in the 
LnmQ/LnmE double mutant, which proves the principle of using synthetic substrates by 
the biosynthetic system. Further efforts are necessary to optimize fermentation times and 
broth conditions, as the degradation of 56 in the broth is probably responsible for the low 
yields of leinamycin in the presence of the LnmQ mutant.  
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5.5. Experimental 
5.5.1. Materials and methods 
Reagents were purchased from the following suppliers and were of the highest 
purity available: technical grade solvents (ethyl acetate, hexane, ether) and HPLC grade 
solvents (acetonitrile), Fisher; ethanol, McCormick Distilling company. All other 
reagents were purchased from Aldrich Chemical Company, except Lawesson’s reagent, 
ethyl bromopyruvate (Lancaster). Water was distilled, deionized and glass redistilled. 
Thin layer chromatography was performed on silica gel plates (0.25) with F254 fluoropore 
(Aldrich) and visualization of compounds was achieved with UV light at 254 nm. 
Column chromatography was performed using 200-300 mesh silica gel (Merck) with 
technical grade solvents that were distilled prior to use. High resolution mass 
spectrometry was performed at the University of Missouri-Columbia Department of 
Chemistry Mass Spectrometry Center. Nuclear magnetic resonance spectra were recorded 
on Bruker 200 MHz or 250 MHz spectrometers. HPLC was performed on the Varian 
HPLC system equipped with single wavelength UV absorbance detector. pH 
measurements were performed with pH meter (Orion, model 420A). Dry CH2Cl2 was 
distilled from CH2. THF was distilled from sodium benzophenone ketyl. Actonitrile and 
dichloromethane were distilled from CaH2, and toluene was distilled from LiAlH4. 
HPLC: Varian Prostar Dynamax, vs. 5.1. LC-MS: ThermoFinnigan TSQ7000 triple-
quadrupole with API2 source. 
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CONH2
NHBoc
R
66
5.5.2. Synthesis of our target molecule and its analogs 
(1-Carbamoyl-ethyl)-carbamic acid tert-butyl ester, 66 
The synthesis of our target molecule (56) started from the commercially 
available R-N-Boc alanine (65). To 26 g of 65 (70 mmol, 1 equiv) in THF 
(90 mL) at 0 °C was added N-methylmorpholine (16 mls) (146 mmol, 2 
equiv) and isobutyl-chloroformate (13 mls, 100 mmol, 1.4 equiv, dropwise). The reaction 
was stirred for 10 min, when concentrated ammonium-hydroxide solution (18.5 mL) was 
added to the system. The mixture was further stirred for 10-15 min. This solution was 
filtered at room temperature through a pad of Celite 545. The Celite pad was further 
washed by 50 mL of diethyl ether. The filtrate was concentrated under reduced pressure 
to approximately 15 mL volume. This concentrate was transferred into a 500 mL 
extraction funnel and brine (30 mL) was added to the filtrate followed by diethyl ether 
(100 mL). The organic layer was washed with saturated citric acid solution (pH 3.0) until 
the aqueous layer became weakly acidic (~ pH 4.0). System was further washed with 
brine (20 mL) and dried over K2CO3. The ether was evaporated on rotavap. The 
remaining powder was powdered and dried over high vacuo. This product (66) (23 g, 
93%) was used without further purification. Rf (ethyl acetate:hexane 1:1 v/v%) = 0.2. 1H-
NMR: (500 MHz, CDCl3): δ 6.1 (1H), 5.3 (1H), 4.9 (1H), 4.3 (1H), 1.45 (9H), 1.38 (d, J 
= 7 Hz, 3H). 
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(1-Thiocarbamoyl-ethyl)-carbamic acid tert-butyl ester, 67 
20.1 g of the amide 66 (106 mmol) was dissolved in THF (330 mL). In a 
separate flask, Lawesson’s reagent (48 g, 120 mmol, 1.2 equiv) was 
dissolved in dry THF (500 mls). The solution of 66 was transferred to the 
solution of the Lawesson’s reagent in 5 min. The reaction was stirred for 
20-28 h at room temperature. The solution was filtered through a pad of Celite 545 and 
SiO2 (2:1), and the pad was further washed with methylene-chloride (~ 500 mL). The 
organic layer was washed further with NaHCO3 (3 x 250 mL). The sodium carbonate 
layer was re-extracted once with methylene-chloride (250 mL). This process resulted in a 
white solid 67 (18 g, 88% yield). Rf (ethyl acetate:hexane 1:1 v/v%) = 0.25. 1H-NMR 
(250 MHz, CDCl3): δ 7.9 (1H), 7.6 (1H), 5.4 (1H), 4.5 (1H), 1.47 (d, J = 7 Hz, 3H), 1.44 
(s, 9H); 13C-NMR (62.5 MHz, CDCl3): δ 210.5, 155.6, 80.5, 28.3, 21.6. 
 
2-(1-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carboxylic acid ethyl ester, 68 
A heterogenous mixture of the thioamide 67 (4 g, 19.5 
mmol) and powdered KHCO3 (15.35 g, 8 equiv, 156 mmol) 
in DME (100 mL) was stirred vigorously in a 250 mL 
round bottom flask for 5-10 min at room temperature (Note: earlier reports from our lab 
applied lower temperatures, which did not result in the desired reaction). To this mixture 
ethyl-bromopyruvate was added (11.4 g, 58.5 mmol, 3 equiv, 7.6 mls). After stirring the 
mixture for 2 min at room temperature, the flask was immersed into a coolant at 0 °C 
with further stirring. In a separate flask a solution of trifluoroacetic anhydride (16.12 g, 
76.8 mmol, 4 equiv, 10.8 mL) and pyridine (12.13 g, 154 mmol, 8 equiv, 12.4 mls) was 
CNH2
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dissolved in DME (30 mL) and precooled to 0 °C. This pyridine solution was transferred 
to the solution of 67 (above), which results in a yellow solution. After the transfer was 
accomplished, the flask was allowed to equilibrate to room temperature on air. In the 
meantime the yellow solution became orange, red and brownish gradually. After 
approximately 3 h the volatile components were removed on rotatory evaporator and the 
residue was resuspended in chloroform (300 mL) and extracted with water (2 x 100 mL). 
The organic layer was further extracted with cc. CuSO4 (2 x 30 mL) to chelate pyridine. 
The remaining organic solution was washed with brine (100 mL) and dried over Na2SO4, 
and purified via flash chromatography after filtration. (6:1 – 4:1 hexane:ethylacetate). 
This resulted in a white solid 68 (4.2 g, 75%). Rf (ethylacetate:hexane 2:1 v/v%) = 0.75. 
1H-NMR (250 MHz, CDCl3): δ 8.07 (s, 1H), 5.3 (1H), 5.09 (m, 1H), 4.4 (q, J = 7.2 Hz, 
2H), 1.61 (d, J = 7 Hz, 3H), 1.43 (s, 9H), 1.38 (t, J  = 7.2 Hz, 3H); 13C-NMR (62.5 MHz, 
CDCl3): δ 174.8, 161.3, 154.8, 147.1, 127.0, 80.2, 61.3, 48.9, 28.2, 21.7. 
 
2-(1-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carboxylic acid, 69 
4.3 g of 68 (14.4 mmol) was dissolved in 100%-ethanol (65 mL). 
The solution was cooled to 0oC. 400 mg sodium was added to 
this mixture in small pieces (17.3 mmol, 1.3 equiv). After the 
sodium dissolved, water (285 µL, 285 mg, 15.8 mmol, 1.2 equiv) was injected into the 
flask. This solution was allowed to warm up to room temperature, and the starting 
material gradually disappeared during the course of the following 6-12 h. After the 
disappearance of the starting material the ethanol was evaporated on the rotavap and 
water (400 µL) and cc. citric acid (80 mL, pH 3.0) were added. This system was extracted 
S
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with methylene chloride (3 x 600 mL). The organic phase was dried over Na2SO4 and 
evaporated under decreased pressure. This reaction yields in a yellowish foam 69 (4 g, 
95%). Rf (ethyl acetate): 0-0.15 streaking. 1H-NMR (250 MHz): δ 11.0 (bs, 1.3 H), 8.2 
(s, 1H), 5.5 (bs, 0.5 H), 5.1 (bs, 1H), 1.63 (d, J = 7.5 Hz, 3H), 1.4 (s, 9H). 13C-NMR (62.5 
Hz, CDCl3): δ 176.8, 164.4, 146.3, 128.5, 81.5, 80.3, 48.8, 28.2, 20.9. 
 
 2-(1-tert-Butoxycarbonylamino-ethyl)-thiazole-4-carbothioic acid S-(2-acetylamino-
ethyl) ester, 70 
3.1 g of 69 (11.41 mmol, 1 equiv) was dissolved in 
DMF (60 mL) and treated with diphenyl-
phosphorylazide (3.8 mL, 17.12 mmol, 1.5 equiv) and 
ethylamine (3.3 mL, 2 equiv, 22.82 mmol) at 0 °C. This reaction mixture was stirred at 0 
°C for 2-3 h. In the meantime the reaction mixture gradually grew darker. Then, 2N-
acetylcysteamide (2.6 mL, 22.9 mmol, 2 equiv) was added, and the mixture was allowed 
to reach room temperature on air. The mixture was further stirred for 2-3 h at room 
temperature. After this, water (100 mL) and ethyl acetate (400 mL) was added. The 
aqueous layer was further extracted with ethyl acetate (2 x 400 mL). The organic layer 
was dried with Na2SO4 and the solvent was removed by rotavap. The compound was 
purified by flash chromatography (gradient elution, 5:1 – 3:1 ethylacetate:hexane v/v%).  
(Note: this synthetic step was attempted with the use of isobutyl-chloroformate hydroxyl-
activating agent. In that process impurities co-eluted with the product, and they could not 
be removed with recrystallization either.). This step results in a white powder 70 (2.6 g, 
60% yield). Rf (ethylacetate:hexane, 2:1 v/v%): 0.3. 1H-NMR (300 Mhz, CDCl3): δ 8.0 
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(s, 1H), 5.9 (bs, 1H), 5.1 (bs, 2H), 3.5 (t, J = 6 Hz, 2H), 3.2 (t, J = 6 Hz, 2H), 2.0 (s, 3H), 
1.7 (d, J = 6 Hz, 3H), 1.5 (s, 9H).  13C-NMR (62.5 Mhz, CDCl3): δ 186.2, 170.1, 152.1, 
123.3, 116.0, 106.0, 82.0, 48.8, 39.5, 28.3, 23.1, 21.3. 
 
2-(1-Amino-ethyl)-thiazole-4-carbothioic acid S-(2-acetylamino-ethyl) ester, 71 
This reaction was run under inert athmosphere and the 
reagent and product are highly hygroscopic. 2.1 g of 70 
(5.43 mmol) was dissolved in dry methylene chloride (120 
mL). 5.8 g of lutidine-2,6 (6.4 mL, 55 mmol, 10 equiv) and trimethyl silyl triflate (6.05 g, 
5 mL, 27.2 mmol, 5 equiv) and the reaction was stirred for the next approximately 6 h. 
Methylene chloride (50 mL) was added and solution was washed with NaHCO3 (2 x 60 
mL, pH 11.0). The organic layer was further washed with brine (60 mL). Crude was 
purified by flash column-chromatography (gradient elution: ethylacetate 100% to ethyl 
acetate:methanol 5:1 v/v%). This process results in a lime yellow powder 71 (1.2 g, 55% 
yield). Rf (ethylacetate:methanol, 5:1 v/v%): 0.25. 
(Note: The removal of the Boc-group was attempted with the present method in the 
presence of TEA, a base that would be easier to remove from the crude. TEA at pH 9.0 
does not give efficient cleavage. Lutidine works at pH 5.0. Attempts to deprotect the 
amino group in the presence of SiCl4 and phenol failed.) 1H-NMR (500 MHz, CDCl3): δ 
8.3 (1H), 7.3 (1H), 4.8 (q, J = 7.5 Hz, 1H), 3.3 (d, J = 7.5 Hz, 2H), 3.0 (d, J = 7.5 Hz, 
2H), 1.8 (s, 3H), 1.6 (d, J = 7.5 Hz, 3H). 13C-NMR (125 MHz, CDCl3): δ 188.7, 175.1, 
168.7, 152.2, 129.2, 127.4, 48.8, 39.2, 28.8, 22.6, 19.8. 
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2-(1-Amino-ethyl)-thiazole-4-carbothioic acid S-(2-acetylamino-ethyl) ester 
hydrochloride, 56 
 
71 was dissolved in minimal amounts of THF at room 
temperature, and dry HCl gas was bubbled into the solution 
for the time course over 5-1 min. This hydrogen chloride gas was generated by dropping 
cc. H2SO4 over NaCl in a closed round bottom flask. The white precipitate was 
centrifuged in a benchtop centrifuge to compactness. The supernatant THF was removed, 
and the collected crystals washed with ether followed by ethyl-acetate and by hexane. In 
between each washing crystals were centrifuged to compactness. This treatment resulted 
in a quantitative transformation of 71 to 56 (lemon yellow powder , water soluble, 99% 
yield). Water was removed by lyophilization. Lyophilized samples are highly 
hygroscopic, they need to be stored in sealed vials in the presence of drierite. 1H-NMR 
(300 MHz, CDCl3):  δ: 8.4 (1H), 7.3 (1H), 4.9 (q, J = 6.5 Hz, 1H), 3.4 (t, J = 6.5 Hz, 2H), 
3.2 (t, J = 6.5 Hz, 2H), 1.9 (s, 3H), 1.7 (d, J = 6.5 Hz, 3 H). 13C-NMR (72.5 Mhz, 
CDCl3): δ: 186.6, 173.6, 169.0, 153.4, 129.3, 126.7, 40.1, 29.0, 22.4, 20.9. 
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2-(1-Amino-ethyl)-thiazole-4-carboxylic acid-hydrochloride, 72 
800 mgs of 69 (2.95 mmol) was dissolved in a mixture of 1 mL of 
cc. HCl + 3 mL of dioxane (4M to HCl). The solution was stirred for 
6 h under nitrogen at room temperature. The solution was then 
removed by rotavap and toluene (30 mL) was added to the system and removed on the 
rotavap. Alternatively samples can be lyophilized to dryness. Solid was triturated from 
ether. This process resulted in a qualitative transformation (72, off white powder, 99% 
yield, water soluble). 1H-NMR (500 Mhz, DMSO): δ 13.2 (bs, 1H), 8.8 (bs, 3H), 8.5 (s, 
1H), 4.85 (q, J = 7.5 Hz, 1 H), 1.60 (d, J = 7.5 Hz, 3H). 13C-NMR (125 Mhz, DMSO): δ 
168.8, 163.8, 148.6, 130.7, 20.22. 
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Chapter 6. Noncovalent DNA Binding and Oxidative DNA Damage by 
the Endogenous Mutagen: Fecapentaene-12 
 
 
6.1. Discovery of Fecapentaenes and Introduction to their Biological Activity 
 
 Fecapentaenes (Figure 95) are a class of mutagenic polyunsaturated lipids that are 
produced endogenously in the human gastrointestinal tract. These compounds were 
discovered in etheral extracts of human feces in the late 1970’s. 1-3 Since the amount of 
fecal mutagens were found to correlate with increased risks of colon cancer, 4 
investigations began to find the responsible components. A wide variety of compounds 
were found to lend mutagenicity to human feces3 like the heterocyclic aromatic amines, 
polycyclic aromatic hydrocarbons, N-nitroso compounds, fecal-steroids and the 
fecapentaenes. In works of Bruce and Kingston, direct acting mutagenic activity was 
soon correlated to acid and light sensitive compounds with a polyunsaturated 
hydrocarbon chain attached to a glycerol moiety, the fecapentaenes (73, 74).5,6 Of these, 
the most abundant species is that of fecapentaene-12 (73). It is interesting to note that 
these molecules can be found only in samples from people on a non-vegetarian diet, but 
not in that of people on vegetarian eating.4 
 
 
Figure 95. The structure of fecapentaenes, fecapentaene-12 (73) and fecapentaene-14 (74). 
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The biological activity of these compounds shows a wide scope of deleterious 
reactions both in vivo and in vitro. 7 Fecapentaenes are mutagenic in S. typhimurium 
strain TA 98 (a frameshift sensitive mutant) and TA 100 (a base pair substitution 
sensitive mutant) at micromolar concentrations.8 Human fibroblasts grown in vitro 
exposed to 1-20 µM fecapentaene-12 for 1-3 h produced DNA single-strand breaks and 
DNA-DNA crosslinks. In human lymphocytes, a dose-response relationship between FP-
12 exposure and DNA damage was established. 9 Finally, comparing the genotoxic 
potential of fecapentaenes and that of other direct acting mutagens (N-methyl-N-
nitrosourea and formaldehyde) showed an average of 900-fold higher mutagenic activity 
of the fecapentaenes.10 
Since DNA is a known biological target of these compounds, the nature of the 
DNA-damage processes underlying their potent mutagenic properties are of interest. The 
chemical mechanisms by which this occurs have been the subject of debates. 3,7,11-15 It has 
been shown that a decrease in the number of double-bonds results in diminished 
mutagenicity, which implies the importance of the conjugated pi-bond system in the 
generation of mutagenic responses 16 either via DNA-alkylation or oxidative DNA 
damage (Figure 97).  
Fecapentaenes were suspected to damage DNA via the alkylation of DNA bases 
directly by the electrophilic parent compound17 or its aldehyde degradation products.18 
Once 73 was noticed to induce 2’-deoxy-7,8-dihydro-8-oxoguanosine (8-oxodG, Figure 
96) in calf thymus and rat liver DNA, the involvement of reactive oxygen species was 
suspected behind its DNA-damaging potentials.  
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The generation of superoxide radical (O2-.) by micromolar concentrations of 
fecapentaene-12 was shown to necessitate the actions of enzymatic peroxidation systems 
and the generation of singlet-oxygen was also suggested in the same report. 14 However, 
experiments to provide direct molecular analysis of the mechanism of DNA-damage and 
the direct generation of ROS without the involvement of cellular enzymes have not been 
performed yet.  
 
 
 
Figure 96. 2’-deoxy-7,8-dihydro-8-oxoguanosine (8-oxodG) as an indicator of ROS in the DNA damaging 
reactions of fecapentaenes 
 
 
 
Figure 97. Review of potential DNA damage mechanisms by fecapentaene-12. 
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6.2. Rationale in Studying These Molecules 
 
Difficulties in handling the fecapentaenes due to their intrinsic lability have been 
reported, 18-20 but a qualitative understanding of their stability under well-defined 
conditions has not been attained. We measured the stability of fecapentaene-12 under 
various conditions to develop storage conditions and conditions for our biochemical 
assays.  
The role of reactive oxygen species (ROS) were clear in the DNA damaging 
potential of these molecules14 however, nobody questioned the necessity of peroxidase 
enzymes in the DNA-damaging reactions of FP-12.14 In addition, the role of singlet-
oxygen or superoxide radicals in the direct oxidative DNA damage has not been 
elaborated. We carried out plasmid DNA based assays to study the mechanism of direct 
oxidative DNA damage by synthetic fecapentaene-12. 
We also investigated the ability of 73 to associate with duplex DNA 
noncovalently. This is important because it is known that the DNA-damaging potential of 
agents that generate reactive oxygen species can be enhanced by noncovalent association 
with duplex DNA.21 The grooves of the double helix are hydrophobic, 22-25 and  there are 
indications that long-chain hydrocarbons can associate the duplex DNA noncovalently. 
Aware of the electrophilic properties of 73 and of reports suggesting its 
degradation to aldehydes under physiological conditions, 13,18  we attempted to find 
covalent DNA adducts formed under a variety of conditions (Section 6.10.).  
The identification of the degradation products of fecapentaene-12 is in progress 
during the completion of this thesis. 
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6.3. Overview of the Synthesis of Fecapentaene-12 (73) 
We prepared compound 73 via the eight step synthetic route (Scheme 25 and Scheme 
26) devised by Nicolaou and coworkers, 26,27 with one minor modification. We employed 
the tert-butyl dimethylsilyl groups to protect the alcohol moieties rather than the tert-
butyl diphenylsilyl groups used previously. This approach decreased the reaction time 
required for the final deprotection step, thus minimizing degradation of the unstable 
product (Scheme 27). 
 
Scheme 25. The total synthesis of fecapentaene-12(73) as designed by Nicolaou et al. 
 
 
We started our synthesis from the commercially available glycerol (75) and 
protected two of its adjacent hydroxyl groups selectively to form 76 (acetone-
dimethoxyacetal). This allowed us to activate the terminal OH-group selectively (tosyl-
chloride, pyridine), which gave us 1,2-O-acetonide-3-(R/S)-tosyl-glycerol (77). The 
acetal compound was hydrolyzed (acetone, HCl, reflux) to yield (S/R)-3-tosyloxi-
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propanediol (78), and the free hydroxyl groups were again protected with tert-butyl 
dimethylsilyl chloride to get 1,2-O-(t-butyl-dimethylsilyl)-3-O-tosyl-(S/R)-glycerol (79). 
The terminal tosyl function of this molecule was substituted by potassium-glutaconate 
(80) that had been prepared in a separate effort from the commercially available sulfur-
trioxide piridinium complex (Scheme 26). This substitution (in DMF, 90 °C) results in an 
aldehyde 81. The hydrocarbon chain of this aldehyde (81) was extended in a Horner-
Wittig reaction, using hepta-(2E,4E)-dienyl diphenyl-phosphineoxide (85). The 
phosphineoxide compound 85 had been prepared in a four step route from the 
commercially available heptadienal (Scheme 26). 
 
 
Scheme 26. Synthesis of intermediate synthons 80 and 85. 
 
The result of the extended chain product was an adduct (86) with isolated butadiene 
systems. The Horner-Wittig reaction was accomplished via an elimination reaction from 
86 (KOtBu, -20 °C, THF) yielding the protected fecapentaene-12 (87). The deprotection 
N
SO3
KO O
KOH
-20OC to 45 OC
80
O OHNaBH4, CeCl37H2O
MeOH, RT
82
OCl
ClCl
N N
N
O
83 O
Cl
Cl
CH2C2, RT
(Ph)2PH, n-BuLi, -78OC P P
O
84 85
10% H2O2, RT
Synthesis of  80
Synthesis of  85
THF THF, ether
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 241 
was carried out by TBAF, which yields the target compound fecapentaene-12 (73, 
Scheme 27). 
 
 
Scheme 27. Our modification in the synthesis of fecapentaene-12 (73). We applied tert-butyl dimethylsilyl 
protection instead of the tert-butyl diphenylsilyl protecting group to decrease deprotection time. 
 
 
6.4. Quantitative Stability of Fecapentaene-12 in Organic and Aqueous media 
The rapid degradation of pure fecapentaene-12 was reported 27 after its first 
synthesis and was observed in early carcinogenicity studies, too. 19 Confusingly, 73 
showed variable decomposition rates in replicate experiments and it was generally 
accepted that biological assays are hampered due to the compound’s apparent instability. 
20
 The stability of fecapentaene-12 has not been measured yet under well-defined 
conditions. The purity of our material in our assays and its fate during our experiments 
are equally important, since we wanted to identify the exact molecular species (all-trans-
fecapentaene-12, fecapentaene-12 isomers, and degradation products) responsible for the 
observed DNA damaging Chemistry. 
First, we wanted to develop storage conditions for repeated use. Storage at -70 °C 
in DMSO solutions, in sealed and dark vials, had been suggested in the literature. 19 
However, due to the slow evaporation of DMSO, which makes it difficult to concentrate 
samples, we did not find this solvent an optimal solution. Aware of the reported aerobic 
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lability of 73 and its ability to generate radicals that can further catalyze the degradation 
of the parent compound, we thought, that a radical scavenger medium: ethanol would be 
a better choice. We stored our samples at different temperatures (1-2 mM) in ethanol. The 
concentration of our FP-12 stock solutions were determined by U.V. absorbance 
measurements (Figure 98.; ε355nm ~ 100 000 M-1cm-1). 19 We followed the degradation of 
our stock solution by HPLC (Figure 99). The identity of fecapentaene in our 
chromatograms had been established by diode array HPLC method (Figure 102). We 
plotted the percentage of intact fecapentaene-12 vs. time (Figure 100). We observed that 
the lower the temperature and the more dilute the solution of FP-12, the longer its life-
time. 
 
 
 
 
 
 
 
Figure 98. UV scan of freshly synthesized fecapentaene-12 in 100% ethanol (ε355nm ~ 100 000 M-1cm-1) 
 
 
 
 
 
 
 
 
 
 
Figure 99. The HPLC of fecapentaene-12 (73). Peaks: 8 min: suggested polyconjugated hydrolytic 
degradation product, 18-20 min small peaks: cis-trans fecapentaene-12, 21 min: fecapentaene-12. Diode 
array HPLC was used in the identification of the 21 min peak as of 73. 
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Figure 100. The degradation of fecapentaene-12 stock in absolute ethanol under refrigeration at different 
temperatures and concentrations 
 
 
 
Next, we studied the stability of 73 under physiological conditions. In our DNA-
damage studies with small organic molecular analogs of natural products 28 we mostly 
have used acetonitrile co-solvents and sodium phosphate buffer. We measured the half-
life of 73 at different concentrations at 37 °C in the presence of 50 mM sodium phosphate 
buffer and 10% acetonitrile (v/v). The degradation of fecapentaene-12 (73) is first-order 
in 73 (Figure 101). This kinetic data and later spectral analysis suggested that the primary 
degradation is the hydrolysis of  73. 
 
 
 
 
 
 
 
Figure 101. The rates of degradation of 73 vs. its concentration. Conditions: 50 mM sodium phosphate 
buffer, pH 7.0, 10 % acetonitrile (v/v), 37 °C incubation. Concentrations of fecapentaene-12: 0.2 M, 0.3 M, 
0.4 M, 0.75 M, 1 M. 
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6.5. Semi-Qualitative Analysis of the Degradation of 73 Under Inert, Dark, 
Ambient Conditions and Exposed to Sunlight Using Diode-Array HPLC. 
 
To confirm the identity of the 21 min peak found in our earlier HPLC-s and to 
understand of the fate of 73 under physiological conditions we followed the degradation 
of  fecapentaene-12 by diode-array HPLC. The 21 minute peak was positively identified 
as of 73 (Figure 102).  
Upon exposure to aqueous buffer under inert conditions we observed that 73 (21 
min) deconjugates to a compound with a possibly smaller molecular weight (8 min)29 
(Figure 103, left panel) with an intact conjugation system. Based on information about 
the hydrolysis of enolether compounds, 18 we suspect that 73 hydrolyzes with the 
disruption of the C-O-bond  similar to the hydrolysis shown in Scheme 28.  
Additional buffered samples of 73 were exposed to ambient air and their diode 
array HPLC (Figure 103, right panel) showed the appearance of a compound with longer 
retention time (31 min) and the disruption of the polyconjugated pi-system. With 
information about the potential products in lipid peroxidation reactions 30 we suggest that 
under such conditions 73 polymerizes possibly via radical intermediates (Scheme 29). 
 
 
 
 
Scheme 28. Suggested degradation pathway of fecapentaene-12 in aqueous buffer under inert conditions. 
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Scheme 29. Suggested degradation processes of 73 in aqueous buffers exposed to air. 
 
 
Figure 102. Diode array HPLC of 73 (21 min). 
 
 
Figure 103. Diode array HPLC of a sample of fecapentaene-12 exposed to aqueous buffer under nitrogen 
(left panel) and ambient air (right panel). 
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Finally, we exposed a freshly made sample of 73 (200 µM) in sodium phosphate 
buffer to sunlight for 5 min. Diode array HPLC of the resulting mixture showed that 73 
(21 min) and the hydrolytic aldehyde degradation peak (89, 8 min) appeared to turn into 
multiple peaks of close retention times (Figure 104) suggesting the cis-trans 
isomerization of their hydrocarbon chain. Prolonged exposure to neon-light did not result 
in such isomerizations, which suggests that the high-energy UV-component of sunlight is 
important in generating these isomers. 
 
 
 
 
 
 
 
 
Figure 104. HPLC of freshly made fecapentaene-12 solution in 50 mM sodium phosphate buffer (pH 7.0), 
exposed to sunlight for 5 min under nitrogen. 
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6.6. The Mechanism of Oxidative DNA-Damage Caused by Fecapentaene-12 and 
Authentic Superoxide-Radical Generators: Vitamin A and Hydroquinone 
 
We employed a plasmid-based assay to characterize the DNA-cleaving properties 
of 73. In this assay, a single-strand DNA-cleavage converts supercoiled double-stranded 
plasmid (form I) into the open circular form (II). 31 The two forms of plasmid DNA are 
then separated using agarose gel electrophoresis and visualized by staining with ethidium 
bromide. We find that incubation of 73 with plasmid DNA leads to the production of 
direct single-strand breaks, and the amount of DNA cleavage increases with 
concentration of 73 and is more enhanced under aerobic compared to unaerobic 
conditions. Furthermore, when we used deionized (Chelexed) water and buffer an evident 
decrease in the cleavage efficiency was observed. (Figure 105). 
 
 
 
 
 
 
 
 
Figure 105. Plasmid DNA cleavage by increasing concentrations of freshly synthesized fecapentaene-12 
under aerobic and anaerobic conditions, and using chelexed water and buffer under ambient conditions. 
Conditions: PGL2BASIC plasmid DNA (35 mM), sodium phosphate buffer (50 mM), acetonitrile (10% 
v/v). The concentrations of 73 were: 0 µM, 40 µM, 80 µM, 120 µM, 160 µM, 200 µM. Errors were 
calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
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We then carried out a series of experiments designed to examine whether DNA 
strand cleavage by 73 occurs via the cascade of reactions involving reduced oxygen 
species shown in Equation 56, Equation 57, Equation 58 and Equation 59. We find that 
DNA cleavage by 73 can be inhibited by addition of typical radical scavengers methanol, 
ethanol and mannitol, by the hydrogen peroxide-destroying enzyme catalase, and by the 
chelator of adventitious trace metals, desferal, which is known to suppress the metal-
dependent Fenton reaction (Equation 58, where Mn+ is a transition metal such as Fe2+). 
30Addition of the enzyme superoxide dismutase (SOD) also inhibits DNA strand 
cleavage, presumably by preventing superoxide-dependent reduction of the trace metals 
(Equation 59)30 that are required for the Fenton reaction (Equation 58). The effect of 
these additives are summarized in Figure 106 and Table 12. The effect of SOD will be 
further discussed for authentic superoxide radical (O2•-) generators in Section 6.6. 
 
Equation 56 
 
 
Equation 57 
 
Equation 58 
 
Equation 59 
 
 
 
 
 
73   +   O2                  O2   +   73
O2   +   HO2                    H2O2   +   O2
H2O2   +   Mn+                     HO    +    OH    +   M(n+1)+
O2   +   M(n+1)+                     O2   +   Mn+
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Figure 106. Plasmid DNA cleavage by fecapentaene-12 (200 µM) in the presence of various additives. 
Conditions: sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v). The additives used were: 
methanol (200 mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), SOD (100 µg/mL),  
catalase (100 µg/ml). Errors were calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
 
We compared DNA damage by 73 to that by other authentic superoxide-radical 
generators vitamin A32 (Figure 107) and hydroquinone33 (Figure 107). Previous works 
have shown these agents to produce superoxide radical under physiologically relevant 
conditions, and accordingly we observed that they caused oxidative DNA damage via a 
mechanism similar to that of fecapentaene-12, but with lower efficiency (Figure 109, 
Figure 111). 
 
 
 
 
Figure 107. The structure of vitamin A and hydroquinone, known superoxide radical generators, used as 
positive controls in our experiments.  
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Figure 108. Plasmid DNA cleavage by increasing concentrations of vitamin A under aerobic and anaerobic 
conditions. Conditions: PGL2BASIC plasmid DNA (35 mM), sodium phosphate buffer (50 mM), 
acetonitrile (10% v/v). The concentrations of vitamin A were: 0 µM, 40 µM, 80 µM, 120 µM, 160 µM, 200 
µM. Errors were calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
 
 
 
 
 
 
 
 
Figure 109. DNA cleavage by vitamin A (300 µM) in the presence of various additives. Conditions: 
sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v). The additives used were: methanol (200 
mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), SOD (100 µg/mL),  catalase (100 
µg/ml). Errors were calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
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Figure 110. Plasmid DNA cleavage by increasing concentrations of hydroquinone under aerobic and 
anaerobic conditions. Conditions: PGL2BASIC plasmid DNA (35 mM), sodium phosphate buffer (50 
mM), acetonitrile (10% v/v). The concentrations of hydroquinone were: 0 µM, 80 µM, 160 µM, 240 µM, 
320 µM, 400 µM. Errors were calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 111. Plasmid DNA cleavage by hydroquinone (HQ: 250 µM) in the presence of various additives. 
Conditions: sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v). The additives used were: 
methanol (200 mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), SOD (100 µg/mL),  
catalase (100 µg/ml). Errors were calculated using 67% confidence (n=2). S value = - ln (%uncut / 100). 
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6.7. Discussion of the Differences in the Effect of SOD on the Plasmid-DNA 
Cleavage by 73, Vitamin A and Hydroquinone 
 
Vitamin A and hydroquinone are known superoxide radical generators. However, 
they respond differently in their DNA cleavage SOD (Figure 112). Vitamin A is inhibited 
by SOD, which we can understand in view of the fact that superoxide is removed by 
SOD, and superoxide is necessary to recycle the trace metals that have been oxidized in 
the production of hydroxyl radicals (Equation 58). Inhibition by SOD is observed in the 
context of in vitro systems where alternative metal-reducing agents such as ascorbate or 
thiols are not present.30  
On the other hand SOD induces strand cleavage in the presence of hydroquinone, 
which we explain by the fact that HQ is known to generate superoxide radical in an 
equilibrium fashion (Scheme 30).30 This equilibrium explains why our calibration curve 
was not linear (Figure 110).  Addition of SOD will pull this equilibrium to the production 
of superoxide radical, and an immediate dismutation of this radical agent to hydrogen 
peroxide. An increased concentration of H2O2 will help the formation of hydroxyl radical 
(Equation 58), which is eventually the DNA damaging ROS. In addition, SOD generates 
H2O2 which further yields the DNA-damaging hydroxyl radical. 
  
 
 
 
Scheme 30. Superoxide radical generation by hydroquinone is an equilibrium process. 
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Figure 112. The response of different superoxide-radical generators to the presence of SOD in their DNA 
cleavage assay. (Cleavages were isoscaled). S value = - ln (%uncut / 100). 
 
 
6.8. DNA Damage by Partially Degraded Fecapentaene-12 
 
A number of reports have detailed that degraded fecapentaene-12 has vastly 
decreased ability to cause DNA strand breaks (Figure 113). As we described in sections 
6.4 and 6.5 73 indeed is labile. Here we further demonstrate that exposure of 
fecapentaene-12 for 5 h to buffered solutions in the resence of acetonitrile co-solvent 
(Figure 113, curve B) or ethanol co-solvent (Figure 113, curve C), essentially no DNA-
cleaving activity remains. Earlier work has shown that the mutagenic activity of the 
fecapentaenes diminishes upon preincubation. 19 
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Figure 113. DNA cleavage by fecapentaene-12 (A)that of FP-12 pre-incubated in acetonitrile-buffer for 5 h 
(B) and that of FP-12 pre-incubated in ethanol-buffer for 5 h (C). Errors were calculated using 67% 
confidence (n=2). S value = - ln (%uncut / 100). 
 
6.9. Noncovalent Binding by Fecapentaene-12 
 
We investigated the ability of 73 to associate noncovalently to duplex DNA. 
Noncovalent binding is known to enhance the DNA damaging potential of natural 
products in general and that of agents that generate reactive oxygen species. 21 The 
grooves of the double helix are hydrophobic22-25 and there are some intriguing indications 
that long-chain hydrocarbons can associate noncovalently with duplex DNA. 34-36 To date 
however, this mode of DNA binding has not been well characterized. 
6.9.1. Ethidium Bromide Displacement by 73  
To explore whether 73 associates noncovaletnly with DNA, first, we used the 
well-known ethidium-displacement assay. 37,38 This technique employs fluorescence 
spectroscopy to quantitatively monitor the ability of a putative DNA-binding agent to 
displace intercalated ethidium from the DNA double helix. A wide variety of DNA-
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binding molecules including intercalators, groove binders and polycations are able to 
displace ethidium in this type of assay. 37-42 
 We find that titration of the ethidium-DNA complex with micromolar 
concentrations of 73 causes displacement of the ethidium fluorophore from the duplex 
(Figure 114). 
 
Figure 114. The remaining fluorescence of intercalated ethidium bromide vs. the concentrations of 73. 
 
Calculations 37,38 based upon the concentration of 73 required to displace 50% of the 
DNA-bound ethidium yield an association constant of 6.5 ± 1.1 x 104 M-1 for the 
noncovalent association of 73 with duplex DNA. These calculations assume that 73 and 
ethidium bromide compete for the same binding sites on DNA and most likely 
overestimate the binding constant. Nonetheless, this measurement offers a useful estimate 
regarding the affinity of 73 for the double helix. 
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6.9.2. Effect of Added Duplex DNA on the UV-vis Spectrum of 73 
 We further confirmed the noncovalent interaction of 73 with duplex DNA using a 
UV-vis spectroscopic assay.  The UV-vis spectra of organic ligands are often perturbed 
upon association with DNA. 38,43,44 We find that titration of 73 with duplex DNA yields a 
concentration-dependent change in the UV-vis spectrum of 73 (Figure 115., left panel). 
Specifically, addition of DNA to 73 causes a 40% decrease in the absorbance, without 
any significant change in the absorbance maxima. This type of hypochromism without a 
concurrent red shift or blue shift in the spectrum has been reported for other agents that 
associate with the duplex via a groove-binding mode. 45 A control experiment indicates 
that the changes observed in the UV-vis spectrum of 73 during the titration are not due to 
decomposition of the compound (Figure 115., right panel). While decomposition yields 
qualitatively similar changes in the spectrum of 73, the control reaction shows that 
incubation of 73 with 10 mM bp DNA (in water) for 25 min yields relatively small (10%) 
changes in the UV-vis spectrum. The observed changes in the UV-vis spectrum of 73 
also cannot be ascribed to a salt effect resulting from the addition of DNA-phosphate 
residues, as we find that addition of analogous amounts of sodium phosphate buffer does 
not cause a marked change in the spectrum. Perturbation of the UV-vis spectrum of 73 
upon addition of DNA has been observed previously, 46 although the exact experimental 
conditions were not described. 
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Figure 115. Changes in the UV-vis spectra of 73 with increasing concentration of duplex DNA. Aliquots 
of herring sperm (A, left panel)  and UV-vis absorption of 73 ( 40 µM ) in 50 mM sodium phosphate buffer 
(pH 7.0) and 25 % acetonitrile vs time (B, right panel). DNA were added to a solution of 73 (40 µM) in 50 
mM sodium phosphate buffer (pH 7.0, containing 25% acetonitrile). The concentration of 73 was 
maintained at 40 µM for each measurement. The absorbance of 73 decreases with increasing DNA 
concentration. The DNA concentrations (in bp) for each curve (from top to bottom) were: 0, 1 mM, 2 mM, 
4 mM, 6 mM, 8 mM. Right panel: Recordings were done at the following times: 0 min, 2 min, 5 min, 10 
min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min. 
 
6.9.3. Determining the Binding Constant and the Binding-Site Size by the 
McGhee-von Hippel Analysis47 
 To determine the size of space one fecapentaene-12 molecule can occupy in 
DNA, and to refine its binding constant, we followed the procedure described by 
McGhee and von Hippel earlier. 47 Accordingly, with a few iterations for different 
binding site sizes (Equation 60) we determined that fecapentaene-12 spans a range of 6 to 
10 bp in DNA with a modest binding constant (KB = 1029 ± 190 M-1 and n = 8 ± 2, 
Figure 116).  
         Equation 60 
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Figure 116. McGhee von Hippel analysis of the DNA binding by fecapentaene-12. 
 
 
6.10. Searching for DNA-adducts of 73 by Nuclease Digestion 
 
 We have tried to study DNA alkylation in a few different ways. Base mediated 
workup of our plasmid assays (using DMEDA) did not prove the presence of base labile 
DNA-adducts. Incubation of DNA in the presence of  73 and sodium cyanoborohydride 
to stabilize suspected adducts of the aldehyde degradation products, similar to the work 
of Lawrence J. Marnett,48 and subsequent HPLC analysis of the reaction mixtures did not 
provide us with evidence for labile DNA adducts either.   
 Finally, we investigated the likelihood for the presence of non-labile DNA 
adducts, applying rapid acidic nuclease digestion as has been shown by Peter F. 
Guengerich et al. 49 Analysis of digests by HPLC (Figure 117) disclosed extra peaks in 
the presence of 73 but a more elaborate investigation of the origins of these peaks is still 
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required in the future. A revision of this work is strongly suggested along with the 
identification of degradation products of 73 after its incubation under physiological 
conditions, possibly using GC-MS and LC-MS methods. 
 
 
 
 
 
 
 
 
 
Figure 117. HPLC analysis of the digestion mixture of DNA + 73 after digestion with PDE + DNAse II + 
AcP-ase. The experiment revealed new peaks (10 min, 15 min, 17 min, 21 min, labelled) in the presence of 
73 the origin of these is under investigation. 
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6.11. Chapter Conclusions 
 
We synthesized fecapentaene-12 and managed to find optimal conditions for its 
extended storage in absolute ethanol solution at minus 80 °C at a stock concentration of 
1.5 mM. Higher concentrations and temperatures resulted in faster degradation of the 
molecule. To estimate the purity of our stocks we used RP-HPLC and we found the 
average purity of fecapentaene-12 used in our DNA reactions above 85%. Impurities 
were mostly constituted of light induced cis-trans-isomerization products of the parent 
compound. From the concentration dependence of its stability (Figure 101), we assume 
that degradation of 73 in buffers is the result of self-catalytic processes. After exposure of 
73 to aqueous buffers under anaerobic and aerobic conditions and analyzing the samples 
by diode array HPLC, we suspected hydrolytic and oxidative processes as key players in 
the degradation of our molecule (Scheme 28 and Scheme 29). We also showed this by 
diode-array-HPLC analyses of the degradation mixture. Furthermore, quick exposure of 
freshly made buffer solutions of 73 to sunlight under inert conditions showed very rapid 
cis/trans isomerization of the hydrocarbon tail (Figure 99), which did not happen when 
samples were similarly exposed to neon-light. 
Our synthetic fecapentaene-12 is a potent DNA damaging agent, more effective 
under aerobic than deoxygenated conditions. With the knowledge that oxidative 
chemistry can lend mutagenecity to a compound,50-52 we wanted to identify the ROS 
responsible for the DNA damage by FP-12. We identified the ROS in the direct 
generation of superoxide-radical (O2•-), H2O2 and OH•, and they clearly can contribute 
to the potent mutagenicity of the fecapentaenes.52 Interestingly, authentic superoxide-
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radical generators respond differently to the addition of SOD in their plasmid DNA 
cleavage assays (Figure 112). The findings presented in Figure 112 are consistent with a 
mechanism where 73 causes DNA strand cleavage via the well-known 30 cascade of 
reactions shown in Equation 56 to Equation 59, in which hydroxyl radical is produced as 
the ultimate DNA-cleaving agent. Hydroxyl radical is a well-known DNA-damaging 
agent. 50,51,53,54 Additionally, it is reported that fatty acids generate superoxide radical 
upon their breakdown. 3 The initial steps in this overall process likely involve oxidation 
of the polyene framework in 73 to yield superoxide radical (O2•-) and the resonance 
stabilized polyene radical cation. 18,55 Subsequent reactions involved in the aerobic 
degradation of 73 are poorly defined and undoubtedly complex. 55,56  While much recent 
work has focused on peroxidase dependent 57 production of superoxide by 73, 3,14,15 our 
results demonstrate the potential of this compound to directly generate DNA-damaging 
reactive oxygen species via interaction with molecular oxygen. 
 Others have suggested 14,15 that the fecapentaenes may produce the DNA 
damaging species singlet oxygen and hydroxyl radical by means of the Haber-Weiss 
reaction (Equation 61). However, this seems unlikely in light of studies from several 
groups showing that this general pathway essentially does not occur under physiological 
conditions. 58-61 In fact, the evidence supporting the generation of singlet oxygen by the 
fecapentaenes is not overwhelming. For example, inhibition of DNA damage by sodium 
azide has been taken as a sign of singlet oxygen involvement. 15 However, while sodium 
azide does, indeed, quench singlet oxygen 62-64 it also effectively scavenges hydroxyl 
radical, with a rate constant of 1.2 x 1010 M-1s-1 .65  Furthermore, reactions of 
fecapentaene with DNA have been carried out in D2O, which increases the lifetime of 
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singlet oxygen, but only minimal increases in damage yields were observed. 14 In cases 
where singlet oxygen is clearly involved, large increases in the yields of DNA damage 
typically are observed when the reaction is preformed in D2O. 66 Rather than invoking 
singlet oxygen, it seems likely that much of the published data regarding oxidative DNA 
damage by the fecapentaenes (both enzyme dependent and spontaneous) can be 
rationalized in terms of the chemical reactions shown in Equation 56Equation 57 and 
Equation 58. 
 
Equation 61 
 
 
 We have shown that the degradation products of fecapentaene-12 are less 
effective DNA damaging agents (Figure 113). 
 Studying fecapentaene-12-DNA complexes by two different spectroscopic 
methods revealed that 73 shows noncovalent association to duplex DNA with a modest 
binding constant (2 x 103 M-1 < KB < 6.4 x 104 M-1). Thus, the fecapentaenes provide an 
interesting new example highlighting the potential for long chain hydrocarbons to 
associate noncovalently with double-helical DNA. With the help of McGhee and von 
Hippel analysis, we refined our binding constants, and calculated that fecapentaene-12 
might occupy a 6 to 8 base-pair size space on DNA. 
 Several of our attempts to find DNA adducts formed by fecapentaene-12, using 
stabilization of labile adducts and searching for base-labile and nonlabile adducts, failed 
to provide clues about DNA adducts. However, revision of adduct detection and that of 
the identification of degradation products of 73 is strongly suggested. 
H2O2   +   O2                      HO   +   O2   +   HO
singlet
oxygen
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Our achievements clarified the mechanism of oxidative DNA damage directly by 
the endogenous fatty-acid metabolite: fecapentaene-12 without the involvement of any 
enzymes. 
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6.12. Experimental 
 
6.12.1. Materials and Methods 
Materials were obtained from the following suppliers and were of the highest purity 
available: tetrabutylammonium fluoride, potassium carbonate, sodium phosphate, 
bromophenol blue, sucrose, EDTA, HEPES buffer, desferal, glycerol, tert-butyl 
dimethylsilyl chloride, tosyl chloride, imidazole, pyridine, N, N’-dimethyl amino 
pyridine, pyridine sulfur-trioxide complex, lithium di-isopropyl amide, n-butyl lithium, 
diphenyl phosphine, hepta-(2E, 4E)-dienal, Aldrich Chemical Co. (Milwaukee, WI); 
HPLC grade solvents (water, acetonitrile, ethanol, methanol, diethyl ether, 
tetrahydrofuran), 30% H2O2, Fisher (Pittsburgh, PA); ethidium bromide, herring perm 
DNA, Roche Molecular Biochemicals (Indianapolis, IN); agarose, Seakem; catalase, calf 
thymus DNA, SOD, DNA-digestion enzymes (nuclease, phosphatase), Sigma Chemical 
Co. (St. Louis, MO). The plasmid pGL2BASIC was prepared using standard methods.67 
 Instrumentation: balances: Denver Instrument M-220 D and Denver Instrument 
TR-4102; pipetmans: Gilson; HPLCs: RAINN 10 SS pump, VARIAN ProStar 210 25 SS 
pumps with Star Chromatography vs. 5.51 software; WATERS with Breeze Basic; pH 
meter: thermo-ORION 420; UV: Hewlett Packard HP8452A Diode Array w/89090A 
cuvette temperature controller; NMRs; Bruker; Agarose electrophoresis power supply: 
EC 154; Gel-imaging system: Alfaimager; Fluorimeter: Interational Technologies; 
Benchtop centrifuge: CLOVER LABS (6 x 2 mL); Medium-size centrifuge: Eppendorf 
5415C; SpeedVac Instrument: SAVANT  Speed Vac. SC 110; Vortex: Fischer VORTEX 
Genie 2. LC-MS: ThermoFinnigan TSQ7000 triple-quadrupole with API2 source. 
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6.12.2. Synthesis of Fecapentaene-12 (73) 
 
1,2-O-acetonide-3-hydroxyglycerol (76)68 
To a solution of glycerol (75, 12.8 g, 140 mmol) in ethylene glycol 
dimethyl ether (72 mL) acetone dimethoxyacetal was added (32.6 mL, 
25.58 g, 168 mmol, 1.2 equiv) under stirring at room temperature. A catalytic amount of 
stannous chloride, SnCl4, (30 mg, 0.7 mmol, 0.005 equiv) was added and the solution was 
refluxed for 1.5 h. The reaction mixture was cooled and treated with pyridine (25 µL). 
Solvents were removed via rotavap ( 100 Hgmm, 35-45 °C) and the concentrate was 
redissolved into ethyl acetate (80 mL). This solution was washed in a separatory funnel 
with an aqueous salt solution (5% NaOH in saturated NaCl, 3 x 25 mL). The organic 
layer was dried over Na2SO4 and concentrated on rotavap. This resulted in a crude 
mixture as a glacial transparent oil (76) (14 g, 98% yield). 1H-NMR: (CDCl3, 250 MHz) 
σ 1.3 (3H, s), 1.4 (3H, s), 3.2 (1H, m), 3.4 (1H, m), 3.5 (1H, m), 3.55 (1H, m), 3.75 (1H, 
m), 4.0 (1H, m), 4.3 (1H, m), 13C-NMR: (CDCl3, 62.9 MHz) σ 24, 25, 27, 48, 58, 63, 66, 
71, 75, 76, 100, 110. 
 
1,2-O-acetonide-3-(R/S)-tosyl-glycerol (77) 
Compound 76 (14g, 106 mmol) was added to pyridine (58 mL) and the 
solution was ice cooled. To the cooled solution, p-toluolsulfonic acid 
chloride (20.2 g, 98 mmmol, 1 equiv) was added in small portions over a period of 5 
minutes. This results in a clear lemon-yellow solution. This was stored at 4°C overnight 
until ale-red needle crystals showed up in the reaction flask. Without filtration of the 
OH
O
O
OTs
O
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mixture diethyl ether was added (60 mL), and the solution turned turbid. The organic 
layer was washed with HCl (1N in portions of 10 mL) until the washing liquid turned 
acidic. The organic layer was further washed with a saturated solution of NaHCO3 (20 
mL) and dried over Na2SO4, concentrated on rotavap. The resulting pink oil slowly 
solidifies into a pale yellow soap (77) (20 g, 75 % yield). 1H-NMR: (CDCl3, 250 MHz) σ 
1.4 (3H, s), 1.5 (3H, s), 2.45 (3H, s), 3.7 (2H, dd), 4.0 (1H, d), 4.05 (1H, s), 4.2 (1H, p), 
7.35 (2H, d), 7.85 (2H, d); 13C-NMR: (CDCl3, 62.9 MHz) σ 21, 25, 26, 66, 70, 73, 110, 
127, 130, 133, 145. 
 
(S/R)-3-tosyloxi-propanediol (78) 
Compound 77 (7.1 g, 55 mmol) was dissolved in acetone (5.5 mL) and to 
this solution 1N HCl (16 mL) was added. The resulting mixture was 
heated on an oil bath for 30 min, then cooled and frozen on a dry ice-acetone cooling 
mixture. The frozen material was lyophilized at minus 43 °C temperature and 10-3 bar 
pressure overnight. This resulted in a yellow viscous oil (6.5 g, 98 % yield). 
Alternatively, the cooled reaction mixture can be extracted with ethylacetate (100 mL) 
washed with water (20 mL) twice and brine (20 mL), then dried over Na2SO4 and purified 
on a thin pad of silica (gel filtration). 1H-NMR: (CDCl3, 250 MHz) σ 2.4 (3H, s), 3.3 
(2H), 3.5-3.7(3H, m), 3.9(1H, m), 4.1 (1H, dd), 7.35(2H, d), 7.85(2H, d).; 13C-NMR: 
(CDCl3, 62.9 MHz) σ 21, 62, 69, 71, 128, 130, 133, 145. 
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1,2-O-(t-butyl-dimethylsilyl)-3-O-tosyl-(S/R)-glycerol (79) 
Compound 78 (14.4 g, 59 mmol) was dissolved in DMF (50 mL, 
predried on molecular sieves, or frehly purchased). Imidazole (25 g, 
368 mmol, 6.3 equiv) was added to the system. Stirring began, and after all the 
components dissolved (clear yellow solution), dimethyl tert-butyl silylchloride (35 g, 128 
mmol, 2.2 equiv) was added to the solution dropwise over a period of 5 minutes. After 1-
2 h the reaction mixture turned turbid. After 8 h water (50 mL) and diethyl ether (1200 
mL) were added. The organic layer was further washed with water (50 mL), brine (2 x 50 
mL) and dried over K2CO3 and purified by flash column chromatography (10% diethyl 
ether in hexane), and 79 was isolated (23 g, 92% yield). Rf.: 0.3 (30% ether in hexane). 
1H-NMR: (CDCl3, 250 MHz) δ 0.93 (9H, s), 0.98 (9H, s), 2.40 (3H, s), 3.55 (1H, t, J=4.7 
MHz), 4.05 (2H, dd, J=5.2 Hz); 7.24 (4H, dd), 7.32 (6H, m), 7.39 (4H, t), 7.45 (4H, q), 
7.54 (4H, q), 7.66 (2H, d); 13C-NMR: (CDCl3, 62.9 MHz) δ 19 (m), 20 (m), 22 (m), 28 
(str), 28 (str), 65 (m) 71 (m), 72 (m), 128 (m), 129 (m), 131 (m), 136 (str), 136.5 (str), 
137 (str), 137.5 (str). 
 
Potassium glutaconate (80) 
Potassium hydroxide (52 g) was dissolved in water (126 mL). This 
solution was cooled to minus 20 °C, and sulfur-trioxide pyridinium complex salt was 
dissolved in it (36 g, 225 mmol). The solution turned a lemon yellow color. A mechanical 
stirrer with a stirring rod was used for stirring of the mixture, and the temperature was 
maintained for one hour. After 1h the temperature was raised to room temperature over 
the course of four hours. During this time the color of the solution deepens to orange and 
OTs
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red, eventually. The mixture was heated quickly to 40 °C and stirred further at this 
temperature for 30 min. The mixture was finally cooled to 5 °C to facilitate the 
crystallization of the product. The crude material was filtered off and washed with 
acetone to remove water. The pad of brownish solid material was air dried for an hour on 
respirator vacuum. The remaining solid was further dried in high vacuum overnight at 60 
°C, using a sand-bath. At this point checking the activity of 80 in our SN2 displacement 
should be done. If compound does not show activity, then recrystallize it again from 
methanol (400 mL) at refluxing temperature; add charcoal (5-8 g) to remove impurities. 
After filtration, methanol was removed by rotavap at low temperature, and the resulting 
solid needs to be dried under vacuum overnight. This operation results in a redish-yellow 
to lemon yellow powder with matching NMR. (25 g, 70 % yield). 1H-NMR: (CDCl3, 250 
MHz) δ 5.1 (2H, q, J1 = 12 Hz, J2 = 15 Hz), 7.0 (1H, t, J=15 Hz), 8.6 (2H, d, J = 12 Hz). 
13C-NMR: (CDCl3, 62.9 MHz) δ 105 (m), 160 (m), 185 (m). 
 
5-[2,3-Bis-(tert-butyl-dimethyl-silanoxy)-propoxy]-penta-2,4-dienal (81) 
Compound 79 (1 g, 1.38 mmol) was dissolved in DMF (7 
mls) or for better reults THF might be used. Potassium glutaconate  (80, 0.85 g, 6.25 
mmol, 4.5 equiv) was dissolved and the reaction mixture was kept under argon and 
stirred at 90 °C for 3-4 hrs. The appearance of the product should be followed by TLC 
(Rf.: 0.25 in 30% diethyl ether in hexane), as long exposures to this temperature also 
degrades the target aldehyde (81). The reaction mixture was cooled on ice and diethyl 
ether was added to it (150 mL), followed by water (20 mL). The organic layer was 
washed with water twice (20 mL), followed by brine (20 mL), then dried over potassium 
O
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carbonate. The solution was concentrated on rotavap and purified by quick flash column 
chromatography (gradient, 10-20% diethyl ether in hexane) on a short column. Silica gel 
was deactivated by TEA (3% w/w). After isolation the process results in a clear labile oil 
(400 mg, 64 %)that needs to be refrigerated. Alternatively, an aseotropic drying and 
storage over benzene at minus 20 °C is suggested. Rf.: 0.25 in 30% diethyl ether in 
hexane. 1H-NMR: (CDCl3, 250 MHz) δ 1.02 (9H, s), 1.04 (9H, s), 3.60-3.72 (2H, m), 
3.86-4.06 (3H, m), 5.63 (1H, t, J = 12 Hz), 5.99 (1H, dd, J1 = 8 Hz, J2 = 15 Hz), 6.78 (1H, 
d, J = 12 Hz), 6.94 (1H, dd, J1 = 12 Hz, J2 = 15 Hz), 7.27-7.48 (12 H, m), 7.53-7.64 (8H, 
m), 9.43 (1H, d, J = 8.1 Hz); 13C-NMR: (CDCl3, 62.9 MHz) δ 0 (m), 25 (m), 30 (str), 70 
(m), 75 (m), 77 (m), 110 (m), 132 (m), 155 (m), 165 (m), 198 (m). 
 
Hepta-(2E, 4E)-dienol (82) 
To avoid foaming out of the reaction flask, this procedure requires a 
round bottom flask with a minimum 250 mL volume. Hepta-(2E, 4E)-dienal (2.55 g, 23.2 
mmol) was dissolved in methanol (26 mL), and CeCl37H2O (10.2 g, 27.3 mmol, 1.2 
equiv) was added to the solution. In small portions NaBH4 (1.2 g, 31.5 mmol, 5.5 equiv) 
was added and heavy bubbling of hydrogen gas was observed. The progress of the 
reaction was followed by TLC (30% diethyl ether in hexane, Rf starrting material.: 0.6, Rf 
product: 0.25). After 20 minutes methylene chloride (650 mL) was added to the reaction 
mixture followed by water (16 mL). The organic layer was further washed with water (25 
mL) and brine (25 mL). Product was dried over K2CO3, concentrated and purified on a 
flash chromatographic column (30% ether in hexane), which yields a rancid fatty-acid 
smelling viscous oil (2.3 g, 95% yield). 1H-NMR: (CDCl3, 250 MHz) δ 0.95 (3H, t, J = 
OH
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12 Hz), 2.1 (2H, q, J =  12 Hz), 4.1 (2H, t), 5.6-5.8 (2H, m, J = 15 Hz), 6-6.2 (1H, t, J = 
15 Hz). 13C-NMR: (CDCl3, 62.9 MHz) δ 13, 25, 63, 127, 129, 131, 137. 
 
Hepta-(2E, 4E)-dienyl-1,6-dichlorobenzoate (83) 
Hepta-(2E, 4E)-dienol (82, 2 g, 18 mmol) was dissolved in 
methylene chloride (20 mL) under argon/nitrogen. Pyridine (10 
mL, 123 mmol, 6.8 equiv) was added to the system. Note: the catalytic amounts of 
pyridine suggested by the literature do not result in appreciable reaction. DMAP (285 mg, 
2.3 mmol, 0.13 equiv) was added and  2,6-dichlorobenzoyl chloride (4.42 g, 21 mmol, 
1.18 equiv). The reaction mixture was stirred at room temperature for 24-48 h. During 
this time, the mixture turns darker. Diethyl ether (450 mL) and water (25 mL) were added 
to the reaction. The organic layer was washed with portions of cupper sulfate solution 
(1M, ~ 2 x 70 mL) until pyridine is removed from the solution (R.f.: 0.2 in 30% ether in 
hexane). The organic layer was further washed with water (40 mL) and brine (40 mL), 
then dried over MgSO4, concentrated and purified by flash chromatography (R.f. 0.7, 
30% diethyl ether in hexane). The product is a viscous oil (3g, 78 %). 1H-NMR: (CDCl3, 
250 MHz) δ 1.0 (3H, t, J = 12 Hz), 2.1 (2H, p, J = 12 Hz), 4.9 (2H, d, J = 12 Hz), 5.7-5.9 
(2H, m, J1 = 12 Hz, J2 = 15 Hz), 6.0 (1H, t, J = 15 Hz), 6.4 (1H, dd, J1 = 12 Hz, J2 = 15 
Hz), 7.2-7.4 (3H, m, J = 8 Hz). 
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Hepta-(2E, 4E)-dienyl-diphenylphosphine (84) 
Hepta-(2E, 4E)-dienyl-1,6-dichloro benzoate (83, 3.52 g, 13.1 mmol) 
was dissolved in THF (30 mL) and cooled to minus 78 °C. In a 
separate flask in THF (30 mL), diphenyl phosphine (4.24 g, 23 mmol, 
1.7 equiv) was dissolved and cooled to minus 78 °C. nBu-Li (1.85 M, 2.3 equiv) was 
injected and the solution turned red. After this step, the first solution of 83 was 
transferred to the solution of nBu-Li-diphenyl phosphine mixture, using a canula and 
applied nitrogen pressure on the source flask. The disappearance of the benzoate 
derivative and the appearance of the phosphine product was followed by TLC (10% 
diethyl ether in hexane). After 20-40 minutes, the reaction was quenched with a saturated 
solution of NH4Cl (22 mL) and the material was used in the next step without 
purification.  
 
Hepta-(2E, 4E)-dienyl-diphenylphosphineoxide (85) 
After quenching the reaction in the preparation of 84 with NH4Cl, 
diethyl ether (600 mL) was added to the mixture, followed by water 
(55 mL). The organic layer was then washed with hydrogen peroxide (10-30% H2O2, 20 
mL portions) until the appearance of the oxidized product 85 (R.f.: 0.28 in 2% methanol 
in ether). Then sodium sulfite (Na2SO3, 10% in water, 35 mL) was added to the system to 
degrade the excess hydrogen peroxide. The mixture was dried over MgSO4, concentrated 
on the rotavap and purified via flash column chromatography (gradient elution, 1-2% 
methanol in ether). The product is a pale-yellow powder with an overall yield in the 
formation of 84 and 85 of ~ 2.5 g (70 % yield). 1H-NMR: (CDCl3, 250 MHz) δ 0.9 (3H, 
P
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d-tr, 7 Hz), 2.05 (2H, m), 3.15 (2H, dd, J1=16Hz, J2=8 Hz), 5.43-5.68 (2H, m), 5.84-6.14 
(2H, m), 7.4-7.88 (10H, m). 
 
 
1-[2,3-Bis-(tert-butyl-dimethyl-silanyloxy)-propoxy]-6-(diphenyl-phosphinoyl) 
dodeca-1,3,7,9-tetraen-5-ol (86) 
Our intermediate aldehyde product 5-[2,3-Bis-
(tert-butyl-dimethyl-silanoxy)-propoxy]-penta-
2,4-dienal (81, 70 mg, 0.11 mmol) was 
dissolved in THF (1 mL) and cooled to minus 78 °C. In a separate flask hepta-(2E, 4E)-
dienyl phosphineoxide (30 mg, 0.12 mmol, 1.1 equiv) was dissolved in THF (1 mL) and 
cooled at minus 78 °C. This later solution was treated with LDA (1.8 M, 135 µL, 0.24 
mmol, 2 equiv), and the solution turned deep red. Two minutes later, the solution of our 
aldehyde 81 was transferred via a canula applying nitrogen pressure on the source flask. 
After 20-30 minutes, the reaction was quenched by adding brine (1.5 mL) to the solution 
at minus 78 °C and adding ether (50 mL). The organic layer was further washed with 
water (3 mL) and brine (3 mL) and dried over K2CO3. After concentration of the organic 
phase we had a crude mixture containing the adduct 86. This mixture was dried 
azeotropically over benzene (3 x 6 mL), dried and used without further purification in the 
next step. 
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Protected fecapentaene-12 (87) 
The azeotropically dried mixture of 86 was 
redissolved in THF (1 mL), cooled to minus 
20 °C and treated with potassium tert-butoxide solution in THF (1 M, 0.165 mmol, 165 
µL, 1.5 equiv). The appearance of product was observed by TLC (R.f.: 0.3 in 5% diethyl 
ether in hexane). After apprx. 20 minutes, the reaction was quenched with ice-water (1.5 
mL) and ether (40 mL). The organic layer was washed with water (1.5 mL) and brine (3 
mL) and dried over K2CO3 under a stream of nitrogen to protect against the flow of air. 
The solution was filtered off from the drying agent under nitrogen athmosphere, and 
solvents were removed with a purge of nitrogen. Flasks and glassware are suggested to be 
covered by aluminum foil, as later, sunlight was observed to cause isomerization of the 
double bonds. The crude mixture was purified quickly on silica column (gradient: hexane 
to 2% ether in hexane) and resulted in 87 (oil, fluoresce green on TLC under 320 nm 
light, 40 mg, 70% yield). 1H-NMR: (CDCl3, 250 MHz) δ 1.0 (9H, s), 1.02 (9H, s), 2.13 
(2H, m), 3.63 (1H, d, J = 4.9 Hz), 3.74 (1H, dd, J1 = 4.8 Hz, J2 = 9.8 Hz), 3.87 (1H, dd, J1 
= 4.8 Hz, J2 = 9.8 Hz), 3.96 (2H, dd, J1=5 Hz, J2 = 10 Hz), 5.0 (1H, d), 5.2 (1H, d), 5.41-
5.54 (1H, m, olefinic), 5.82-5.66 (1H, m, olefininc), 5.98-6.28 (7H, m, olefinic), 6.39 
(1H, d, J = 13 Hz). 
 
 
 
 
 
O
OSTBDM
TBDMSO
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Fecapentaene-12 (73) 
At this step, the absolute exclusion of sunlight and 
ambient air is important. Extractions, filtrations, solvent evaporation, purfication need to 
be done under inert conditions, and with deoxygenated solvents. Solvents were 
deoxygenated with fresh bubbling of a stream of nitrogen or argon for a minimum of 30 
min. The protected fecapentaene-12 (87, 40 mg, 0.06 mmol) was dissolved in THF (1 
mL) at room temperature. The solution was treated with a fresh TBAF solution (1 M in 
THF, 200 µL, 0.2 mmol, 1.7 equiv). The appearance of the product was followed by TLC 
(2% methanol in ether, R.f.: 0.35) and the reaction was strirred until the disappearance of 
the starting material. The product shows green fluorescence under long-wave lamp (320 
nm). After approximately 10 minutes (2 h if the tert-butyl diphenylsilyl protecting group 
is used) the solution was quenched by the addition of degassed diethyl ether (60 mL). The 
organic layer was washed with water (1 mL) and brine (1 mL) and dried over K2CO3. 
The organic phase was filtered off from the drying agent, and the ether was removed by 
purging with nitrogen in a sealed round-bottom flask covered with aluminum foil. The 
mixture was purified for fecapentaene-12 quickly with deactivated silica gel column 
using degassed solvent (gradient: ether to 2% methanol in ether). Fraction collection and 
chromatography should be done under a stream of nitrogen/argon gas. Solvent was 
removed by nitrogen purging, and this resulted in lemon yellow crystals (3 mg, 30% 
yield). NMR, HPLC and UV matched the literature. Due to the incomplete removal of 
organic solvent and the fast degradation of the samples, the NMR showed identifiable 
impurities (20%). The purity of our fecapentaene-12 stock solution (2 mM in abs. 
ethanol, minus 80 °C) was assayed each time prior to DNA assays, using HPLC and UV. 
O
OH
HO
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1H-NMR: (CDCl3, 500 MHz) δ 0.95 (3H, m), 2.5 (2H, m), 3.68 (1H, m), 3.75 (2H, m), 
3.85 (1H, m), 3.90 (1H, m), 3.92 (1H, m), 5.1 (1H, dd), 5.6 (1H, m), 5.7 (2H, m), 6.0-6.4 
(4H, m), 6.5 (1H, dd), 6.6 (1H, d). 
 
6.12.3. Quantitative Stability of Fecapentaene-12 in Organic and Aqueous Media 
The freshly synthesized fecapentaene-12 had been redissolved into degassed absolute 
ethanol to a final 1.5 mM concentration. Higher concentrations result in more rapid 
decompositions. Samples were stored at minus 80 °C for a month without noticeable 
degradation (Figure 100). For the determination of the actual fecapentaene-12 
concentrations UV absorbance was measured at 355 nm, and concentrations calculated 
using light extinction coefficient: ε355nm ~ 100 000 M-1cm-1.19 
 
6.12.4. HPLC Method for the Analysis of Fecapentaene-12 
Reverse phase HPLC (C18 column: 4.2 mm x 25 cm) was used with gradient elution 
using acetonitrile and water eluent as shown in Table 12. 
Time % Acetonitrile % Water 
0-25 min Gradient: 40 – 70 Gradient: 60 – 30 
25-30 min Gradient: 70 – 90 Gradient: 30 – 10 
30-35 min 90 10 
35-40 min Gradient: 90 – 40 Gradient: 10 – 60 
 
Table 12. The gradient elution method for the HPLC separation and analysis of products in our reactions 
with fecapentaene-12 
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6.12.5. Measuring the Percentage Remaining Fecapentaene-12 in Organic Solutions 
under Refrigeration 
Aliquots of fecapentaene-12 stock solution in ethanol (20 µL) were diluted 5 times with 
HPLC eluent (30% acetonitrile – 70% water) and 25 µL of this mixture was injected onto 
RP-HPLC (4.2 mm, 25 cm C18 column). The size of the peak corresponding to all-trans 
fecapentaene-12 (20-21 min) was plotted against time (Figure 101). 
 
6.12.6. Stability of 73 in Aqueous Buffers at Different Concentrations and Semi 
Qualitative Analysis of Degradation Pathways Under Inert Dark, Inert Sunlighted 
and Ambient Buffered Conditions Using Diode-Array HPLC 
We used acetonitrile co-solvent at a final 10% volume. Fecapentaene-12 was removed 
from the freezer. Calculated amounts were injected into an amber HPLC vial and 
evaporated to dryness. This was re-dissolved with HPLC grade acetonitrile and water and 
sodium phosphate buffer to reach the selected final concentration of the drug and 50 mM 
sodium phosphate at pH 7.028 The concentrations of fecapentaene-12 were as follows: 
200 µM, 400 µM, 500 µM, 750 µM, 1 mM. At different time intervals, 25 uL of these 
samples were injected onto HPLC for analyses. For the calculation of half-lives a pseudo-
first order degradation was assumed. The disappearance of the FP-12 HPLC peak was 
fitted onto a decaying exponential function by SigmaPlot (Chapter 1), and half lives were 
calculated as t1/2 = ln 2/k. Half lives were plotted vs. the concentration of fecapentaene-
12 (Figure 101). At the end of reactions compounds were injected onto a BECKMAN 
diode array HPLC and the UV of HPLC peaks were plotted in a 3D view in the 
wavelength range of 220 – 400 nm for analyses. 
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To study the effect of sunlight, freshly made buffered sample of fecapentaene-12 (200 
µM) was exposed to sunlight for 5 min under nitrogen, and analyzed by HPLC as 
described above.  
 
 
6.12.7. The Mechanism of Oxidative DNA-Damage Caused by Fecapentaene-12 and 
Authentic Superoxide-Radical Generators: Vitamin A and Hydroquinone 
 
DNA Cleavage by 73 Under Aerobic and Anaerobic Conditions and Under Ambient 
Conditions in the Presence of Chelexed Water and Chelexed Buffer 
Fecapentaene-12 (73) was used as a stock solution stored in absolute ethanol at minus 80 
°C. The fecapentaene-12 solution was removed from the freezer, evaporated to dryness 
under a stream of nitrogen and dissolved into acetonitrile to a final concentration: 2 mM. 
In an 500-µL Eppendorf tube the following components and final concentrations were 
used: PGL2BASIC plasmid DNA was (35 µM / bp), sodium phosphate buffer (pH 7.0, 50 
mM), acetonitrile (10%) and increasing concentrations of 1 in a final reaction volume 50 
µL. The concentrations of 73 were as follows: 0 µM, 40 µM, 80 µM, 120 µM, 160 µM, 
200 µM. The last component added was 73. Samples were vortexed carefully for 5 sec, 
and placed into an incubator at 37 °C in dark for 15 h.  Following incubation, glycerol 
loading buffer (7 µL) containing 0.25% bromophenol blue and 40% sucrose, and the 
mixture vortexed. The resulting mixtures were loaded onto a 0.9% agarose gel. The el 
was electrophoresed at 80 V for approximately 4 h and then stained in an aqueous 
ethidium bromide solution (0.2 µg/mL) for 6-8 h. The DNA gel was then visualized by 
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UV-transillumination and the data documented using an Alpha Innotech IS1000 digital 
imaging system, with Alphaimager software.  
For the anaerobic assays, the stock solution of buffer (500 mM sodium phosphate, pH 
7.0) and HPLC-water were degassed via three cycles of freeze-pump-thaw, sealed off 
under vacuum, brought into a glove box saturated with argon. All reactions were set up 
and kept for incubation on a heat block at 37 °C in the argon filled glove box. Addition of 
the loading buffer and gel loading were done under ambient conditions. For the reactions 
with chelexed water and buffer, HPLC-water and the buffer stock (500 mM NaPi, pH 
7.0) were run through a column of Chelex100 (Sigma) in plastic column, to chelate 
multiply-charged transition metal trace elements. All experiments were run twice, and 
statistical error analysis was applied to calculate errors. DNA cleavage was converted to 
the mean number of cleavages on a plasmid molecule (S value = - ln (%cleavage/100) 
and these values were plotted vs. the concentration of fecapentaene-12 (Figure 105). 
 
DNA Cleavage by Increasing Concentrations of Vitamin A Under Aerobic and 
Anaerobic Conditions 
Vitamin A was used as a stock in acetonitrile (2 mM). In an 500-µL Eppendorf tube the 
following components and final concentrations were used: PGL2BASIC plasmid DNA 
was (35 µM / bp), sodium phosphate buffer (pH 7.0, 50 mM), acetonitrile (10%) and 
increasing concentrations of vitamin A in a final reaction volume 50 µL. The 
concentrations of vitamin A were as follows: 0 µM, 40 µM, 80 µM, 120 µM, 160 µM, 
200 µM. The last component added was vitamin A. Samples were vortexed carefully for 
5 sec, and placed into an incubator at 37 °C in dark for 15 h. For the anaerobic assays, the 
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stock solution of buffer (500 mM sodium phosphate, pH 7.0) and HPLC-water were 
degassed via three cycles of freeze-pump-thaw, sealed off under vacuo, brought into a 
glove box saturated with argon. All reactions were set up and kept for incubation on a 
heat block at 37 °C in the argon filled glove box. Addition of the loading buffer and gel 
loading happened under ambient conditions. Gel assay and analysis was carried out as 
described above. All experiments were run twice, and statistical error analysis was 
applied to calculate errors. Percentage cleavage was converted to the mean number of 
cleavage in a plasmid molecule (S value) and these values were plotted against the 
concentration of vitamin A (Figure 108). 
 
DNA Cleavage by Increasing Concentrations of Hydroquinone Under Aerobic 
Conditions 
Crystalline hydroquinone was used to make a stock in acetonitrile (4 mM). In an 500-µL 
Eppendorf tube the following components and final concentrations were used: 
PGL2BASIC plasmid DNA was (35 µM / bp), sodium phosphate buffer (pH 7.0, 50 
mM), acetonitrile (10%) and increasing concentrations of hydroquinone in a final 
reaction volume 50 µL. The concentrations of hydroquinone were as follows: 0 µM, 80 
µM, 160 µM, 240 µM, 3200 µM, 400 µM. The last component added was hydroquinone. 
Samples were vortexed carefully for 5 sec, and placed into an incubator at 37 °C in dark 
for 15 h. After incubation the electrophoresis and analysis of DNA was done as described 
above. All experiments were run twice, and statistical error analysis was applied to 
calculate errors. S values were plotted against the concentration of hydroquinone (Figure 
110). 
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6.12.8. Mechanism of Oxidative DNA Cleavage by 73 in the Presence of Various 
Additives 
In 500 µL Eppendorf tubes the following components and their final concentrations were 
used: sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v), PGL2BASIC 
plasmid DNA (35 µM/bp) fecapentaene-12 (200 µM). The components were mixed to a 
final volume of 50 µL. One of the following additives were used in each reaction: 
methanol (200 mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), 
SOD (100 µg/ml), catalase (100 µg/ml). Reaction mixture was gently vortexed and 
incubated at 37 °C for 15h in dark. After incubation the reactions were treated with 
glycerol loading buffer (17 µL) containing 0.25% bromophenol blue and 40% sucrose, 
and the mixture vortexed gently. Samples were loaded onto 0.9% agarose gel and 
elecrophoresed, dyed and analyzed for the percentage DNA-cleavage as described earlier. 
The corresponding S values were calculated from two sets of experiments using statistical 
error-analysis to calculate confidence limits (67%) represented as error-bars and plotted 
in a bar-graph against the applied additives (Figure 106). 
 
 
6.12.9. Mechanism of Oxidative DNA Cleavage by a Known Superoxide-Radical 
Generator: Vitamin A in the Presence of Various Additives 
In 500 µL Eppendorf tubes the following components and their final concentrations were 
used: sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v), PGL2BASIC 
plasmid DNA (35 µM/bp) vitamin A (300 µM). The components were mixed to a final 
volume of 50 µL. One of the following additives were used in each reaction: methanol 
(200 mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), SOD (100 
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µg/ml), catalase (100 µg/ml). Reaction mixture was gently vortexed and incubated at 37 
°C for 15h in dark. After incubation the reactions were treated with glycerol loading 
buffer (17 µL) containing 0.25% bromophenol blue and 40% sucrose, and the mixture 
vortexed gently. Samples were loaded onto 0.9% agarose gel and elecrophoresed, dyed 
and analyzed for the percentage DNA-cleavage as described earlier. The corresponding S 
values were calculated from two sets of experiments using statistical error-analysis to 
calculate confidence limits (67%) represented as error-bars and plotted in a bar-graph 
against the applied additives (Figure 109). 
 
 
6.12.10. Mechanism of Oxidative DNA Cleavage by a known Superoxide Radical 
Generator: Hydroquinone in the Presence of Various Additives 
In 500 µL Eppendorf tubes the following components and their final concentrations were 
used: sodium phosphate buffer (50 mM, pH 7.0), acetonitrile (10%, v/v), PGL2BASIC 
plasmid DNA (35 µM/bp) hydroquinone (250 µM). The components were mixed to a 
final volume of 50 µL. One of the following additives were used in each reaction: 
methanol (200 mM), ethanol (200 mM), mannitol (100 mM), DESFERAL (10 mM), 
SOD (100 µg/ml), catalase (100 µg/ml). Reaction mixture was gently vortexed and 
incubated at 37 °C for 15h in dark. After incubation the reactions were treated with 
glycerol loading buffer (17 µL) containing 0.25% bromophenol blue and 40% sucrose, 
and the mixture vortexed gently. Samples were loaded onto 0.9% agarose gel and 
elecrophoresed, dyed and analyzed for the percentage DNA-cleavage as described earlier. 
The corresponding S values were calculated from two sets of experiments using statistical 
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error-analysis to calculate confidence limits (67%) represented as error-bars and plotted 
in a bar-graph against the applied additives (Figure 111). 
 
6.12.11. DNA Damage by Partially Degraded Fecapentaene-12 (73) 
 Eppendor tubes containing various amounts of neat 1 were prepared as described 
above. Acetonitrile or ethanol (12.5 µL) and sodium phosphate buffer (5 µL of a 500 mM 
stock solution in water), followed by water (31.5 µL) were added and the mixture 
agitated on a vortex mixer for 20 s. Before the addition of plasmid DNA, the mixtures 
were pre-incubated for 5 h at 37 °C. Plasmid DNA (1 µL of a 1 mg/mL solution) was 
added with gentle vortex mixing and the cleavage reactions incubated in the dark for 5 h 
at 37 °C. Analysis of DNA damage was performed as described above.  
 
6.12.12. Noncovalent DNA-Binding by 73 
Displacement of Ethidium from Duplex DNA by 73.  
A solution of calf thymus DNA-ethidium bromide complex was prepared (final 
concentrations: DNA, 4 µM; ethidium bromide, 2 µM; HEPES buffer, 10 mM, EDTA, 
0.5 mM and sodium chloride, 8 mM, pH 7.0; acetonitrile, 30% v/v) and placed into a 
quartz fluorescence cuvette (400 µL). The sample was then analized using a Photon 
International Technology fluorimeter with the following settings: excitation wavelength 
at 545 nm, emission wavelength at 596 nm, optical slits at 8 nm, lamp power 75 W, 
detector amplification at 1000 V. Light was integrated for 0.1 s. The fluorimeter wa 
zeroed on a solution containing ethidium without DNA. Aliquots of a concentrated 
solution of 1 (2-5 µL of a 5 mM solution in ethanol) were added and changes in 
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fluorescence emission of DNA-bound ethidium monitored. As a control, the effect of the 
addition of pure ethanol on the fluorescence of the DNA-ethidium bromide complex was 
studied. The data was used to estimate the binding constant of 73 with duplex DNA using 
the general approach described by Baguley et al.37 (figure 19). The calculations utilized 
the binding constant of 9.6 x 106 M-1 for association of ethidium bromide with calf 
thymus DNA as reported previously.38 
 
Calculation of the Binding Constant of Fecapentaene-12 in the Ethidium Bromide 
Displacement Assay.  
The binding constant of ethidium bromide to calf thymus DNA at pH 7.0 was obtained 
from the literature 69 (Ke = 9.5 x 106 M-1). The concentration of fecapentaene-12 at 50% 
displacement of ethidium bromide was at 155 µM. As a general approach, the drug 
concentration which produces 50% inhibition of fluorescence is used for the calculation 
of the binding constant. This concentration is approximately inversely proportional to the 
binding constant. However, this approximation does not take account of different binding 
site sizes.70 
 
Effect of Added Duplex DNA on the UV-vis Spectrum of 73 
A solution of 73 in sodium phosphate buffer was placed in a UV-vis cuvette (final 
concentrations: 73, 40 µM; sodium phosphate 50 mM, pH 7; acetonitrile, 25% by 
volume). To this mixture, aliquots of a solution containing herring sperm DNA (5 mM 
bp) and 73 (40 µM) in sodium phosphate buffer (50 mM, pH 7) and acetonitrile (25% by 
volume) were added and the resulting mixtures analyzed by UV-vis spectroscopy. The 
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aliquots of added DNA contained fecapentaene to ensure that changes in the spectrum 
were not due to dilution. The DNA titration experiment was complete within 25 min. A 
control experiment was carried out to show that the changes in the UV-vis spectrum are 
not due to chemical degradation of 73 or reaction of the compound with DNA over the 
course of the experiment. Specifically, the control showed that the degradation of 73 in 
the presence of DNA (10 mM bp) over the course of 25 min yields relatively small 
changes in the UV-vis spectrum compared to those seen in the DNA titration (Figure 
115). 
 
Determining the Binding Constant and the Binding-Site size by the McGhee-von 
Hippel Analysis47 
Following our titration of 73 with herring DNA, we calculated the extinction coefficient 
of DNA-bound form of 73 by extrapolating A335nm . We calculated the amount of 73 per 
unit of DNA (r) and the free drug concentration (Cf) at each titration point, and plotted 
these values as r/Cf vs. r Figure 116). The resulting plot was fitted non-linearly according 
to a polynom containing the binding site size (Equation 60), and the binding constant and 
the binding site size were calculated (KB = 1029 ± 190 M-1, n = 8 ± 2 bp.). 
 
6.12.13. Searching for DNA-adducts of FP-12 by Nuclease Digestion 
 73 ( 200 µM ) was incubated in the presence of 2 mM herring sperm DNA in 50 
mM TRIS-EDTA (pH 7.5) and acetonitrile (10%) for 20 h at 37°C in a final volume of 
500 µL. After incubation, small molecules were extracted from the mixture using butanol 
(500 µL, twice). The remaining solution was treated with DNA precipitating solution 
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containing 0.3 M sodium acetate and 70% (v/v) ethanol (500 µL). This cocktail was 
mixed on a vortex mixer and kept on dry-ice for 30 minutes form complete freezing. The 
frozen samples were centrifuged at 10.000 r.p.m. for 30 min at 4 °C. The DNA pellets 
were collected, and further washed with 80% ethanol in water (200 µL, twice). The 
pellets then were redisolved into water (352 µL) and a digestion-buffer mixture (40 µL)  
containing sodium acetate (830 mM) and magnesium sulfate (83 mM). Then 0.2 U of 
PDE and 330 U of DNAse II was added to the system and it was incubated for 1 h at 37 
°C. After incubation, 1.22 mg AcP was added and mixture incubated for additional 2 h at 
37 °C. Enzymes were removed via centrifugation in an amicon filter (3 kD cutoff). 
Filtrate was analyzed by reversed phase HPLC using method reported by Guengerich et 
al.49 (Figure 117). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 286 
References 
 
 
1. Bruce, W. R.; Varghese, A. J.; Furrer, R.; Land, P. C., A mutagen in the feces of 
normal humans. Cold Spring Harbor Conferences on Cell Proliferation 1977, 4, 1641-6. 
2. Kingston, D. G. I.; Van Tassell, R. L.; Wilkins, T. D., The fecapentaenes, potent 
mutagens from human feces. Chem. Res. Toxicol. 1990, 3, 391-400. 
3. de Kok, T. M. C. M.; van Maanen, J. M. S., Evaluation of fecal mutagenicity and 
colorectal cancer risk. Mutat. Res. 2000, 463, 53-101. 
4. Reddy, B. S.; Sharma, C.; Darby, L.; Laakso, K.; Wynder, E. L., Metabolic 
epidemiology of large bowel cancer. Fecal mutagens in high- and low-risk population for 
colon cancer. A preliminary report. Mutat. Res. 1980, 72, 511-22. 
5. Bruce, W. R.; Varghese, A. J.; Land, P. C.; Krepinsky, J. J. F., Properties of a 
mutagen isolated from feces. Banbury Report 1981, 7, 227-38. 
6. Kingston, D. G. I.; Wilkins, T. D.; Van Tassell, R. L.; Macfarlane, R. D.; McNeal, 
C. J., Structural studies on a mutagenic bacterial product from human feces. Banbury 
Report 1981, 7, 215-26. 
7. Plummer, S. M.; Grafstrom, R. C.; Yang, L. L.; Curren, R. D.; Linnainmaa, K.; 
Harris, C. C., Fecapentaene-12 causes DNA damage and mutations in human cells. 
Carcinogenesis 1986, 7, 1607-1609. 
8. Govindan, S. V.; Kingston, D. G. I.; Gunatilaka, A. A. L.; Van Tassell, R. L.; 
Wilkins, T. D.; De Wit, P. P.; Van der Steeg, M.; Van der Gen, A., Synthesis and 
biological activity of analogs of fecapentaene-12. J. Nat. Prod. 1987, 50, 75-83. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 287 
9. Schmid, E.; Bauchinger, M.; Braselmann, H.; Pfaendler, H. R.; Goeggelmann, 
W., Dose-response relationship for chromosome aberrations induced by fecapentaene-12 
in human lymphocytes. Mutat. Res. 1987, 191, 5-7. 
10. Weston, A.; Plummer, S. M.; Grafstrom, R. C.; Trump, B. F.; Harris, C. C., 
Genotoxicity of chemical and physical agents in cultured human tissues and cells. Food 
and chemical toxicology : an international journal published for the British Industrial 
Biological Research Association 1986, 24, 675-9. 
11. Kingston, D. G. I.; Van Tassell, R. L.; Wilkins, T. D., The fecapentaenes, potent 
mutagens from human feces. Chem. Res. Toxicol. 1990, 3, 391-400. 
12. Dypbukt, J. M.; Edman, C. C.; Sundqvist, K.; Kakefuda, T.; Plummer, S. M.; 
Harris, C. C.; Grafstroem, R. C., Reactivity of fecapentaene-12 toward thiols, DNA, and 
these constituents in human fibroblasts. Canc. Res. 1989, 49, 6058-6063. 
13. Povey, A. C.; Wilson, V. L.; Zweier, J. L.; Kuppusamy, P.; O'Neill, I. K.; Harris, 
C. C., Detection by phosphorus-31-postlabelling of DNA adducts induced by free 
radicals and unsaturated aldehydes formed during the aerobic decomposition of 
fecapentaene-12. Carcinogenesis 1992, 13, 395-401. 
14. de Kok, T. M. C. M.; Pachen, D. M. F. A.; van Maanen, J. M. S.; Lafleur, M. V. 
M.; Westmijze, E. J.; Hoor, F. t.; Kleinjans, J. C. S., Role of oxidative DNA damage in 
the mechanism of fecapentaene-12 genotoxicity. Carcinogenesis 1994, 15, 2559-2565. 
15. De Kok, T. M. C. M.; Van Maanen, J. M. S.; Lankelma, J.; Ten Hoor, F.; 
Kleinjans, J. C. S., Electron spin resonance spectroscopy of oxygen radicals generated by 
synthetic fecapentaene-12 and reduction of fecapentaene mutagenicity to Salmonella 
typhimurium by hydroxyl radical scavenging. Carcinogenesis 1992, 13, 1249-1255. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 288 
16. Peters, J. H.; Riccio, E. S.; Stewart, K. R.; Reist, E. J., Mutagenic activities of 
fecapentaene derivatives in the Ames/Salmonella test system. Canc. Lett. 1988, 39, 287-
96. 
17. De Wit, P. P.; Van der Steeg, M.; Van der Gen, A., Remarkable electrophilic 
properties of the pentaenol ether system of fecapentaene-12. Tetrahedron Lett. 1986, 27, 
6263-6. 
18. Nieuwenhuis, S. A. M.; Vertegaal, L. B. J.; de Zoete, M. C.; van der Gen, A., 
Acid-catalyzed solvolysis of polyenol ethers. III. Effect of the alkoxy moiety. 
Tetrahedron 1994, 50, 13207-13230. 
19. Streeter, A. J.; Donovan, P. J.; Anjo, T.; Ohannesian, L.; Sheffels, P. R.; Wu, P. 
P.; Keefer, L. K.; Andrews, A. W.; Bradford, W. W., III; al., e., Decomposition and 
quality control considerations in biological work with fecapentaene preparations. Chem. 
Res. Toxicol. 1989, 2, 162-168. 
20. Shamsuddin, A. M.; Ullah, A.; Baten, A.; Hale, E., Stability of fecapentaene-12 
and its carcinogenicity in F-344 rats. Carcinogenesis 1991, 12, 601-607. 
21. Hertzberg, R. P.; Dervan, P. B., Cleavage of double helical DNA by methidium-
propyl-EDTA-iron(II). J. Am. Chem. Soc. 1982, 104, 313-315. 
22. Jadhav, V. R.; Barawkar, D. A.; Ganesh, K. N., Polarity Sensing by Fluorescent 
Oligonucleotides: First Demonstration of Sequence-Dependent Microenvironmental 
Changes in the DNA Major Groove. J. Phys. Chem. B 1999, 103, 7383-7385. 
23. Jin, R.; Breslauer, K. J., Characterization of the minor groove environment in a 
drug-DNA complex:  bisbenzimide bound to the poly[d(AT)]×poly[d(AT)duplex. Proc. 
Natl. Acad. Sci. Unit. States. Am. 1988, 85, 8939-8942. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 289 
24. Barawkar, D. A.; Ganesh, K. N., Fluorescent d(CGCGAATTCGCG): 
characterization of major groove polarity and study of minor groove interactions through 
a major groove semantophore conjugate. Nucleic. Acids. Res. 1995, 123, 159-164. 
25. Young, M. A.; Jayaram, B.; Beveridge, D. L., Local Dielectric Environment of B-
DNA in Solution: Results from a 14 ns Molecular Dynamics Trajectory. J. Phys. Chem. B 
1998, 102, 7666-7669. 
26. Nicolaou, K. C.; Zipkin, R.; Tanner, D., Total synthesis of the potent mutagen 
(S)-3-(dodeca-1,3,5,7,9-pentaenyloxy)propane-1,2-diol. J. Chem. Soc. Chem. Comm. 
1984, 6, 349-350. 
27. Zipkin, R. E. Ph.D., University of Pennsylvania, Pennsylvania, 1984. 
28. Chatterji, T.; Kizil, M.; Keerthi, K.; Chowdhury, G.; Pospisil, T.; Gates, K. S., 
Small Molecules That Mimic the Thiol-Triggered Alkylating Properties Seen in the 
Natural Product Leinamycin. J. Am. Chem. Soc. 2003, 125, 4996-4997. 
29. Rissler, K., Improved separation of poly(ethylene glycol)s widely differing in 
molecular weight range by reversed-phase high performance liquid chromatography and 
evaporative light scattering detection. Chromatographia 1999, 49, 615-620. 
30. Halliwell, B.; Gutteridge, J. M. C., Role of free radicals and catalytic metal ions 
in human disease:  an overview. Meth. Enzymol. 1990, 186, 1-85. 
31. Behroozi, S. J.; Kim, W.; Dannaldson, J., 1,2-Dithiolan-3-one 1-Oxides: A Class 
of Thiol-Activated DNA-Cleaving Agents That Are Structurally Related to the Natural 
Product Leinamycin. Biochemistry 1996, 35, 1768-1774. 
32. Murata, M.; Kawanishi, S., Oxidative DNA damage by vitamin A and its 
derivative via superoxide generation. J. Biol. Chem. 2000, 275, 2003-2008. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 290 
33. Ikota, N.; Ueda, J.-i.; Gamage, R.; Shimazu, Y.; Hama-Inaba, H.; Takusakawa, 
M.; Ozawa, T.; Satoh, T., Histidine-containing peptides and hydroquinone derivatives as 
synthetic antioxidants. Biodefence Mechanisms against Environmental Stress 1998, 3-12. 
34. Berry, D. E.; Chan, J. A.; MacKenzie, L.; Hecht, S. M., 9-Octadecynoic acid:  a 
novel DNA binding agent. Chem. Res. Toxicol. 1991, 4, 195-198. 
35. Barr, J. R.; Murty, V. S.; Yamaguchi, K.; Singh, S.; Smith, D. H.; Hecht, S. M., 5-
Alkylresorcinols from Hakea amplexicaulis that cleave DNA. Chem. Res. Toxicol. 1988, 
1, 204-207. 
36. Scannell, R. T.; Barr, J. R.; Murty, V. S.; Reddy, K. S.; Hecht, S. M., DNA strand 
scission by naturally occurring 5-alkylresorcinols. J. Am. Chem. Soc. 1988, 110, 3650-
3651. 
37. Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Cain, B. F., Potential antitumor 
agents.  34.  Quantitative relationships between DNA binding and molecular structure for 
9-anilinoacridines substituted in the anilino ring. J. Med. Chem. 1981, 24, 170-177. 
38. Jenkins, T. C., Optical absorbance and fluorescence techniques for measuring 
DNA-drug interactions. . Fox, K. E., Ed.: New Jersey, 1997; p 195-218. 
39. Hsieh, H.-P.; Muller, J. G.; Burrows, C. J., Structural Effects in Novel Steroidal 
Polyamine-DNA Binding. J. Am. Chem. Soc. 1994, 116, 12077-12078. 
40. Schneider, H. J.; Blatter, T., Interaction of acyclic and cyclic peralkylammonium 
compounds and DNA. Angew. Chem. Int. Ed. 1992, 31, 1207-1208. 
41. Tse, W. C.; Boger, D. L., A fluorescent intercalator displacement assay for 
establishing DNA binding selectivity and affinity. Accounts. Chem. Res. 2004, 37, 61-69. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 291 
42. R, M. A.; H, E. D.; S, L. J.; E, P. D., Ethidium fluorescence assays.  Part 1.  
Physicochemical studies. Nucleic. Acids. Res. 1979, 1979, 3. 
43. Long, E. C.; Barton, J. K., On demonstrating DNA intercalation. Accounts. Chem. 
Res. 19909, 23, 271-273. 
44. Suh, D.; Chaires, J. B., Criteria for the mode of binding of DNA binding agents. 
Bioorg. Med. Chem. 1995, 3, 723-728. 
45. Wang, X.; Zhang, X.; Lin, J.; Chen, J.; Xu, Q.; Guo, Z., DNA-binding property 
and antitumor activity of bismuth(3+) complex with 1,4,7,10-tetrakis(2-pyridylmethyl)-
1,4,7,10-tetraazacyclododecane. Dalton Trans. 2003, 12, 2379-2380. 
46. Kassaee, M. Z.; Bekhradnia, A. R., The kinetics of interactions between 
fecapentaene-12 and DNA. J. Biosci. Bioeng. 2003, 95, 526-529. 
47. McGhee, J. D.; Von Hippel, P. H., Theoretical aspects of DNA-protein 
interactions.  Cooperative and noncooperative binding of large ligands to a one-
dimensional homogeneous lattice. J. Mol. Biol. 1974, 86, 469-489. 
48. Chaudhary, A. K.; Reddy, G. R.; Blair, I. A.; Marnett, L. J., Characterization of 
an N6-oxopropenyl-2'-deoxyadenosine adduct in malondialdehyde-modified DNA using 
liquid chromatography/electrospray ionization tandem mass spectrometry. 
Carcinogenesis 1996, 17, 1167-1170. 
49. Marsch, G. A.; Mundkowski, R. G.; Morris, B. J.; Manier, M. L.; Hartman, M. 
K.; Guengerich, F. P., Characterization of Nucleoside and DNA Adducts Formed by S-
(1-Acetoxymethyl)glutathione and Implications for Dihalomethane-Glutathione 
Conjugates. Chem. Res. Toxicol. 2001, 14, 600-608. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 292 
50. Evans, M. D.; Dizdaroglu, M.; Cooke, M. S., Oxidative DNA damage and 
disease: induction, repair and significance. Mutat. Res. 2004, 567, 1-61. 
51. Marnett, L. J., Oxyradicals and DNA damage. Carcinogenesis 2000, 21, 361-370. 
52. Wallace, S. S., Biological consequences of free radical-damaged DNA bases. Adv. 
Free. Radic. Biol. Med. 2002, 33, 1-14. 
53. Pogozelski, W. K.; McNeese, T. J.; Tullius, T. D., What Species Is Responsible 
for Strand Scission in the Reaction of [FeIIEDTA]2- and H2O2 with DNA? J. Am. Chem. 
Soc. 1995, 117, 6428-6433. 
54. Breen, A. P.; Murphy, J. A., Reactions of oxyl radicals with DNA. Adv. Free. 
Radic. Biol. Med. 1995, 18, 1033-1077. 
55. Zuilhof, H.; Vertegaal, L. B. J.; van der Gen, A.; Lodder, G., Quantum chemical 
analysis of the mechanism of the solvolysis of polyenol ethers. PM3 calculations on 
fecapentaene-12 and related compounds. J. Org. Chem. 1993, 58, 2804-2809. 
56. Porter, N. A., Mechanisms for the autoxidation of polyunsaturated lipids. 
Accounts. Chem. Res. 1986, 19, 262-268. 
57. Chamulitrat, W.; Hughes, M. F.; Eling, T. E.; Mason, R. P., Superoxide and 
peroxyl radical generation from the reduction of polyunsaturated fatty acid 
hydroperoxides by soybean lipoxygenase. Arch. Biochem. Biophys. 1991, 290, 153-159. 
58. J, M. G.; A, F. J., Stopped flow spectrophotometric observation of superoxide 
dismutation in aqueous solution. FEBS Lett. 1976, 67, 294-298. 
59. Halliwell, B., An attempt to demonstrate a reaction between superoxide and 
hydrogen peroxide. FEBS Lett. 1976, 72, 8-10. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 293 
60. Liochev, S. I.; Fridovich, I., The Haber-Weiss cycle - 70 years later: an alternative 
view. Comments. Redox Report 2002, 7, 55-57. 
61. MacManus-Spencer; A., L.; McNeill, K., Quantification of Singlet Oxygen 
Production in the Reaction of Superoxide with Hydrogen Peroxide Using a Selective 
Chemiluminescent Probe. J. Am. Chem. Soc. 2005, 127, 8954-8955. 
62. Kochevar, I. E.; Dunn, D. A., Photosensitized reactions of DNA:  cleavage and 
addition. Photochemistry 1990, 1, 273-315. 
63. Li, M. Y.; Cline, C. S.; Koker, E. B.; Carmichael, H. H.; Chignell, C. F.; Bilski, 
P., Quenching of singlet molecular oxygen (1O2) by azide anion in solvent mixtures. 
Photochem. Photobiol. 2001, 74, 760-764. 
64. Catalan, J.; Diaz, C.; Barrio, L., Analysis of mixed solvent effects on the 
properties of singlet oxygen (1Dg). Chem. Phys. 2004, 300, 33-39. 
65. Buxton, G. V.; Greenstock, C. L. H., W. Phillip; Ross, A. B., Critical review of 
rate constants for reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals 
(×OH/×O-) in aqueous solution. J. Phys. Chem. Ref. Data. 1988, 17, 513-886. 
66. Blazek, E. R.; Peak, J. G.; Peak, M. J., Singlet oxygen induces frank strand breaks 
as well as alkali- and piperidine-labile sites in supercoiled plasmid DNA. Photochem. 
Photobiol. 1989, 49, 607-613. 
67. Sambrook, J.; Fritisch, E. F.; Maniatis, T., Molecular Cloning: A Lab Manual. 
Cold Spring Harbor Press, Cold Spring Harbor, NY.: 1989. 
68. Baldwin, J. J.; Raab, A. W.; Mensler, K.; Arison, B. H.; McClure, D. E., 
Synthesis of (R)- and (S)-epichlorohydrin. J. Org. Chem. 1978, 43, 4876-8. 
Chapter 6: DNA binding and damage by fecapentaene-12 
______________________________________________________________________________________ 
 294 
69. Fox, K. R., Drug-DNA Interaction Protocols. Humana Press: Totowa, New 
Jersey, 1997; p 213. 
70. Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; Evans, D. H., 
Ethidium fluorescence assays. Part 1. Physicochemical studies. Nucleic. Acids. Res. 1979, 
7, 547-69. 
 
 
 
Dissertation Conclusions 
______________________________________________________________________________________ 
 295 
Dissertation Conclusions 
 
 We have studied the reactions of small molecules with DNA. Since DNA is the 
central molecule in cells1,2 that determines its proper function, this type of Chemistry is 
relevant to the understanding of the Biology of both anticancer drugs and mutagens.3 
Within this field, we have looked to study molecules that damage DNA by unusual 
chemical mechanisms. Finding new chemical reactions to modify biomolecules 
covalently under physiological conditions is fundamentally relevant to medicinal 
chemistry, toxicology and biotechnology. The novel chemistries will invite the 
development of new experimental methods and analytical tools, too.4-12 
 Finally, it is important to appreciate our position as research scientists. Not too 
many people have access to the fascinating natural products given by nature, and to the 
tools of exploration of their functions. In addition, the ability to wisely utilize the 
information media in the forms of presentations, publications and conferences will help 
our minds and hands unite for this exceptional adventure. 
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